# **Interim Financial Information**

Rede D'Or São Luiz S.A.

September 30, 2025 with Independent Auditor's Review Report

# Interim financial information

September 30, 2025

### Contents

Independent auditor's review report on interim financial information	1
Interim financial information	
Statements of financial position	3
Statements of profit or loss	5
Statements of comprehensive income	
Statements of changes in equity	7
Statements of cash flows	
Statements of value added	
Notes to interim financial information	



Centro Empresarial PB 370 Praia de Botafogo, 370 8° ao 10° andar - Botafogo 22250-040 - Rio de Janeiro - RJ - Brasil

Tel: +55 21 3263-7000 ev.com.br

A free translation from Portuguese into English of Independent auditor's review report on interim financial information prepared in Brazilian currency in accordance with Accounting Pronouncement CPC 21 - Interim Financial Reporting, and IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB)

### Independent auditor's review report on interim financial information

To the Shareholders, Board of Directors and Officers of **Rede D'Or São Luiz S.A.**Rio de Janeiro - RJ, Brazil

#### Introduction

We have reviewed the individual and consolidated interim financial information of Rede D'Or São Luiz S.A. (the "Company"), contained in the Quarterly Information Form (ITR) for the quarter ended September 30, 2025, which comprises the statement of financial position as at September 30, 2025 and the statements of profit or loss and of comprehensive income for the three and nine-month periods then ended, and the statements of changes in equity and of cash flows for the nine-month period then ended, including other explanatory information.

The executive board is responsible for the preparation of the individual and consolidated interim financial information in accordance with Accounting Pronouncement CPC 21 - Interim Financial Reporting, and IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), currently referred to by the IFRS Foundation as "IFRS Accounting Standards", as well as for the fair presentation of this information in conformity with the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of the Quarterly Information (ITR). Our responsibility is to express a conclusion on this interim financial information based on our review.

#### Scope of review

We conducted our review in accordance with the Brazilian and International Standards on Review Engagements (NBC TR 2410 and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

#### Conclusion on the individual and consolidated interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the accompanying individual and consolidated interim financial information included in the quarterly information referred to above is not prepared, in all material respects, in accordance with Accounting Pronouncement CPC 21 and IAS 34 applicable to the preparation of Quarterly Information (ITR), and presented consistently with the rules issued by the Brazilian Securities and Exchange Commission.



#### Other matters - Statements of value added

The abovementioned quarterly information includes the individual and consolidated statements of value added (SVA) for the nine-month period ended September 30, 2025, prepared under the Company's executive board responsibility and presented as supplementary information under IAS 34. These statements have been subject to review procedures performed together with the review of the quarterly information with the objective to conclude whether they are reconciled to the interim financial information and the accounting records, as applicable, and if their format and content are in accordance with the criteria set forth by Accounting Pronouncement CPC 09 - Statements of Value Added. Based on our review, nothing has come to our attention that causes us to believe that they were not prepared, in all material respects, in accordance with the criteria set forth by this Standard and consistently with the individual and consolidated interim financial information taken as a whole.

Rio de Janeiro, November 04, 2025.

ERNST & YOUNG Auditores Independentes S/S Ltda. CRC SP-015199/F

Diogo Afonso da Silva

Accountant CRC RJ-114783/O

Statements of financial position September 30, 2025 and December 31, 2024 (In thousands of reais)

		Indiv	/idual	Conso	lidated
	Note	09/30/2025	12/31/2024	09/30/2025	12/31/2024
Assets	-				
Current assets					
Cash and cash equivalents	4	1,647,274	408,911	5,534,941	6,570,751
Marketable securities	4	10,154,002	9,272,469	37,653,030	32,067,003
Accounts receivable	5	5,578,603	4,934,013	10,185,064	9,463,784
Inventories	6	450,352	430,256	1,063,321	912,877
Taxes recoverable		563,706	606,771	1,235,332	1,224,853
Insurance contract assets	12	-	-	24,855	8,715
Reinsurance contract assets		-	-	40,619	57,088
Derivative financial instruments	24	86,073	174,331	114,012	174,331
Transactions with related parties	7	1,746,646	447,826	584	192,151
Dividends receivable		516,456	563,310	-	-
Other		399,561	347,450	836,478	689,826
Total current assets		21,142,673	17,185,337	56,688,236	51,361,379
Assets classified as held for sale	26	225,005	-	1,366,328	-
Noncurrent assets					
Transactions with related parties	7	2,581,598	1,806,064	91,818	62,003
Marketable securities	4	-	-	1,770,523	1,851,780
Accounts receivable	5	-	-	1,725,595	1,733,842
Taxes recoverable		8,677	8,677	507,514	479,493
Insurance contract assets	12	-	-	18,877	48,314
Reinsurance contract assets		-	-	12,752	16,065
Judicial deposits	14	412,755	376,213	2,608,341	2,770,086
Deferred taxes	17	395,693	-	4,221,925	3,509,725
Derivative financial instruments	24	395,999	380,946	2,784,704	3,550,934
Investments in subsidiaries, associates and joint					
ventures	8	31,796,237	31,679,152	2,451,173	2,483,556
Property and equipment	9	5,954,633	5,712,780	16,388,675	14,978,458
Intangible assets	10	7,456,122	7,497,061	15,853,146	16,242,665
Right of use - leases	11	2,428,912	2,450,179	3,089,429	3,053,023
Other		199,702	220,379	454,221	456,559
Total noncurrent assets		51,630,328	50,131,451	51,978,693	51,236,503

Total assets
See accompanying notes.

**72,998,006** 67,316,788 **110,033,257** 102,597,882

Statements of financial position September 30, 2025 and December 31, 2024 (In thousands of reais)

		Indiv	/idual	Conso	lidated
	Note	09/30/2025	12/31/2024	09/30/2025	12/31/2024
Liabilities and equity					
Current liabilities		700.045	000 540	4 70 4 000	4 50 4 000
Trade accounts payable	0.4	780,345	666,543	1,784,099	1,534,698
Derivative financial instruments	24	671,660	568,616	1,112,404	660,968
Loans, financing and debentures	13 7	1,819,800	3,920,516	1,877,425	3,915,191
Transactions with related parties Salaries, accruals and social charges	,	647,042	- 491,097	16,114 1,366,601	12,231 1,109,208
Tax obligations		277,461	281,746	1,340,700	865,069
Accounts payable for acquisitions		15,135	16,858	407,259	464,989
Dividends and IOE payable	16	452,287	56,938	464,294	69,192
Insurance contract liabilities	12	-02,207	-	7,208,933	7,099,761
Leases	15	622,778	627,124	825,219	776,424
Other	. •	75,412	74,212	1,142,297	1,347,995
Total current liabilities		5,361,920	6,703,650	17,545,345	17,855,726
Liabilities related to assets held for sale	26	-	-	1,125,085	-
Noncurrent liabilities					
Derivative financial instruments	24	1,008,370	1,545,831	1,063,818	1,545,831
Loans, financing and debentures	13	35,895,171	30,107,692	41,001,646	34,955,408
Transactions with related parties	7	<u>-</u>		4,677	3,769
Tax obligations		26,721	34,983	131,082	185,821
Accounts payable for acquisitions		339	827	273,353	288,237
Insurance contract liabilities	12	-	-	12,232,357	13,189,692
Deferred taxes	17	- 	80,171	411,706	368,455
Provision for contingencies	14 8	598,846	743,414	3,080,900	3,358,816
Provision for losses on investments Leases	o 15	865,934 2,329,206	719,421 2,300,596	2,864,662	2,826,049
Other	13	579,172	377,576	1,496,358	1,318,210
Total noncurrent liabilities		41,303,759	35,910,511	62,560,559	58,040,288
Total noncurrent habilities		<del>+1,303,733</del>	55,510,511	02,300,333	30,040,200
Equity	16	.=		.=	4==44.000
Capital		15,711,360	15,711,360	15,711,360	15,711,360
Share issue costs		(253,031)	(253,031)	(253,031)	(253,031)
Capital reserves		5,006,958	4,960,756	5,006,958	4,960,756
Treasury shares		(1,828,733)	(1,458,602)	(1,828,733)	(1,458,602) 4,930,435
Income reserves Retained earnings		3,580,435 3,515,974	4,930,435	3,580,435 3,515,974	4,930,433
Future capital contribution		4,224	4,224	3,515,974 4,224	4,224
Other comprehensive income		595,140	807,485	595,140	807,485
Total equity attributable to the Company's shareholders		26,332,327	24,702,627	26,332,327	24,702,627
		<u> </u>			
Noncontrolling interests			<u> </u>	2,469,941	1,999,241
Total equity		26,332,327	24,702,627	28,802,268	26,701,868
Total liabilities and equity		72 000 000	67 246 700	440 022 257	100 507 000
Total liabilities and equity		72,998,006	67,316,788	110,033,257	102,597,882
See accompanying notes.					

Statements of profit or loss Nine-month periods ended September 30, 2025 and 2024 (In thousands of reais, unless otherwise stated)

			Indiv	ridual		Consolidated				
_	Note	07/01/2025 to 09/30/2025	01/01/2025 to 09/30/2025	07/01/2024 to 09/30/2024	01/01/2024 to 09/30/2024	07/01/2025 to 09/30/2025	01/01/2025 to 09/30/2025	07/01/2024 to 09/30/2024	01/01/2024 to 09/30/2024	
Operating revenue, net	18	4,042,533	11,710,778	3,807,683	10,855,502	14,415,537	41,349,416	13,023,160	37,722,297	
Operating costs	19	(2,753,824)	(7,952,990)	(2,613,176)	(7,483,323)	(11,054,613)	(32,355,128)	(10,580,670)	(30,658,054)	
Gross profit		1,288,709	3,757,788	1,194,507	3,372,179	3,360,924	8,994,288	2,442,490	7,064,243	
General and administrative expenses Selling expenses Equity pickup Other operating income (expenses), net	20 8 21	(230,847) (19,813) 1,403,292 (57,359)	(838,443) (5,137) 3,238,463 (66,386)	(299,573) (4,191) 695,540 306,721	(838,198) (15,568) 2,056,792 219,813	(532,955) (49,689) 16,301 (46,170)	(1,588,063) (33,830) 28,799 (174,988)	(512,617) (4,159) 19,976 241,562	(1,473,436) (29,879) 34,143 84,355	
Income before finance income (costs) and income and social contribution taxes		2,383,982	6,086,285	1,893,004	4,795,018	2,748,411	7,226,206	2,187,252	5,679,426	
Finance income Finance costs	22 22	630,009 (1,714,295)	2,423,503 (5,434,678)	689,096 (1,398,920)	1,804,135 (3,829,461)	2,694,595 (3,543,986)	8,191,258 (10,974,178)	2,065,367 (2,727,092)	5,537,007 (7,459,338)	
Income before income taxes		1,299,696	3,075,110	1,183,180	2,769,692	1,899,020	4,443,286	1,525,527	3,757,095	
Income taxes	17	174,197	440,864	(37,503)	152,228	(360,893)	(790,620)	(357,217)	(757,759)	
Net income for the period		1,473,893	3,515,974	1,145,677	2,921,920	1,538,127	3,652,666	1,168,310	2,999,336	
Income attributable to controlling interests Income attributable to noncontrolling interests		1,473,893 -	3,515,974 -	1,145,677 -	2,921,920	1,473,893 64,234	3,515,974 136,692	1,145,677 22,633	2,921,920 77,416	
Basic earnings per share (in reais) Diluted earnings per share (in reais)	23 23	0.6679 0.6679	1.5933 1.5933	0.5010 0.5010	1.3032 1.3032	0.6679 0.6679	1.5933 1.5933	0.5010 0.5010	1.3032 1.3032	

Statements of comprehensive income Nine-month periods ended September 30, 2025 and 2024 (In thousands of reais)

		Individ	ual		Consolidated			
	07/01/2025 to 09/30/2025	01/01/2025 to 09/30/2025	07/01/2024 to 09/30/2024	01/01/2024 to 09/30/2024	07/01/2025 to 09/30/2025	01/01/2025 to 09/30/2025	07/01/2024 to 09/30/2024	01/01/2024 to 09/30/2024
Net income for the period	1,473,893	3,515,974	1,145,677	2,921,920	1,538,127	3,652,666	1,168,310	2,999,336
Other comprehensive income Cash flow hedge Gain/loss on insurance and reinsurance liabilities	(14,877) -	(105,469) -	(17,875)	12,819 -	(20,702) 52,081	(130,566) (213,780)	(21,716) (90,765)	1,296 474,051
Unrealized gains/(losses) on financial assets at fair value through OCI Tax effects Gains/(losses) on changes in equity interest Other comprehensive income of associates and	5,059 -	35,859 -	6,078 (7,165)	- (4,358) (8,950)	(41,100) (2,408) 34,417	9,100 122,901 -	16,854 37,374 (8,950)	(17,562) (182,498) (8,950)
subsidiaries, by equity pickup	32,106	(142,735)	(40,833)	272,666	-	(040.045)	7,408	5,840
	22,288	(212,345)	(59,795)	272,177	22,288	(212,345)	(59,795)	272,177
Total comprehensive income	1,496,181	3,303,629	1,085,882	3,194,097	1,560,415	3,440,321	1,108,515	3,271,513
Attributable to: Controlling interests Noncontrolling interests	1,496,181 -	3,303,629 -	1,085,882	3,194,097	1,496,181 64,234	3,303,629 136,692	1,085,882 22,633	3,194,097 77,416

Statements of changes in equity Nine-month periods ended September 30, 2025 and 2024 (In thousands of reais)

							Attr	ibutable to con	trolling interest	s				
	Cap	pital		Capital reserves	3		Income	e reserves	_					
Description Capital	Share issue costs	Premium reserve (issue of shares)	Premium on capital transactions	Share-based payment reserve	Treasury shares	Legal reserve	Investment reserve	Other comprehensiv e income	Future capital contribution	Retained earnings	Total equity	Noncontrolling interests	Total	
Balances at December 31, 2023	15,711,360	(253,031)	6,166,442	(1,251,887)	-	(519,418)	8,666	2,499,758	173,592	4,224	-	22,539,706	1,295,940	23,835,646
Acquisitions of subsidiaries (Note 3) Capital transactions in subsidiaries and acquisition of	-	-	-	-	-	-	-	-	-	-	-	-	7,078	7,078
noncontrolling interests	_	_	_	25,556	_	_	_	_	_	_		25,556	672,062	697.618
Changes - RSU (Note 16)	-		18,913	20,000	(14,198)	7.671	-	-		_		12,386	-	12,386
Share-based payment (Note 16)	-		-	-	14,198		-	-		_		14,198		14,198
Income for the period	-	-	-	-	- 1,100	-	-	-	-	-	2,921,920	2,921,920	77,416	2,999,336
Dividends and interest on equity (Note 16)	-	-	-	-	-	-	-	(1,000,000)	-	-	-	(1,000,000)	(65,263)	(1,065,263)
Reinvested dividends	-	-	-	-	-	-	-	25,066	-	-	-	25,066	• • •	25,066
Share buyback	-	-	-	-	-	(341,739)	-		-	-	-	(341,739)	-	(341,739)
Cash flow hedge (Note 16)	-	-	-	-	-	-	-	-	855	-	-	855	-	855
Equity adjustments	-	-	-	-	-	-	-	-	(13,200)	-	-	(13,200)	-	(13,200)
Net finance income (costs) from insurance and														
reinsurance contracts	-	-	-	-	-	-	-	-	284,522	-	-	284,522	-	284,522
Balances at September 30, 2024	15,711,360	(253,031)	6,185,355	(1,226,331)	-	(853,486)	8,666	1,524,824	445,769	4,224	2,921,920	24,469,270	1,987,233	26,456,503
Balances at December 31, 2024	15,711,360	(253,031)	6,190,053	(1,229,297)	-	(1,458,602)	8,666	4,921,769	807,485	4,224	-	24,702,627	1,999,241	26,701,868
Capital transactions in subsidiaries and acquisition of														
noncontrolling interests	-	-	-	31,775	-	-	-	-	-	-	-	31,775	537,040	568,815
Changes - RSU (Note 16)	-	-	14,427	-	(14,198)	802	-	-	-	-	-	1,031	-	1,031
Share-based payment (Note 16)	-	-	-	-	14,198	-	-	-	-	-	-	14,198	-	14,198
Income for the period	-	-	-	-	-	-	-	-	-	-	3,515,974	3,515,974	136,692	3,652,666
Dividends and interest on equity (Note 16)	-	-	-	-	-	<del>.</del>	-	(1,350,000)	-	-	-	(1,350,000)	(203,032)	(1,553,032)
Share buyback	-	-	-	-	-	(370,933)	-	-	<del>.</del>	-	-	(370,933)	-	(370,933)
Cash flow hedge (Note 16)	-	-	-	-	-	-	-	-	(69,610)	-	-	(69,610)	-	(69,610)
Equity adjustments	-	-	-	-	-	-	-	-	(14,454)	-	-	(14,454)	-	(14,454)
Net finance income (costs) from insurance and reinsurance contracts	-	-	-	-	-	-	-	-	(128,281)	-	-	(128,281)	_	(128,281)
Balances at September 30, 2025	15,711,360	(253.031)	6.204.480	(1.197.522)	_	(1,828,733)	8.666	3.571.769	595.140	4.224	3.515.974	26.332.327	2,469,941	28.802.268

Statements of cash flows Nine-month periods ended September 30, 2025 and 2024 (In thousands of reais)

	Individual		Consolidated		
	01/01/2025 to	01/01/2024 to	01/01/2025 to	01/01/2024 to	
Cash flows from operating activities	09/30/2025	09/30/2024	09/30/2025	09/30/2024	
Income before income and social contribution taxes Adjustments to reconcile income before taxes to cash flows from operating	3,075,110	2,769,692	4,443,286	3,757,095	
activities Depreciation and amortization	717,334	695,348	1,404,681	1,198,839	
Gain on disposal of properties	(2,940)	(2,940)	(2,940)	(2,940)	
Gain on divestiture	(=,0.0)	(354,103)	-	(354,103)	
Fair value of debt	603,463	(903,529)	740,136	(674,119)	
Interest, monetary and FX differences, net	2,620,375	3,208,449	(427,586)	1,221,859	
Share-based payment	68,195	58,430	68,195	58,430	
Provision for/(reversal of) contingencies	(111,342)	(64,869)	249,927	264,786	
Equity pickup	(3,238,463)	(2,056,792)	(28,799)	(34,143)	
Income from insurance service Allowance for expected credit loss	576,884	- 575,538	7,758,911 1,094,642	5,634,914 999,031	
(Increase) decrease in assets and increase (decrease) in liabilities					
Accounts receivable	(1,237,107)	(962,528)	(2,000,065)	(2,020,630)	
Inventories	(30,988)	7,667	10,229	(30,056)	
Taxes recoverable	83,402	(155,968)	(23,336)	(184,977)	
Judicial deposits	(36,555)	(21,875)	253,478	33,261	
Other assets	590,738	400,476	499,554	564,772	
Trade accounts payable	126,499	(178)	267,063	98,793	
Salaries and social charges	175,598	50,482	303,390	144,373	
Tax obligations	(140,742)	125,203	(164,532)	7,284	
Transactions with related parties	(2,201,814)	195,983	193,038	(17,993)	
Provision for contingencies Insurance and reinsurance assets (liabilities)	(49,582)	(11,732)	(704,174) (8,803,259)	(312,717) (2,469,390)	
Other liabilities	176,996	97,257	(318,502)	(2,469,390)	
Otter liabilities	1,765,061	3,650,011	4,813,337	7,653,640	
Payment of interest	(3,095,288)	(2,374,535)	(3,124,891)	(2,367,077)	
Payment of income and social contribution taxes	-	-	(896,199)	(891,323)	
Net cash from (used in) operating activities	(1,330,227)	1,275,476	792,247	4,395,240	
Cash flows from investing activities					
Payment in business acquisition, net of cash acquired	-	-	132	(27,706)	
Cash from merger of subsidiary	(6)	-	-	-	
Receipt upon disposal of equity interest, net of cash Acquisition of equity interest	1,225,931 -	147,719 -	- (1,666)	147,135 -	
Future capital contribution	(683,746)	(1,811,240)	-	-	
Additions to property and equipment	(571,631)	(770,049)	(2,268,589)	(2,034,401)	
Additions to intangible assets	(67,545)	(31,031)	(212,186)	(101,621)	
Acquisitions of marketable securities Redemption of marketable securities	(21,776,889) 21,581,910	(16,521,659) 18,569,145	(86,384,286) 84,526,533	(46,931,946) 48,478,827	
Dividends and interest on equity received	1,973,370	603,261	45,071	14,966	
Net cash flows from (used in) investing activities	1,681,394	186,146	(4,294,991)	(454,746)	
Cash flows from financing activities					
Treasury shares	(390,449)	(341,739)	(390,449)	(341,739)	
Payment of dividends and IOE	(822,278)	(641,063)	(1,025,557)	(712,412)	
Loans, financing and debentures raised	5,985,539	2,000,000	8,115,539	2,518,901	
Payment of loans, financing and debentures	(3,504,901)	(1,863,819)	(3,624,777)	(2,570,631)	
(Settlement) receipt of swap	(380,715)	(376,978)	(551,698)	(541,311)	
Accounts payable for acquisitions	-	- (4.000.755)	(56,124)	(61,455)	
Net cash from (used in) financing activities	887,196	(1,223,599)	2,466,934	(1,708,647)	
(Decrease) increase in cash and cash equivalents	1,238,363	238,023	(1,035,810)	2,231,847	
Cash and cash equivalents at beginning of period	408,911	257,423	6,570,751	3,267,408	
Cash and cash equivalents at end of period	1,647,274	495,446	5,534,941	5,499,255	
•		•	•	•	

Statements of value added Nine-month periods ended September 30, 2025 and 2024 (In thousands of reais, unless otherwise stated)

	Indi	vidual	Cons	olidated
	09/30/2025	09/30/2024	09/30/2025	09/30/2024
Revenue	12,437,959	11,537,169	43,160,287	39,298,521
Sales of goods, products and services	13,011,903	12,109,767	19,903,143	18,482,512
Revenues from insurance operations	-	-	24,260,480	21,738,411
Allowance for expected credit loss	(576,884)	(575,538)	(1,094,642)	(999,031)
Other revenues	2,940	2,940	91,306	76,629
Benefits and claims		-	(14,840,788)	(14,738,678)
Expenses with benefits and redemptions	-	-	(14,840,788)	(14,738,678)
Materials acquired from third parties	(4,224,199)	(3,819,283)	(10,332,556)	(9,038,062)
Costs of sales	(4,109,012)	(3,961,173)	(9,581,357)	(8,598,268)
Materials, power, services from suppliers and other	(226,529)	77,021	(501,272)	(175,008)
Loss on/recovery of assets	111,342	64,869	(249,927)	(264,786)
Gross value added	8,213,760	7,717,886	17,986,943	15,521,781
	(=1=001)	(225.242)	(4.404.004)	(4.400.000)
Depreciation and amortization	(717,334)	(695,348)	(1,404,681)	(1,198,839)
Net value added	7,496,426	7,022,538	16,582,262	14,322,942
Value added received from transfers	5,661,966	3,860,927	5,740,381	3,931,991
Equity pickup	3,238,463	2,056,792	28,799	34,143
Finance income	2,423,503	1,804,135	8,191,258	5,537,007
Finance income (costs) from insurance contracts	-	-	(2,479,676)	(1,639,159)
Total value added	13,158,392	10,883,465	22,322,643	18,254,933
		. 0,000, .00	,,	. 0,20 .,000
Value added distributed	(13,158,392)	(10,883,465)	(22,322,643)	(18,254,933)
Personnel and charges	(3,734,477)	(3,404,109)	(7,096,300)	(6,661,954)
Salaries	(3,326,922)	(2,984,309)	(6,228,867)	(5,791,442)
Benefits	(268,166)	(284,175)	(580,198)	(602,324)
Unemployment Compensation Fund (FGTS)	(139,389)	(135,625)	(287,235)	(268,188)
Taxes, charges and contributions	(267,284)	(524,731)	(2,574,487)	(2,325,165)
Federal taxes	15,563	(255,890)	(1,915,636)	(1,755,663)
State taxes	(191)	-	(38,175)	(17,543)
Local taxes	(282,656)	(268,841)	(620,676)	(551,959)
Debt remuneration	(5,640,657)	(4,032,705)	(8,999,190)	(6,268,478)
Interest	(5,434,678)	(3,829,461)	(8,488,006)	(5,810,411)
Rents	(8,059)	(7,661)	(78,022)	(76,156)
Other	(197,920)	(195,583)	(433,162)	(381,911)
Equity remuneration	(3,515,974)	(2,921,920)	(3,652,666)	(2,999,336)
Interest on equity	(1,350,000)	(1,000,000)	(1,350,000)	(1,000,000)
Dividends	- (0.405.05.0)	-	(203,032)	(65,263)
Retained profits	(2,165,974)	(1,921,920)	(2,165,974)	(1,921,920)
Noncontrolling interests on retained profits	-	-	66,340	(12,153)

Notes to interim financial statements September 30, 2025 (In thousands of reais, unless otherwise stated)

### 1. Operations

Rede D'Or São Luiz S.A. (the "Company" or "Parent Company" and jointly with its subsidiaries "Rede D'Or" or "Group"), headquartered at Rua Francisco Marengo, 1312, in the city and state of São Paulo, is engaged in the rendering of hospital services, offering assistance and hospitality concepts, creating medical and diagnostic excellence centers and generating medical knowledge and experience that ensure security to customers, either doctors, patients or healthcare plans. Through its subsidiaries and associates, the Company operates in the health (health and dental insurance, administrative services only (ASO) health and dental plans, and health and wellness solutions), life insurance, private pension, and asset management segments.

Rede D'Or operates in the states of Rio de Janeiro, São Paulo, Pernambuco, Maranhão, Bahia, Sergipe, Paraná, Ceará, Minas Gerais, Mato Grosso do Sul, Paraíba, Alagoas, Pará and the Federal District, with 76 own hospitals in operation and over 30 projects under development, in addition to oncology and radiotherapy clinics and laboratories. Currently, the Group has 10,443 hospital beds in total.

The first hospital unit, Hospital Barra D'Or, was opened in 1998, and Hospital Copa D'Or and Hospital Quinta D'Or were opened in 2000 and 2001, respectively. Since 2004, strategic partnerships have been made with other hospitals, thus increasing its range of expertise and reaching other areas in Rio de Janeiro. Also through partnerships and acquisitions, Rede D'Or started operations in the state of Pernambuco in 2007; in the states of Maranhão and Bahia in 2018; in the state of Sergipe in 2019; in the states of Paraná and Ceará in 2020; in the states of Minas Gerais, Mato Grosso do Sul and Paraíba in 2021; and in the state of Alagoas in 2022.

In December 2022, the business combination between the Company and Sul América S.A. was completed through the merger of Sul América S.A. into Rede D'Or. As a result of the merger, Sul América S.A. was dissolved and succeeded by Rede D'Or as regards all its assets, rights and obligations, and Rede D'Or became the parent company of Sul América Group ("SASA" or "Sul América" - comprising the subsidiaries, associates and investment funds remaining from the merger of Sul América S.A.). Thus, since December 23, 2022, the shares of Sul América S.A. are no longer traded on B3 and the former shareholders of Sul América S.A. have become shareholders of the Company.

#### Seasonality

There are no significant seasonal effects on the Company's operations; however, a smaller volume of customers and, consequently, of claims in the insurance and health insurance businesses, is generally observed in December, January and February due to year-end celebrations and vacation period, and a larger volume of customers is observed in winter.

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# 2. Accounting policies

This individual and consolidated interim financial information was prepared in accordance with Accounting Pronouncement (CPC) 21 (R1) - Interim Financial Reporting, issued by the Brazilian Financial Accounting Standards Board - FASB ("CPC"), and in accordance with IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), and is presented in accordance with the rules issued by the Brazilian Securities and Exchange Commission ("CVM") applicable to the preparation of Quarterly Information (ITR). The statements of value added are presented as supplementary information for IFRS purposes.

The accounting policies as well as estimates and critical accounting judgments adopted by the Group in this interim financial information are consistent with those adopted in the financial statements for the year ended December 31, 2024, disclosed on March 10, 2025, except for the accounting policy presented below, which was implemented in the quarter ended June 30, 2025:

#### Noncurrent assets held for sale

The Company classifies an asset as a noncurrent asset held for sale if its carrying amount will be recovered principally through a sale transaction rather than through continuing use. These noncurrent assets held for sale are measured at the lower of their carrying amount and fair value less costs to sell. Selling expenses are represented by incremental expenses directly attributable to the sale, excluding finance costs and taxes on profit.

The criteria for held-for-sale noncurrent assets classification are regarded as met when the sale is highly probable and the asset or disposal group is available for immediate sale in its present condition, subject only to the terms that are usual and customary for the sale of such assets. The Company's appropriate management level is committed to the asset sale plan, and a firm program has been initiated to locate a buyer and complete the plan within one year from the date of classification.

Assets and liabilities classified as held for sale are presented separately as current items in the statement of financial position. When a set of assets is characterized as a discontinued operation, the results are presented separately in the statements of profit or loss for the current year and the previous year, as provided for in IFRS 5 (CPC 31) - Noncurrent Assets Held for Sale and Discontinued Operations. A discontinued operation is identified by the Company whenever the component represents a major line of business or geographic area of operations, is an integral part of a coordinated plan for the sale of a separate and/or geographic major line of business, or is a subsidiary acquired for the exclusive purpose of resale.

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

### **2. Accounting policies** (Continued)

Profit or loss for the nine-month period ended September 30, 2025 does not necessarily indicate the P&L expected for the entire year ending December 31, 2025. The interim financial information and related notes do not include all the information and disclosures required for the annual financial statements. As such, this interim financial information must be read together with the audited annual financial statements as of December 31, 2024.

Authorization to complete the preparation of this interim financial information was given by the Company management on November 04, 2025.

The individual and consolidated financial statements include the operations of the Company and of its subsidiaries presented in Note 8. Additionally, it should be stressed that as at September 30, 2025, the Company has investments in funds-of-one that are fully consolidated.

### 3. Atlântica Hospitais transaction

On August 16, 2024, the Company entered into a partnership with Atlântica Hospitais e Participações S.A. ("Atlântica Hospitais") - a company focused on hospital investments, indirectly controlled by Bradseg Participações S.A., which in turn is the parent of Bradesco Seguros Group for the creation of the new hospital network "Atlântica D'Or" (Pacífico Holding Imobiliária Hospitalar S.A. and Pacífico Operações Hospitalares S.A.). The Partnership was established as a corporate association aimed at making investments, constructing, developing, and operating hospitals, with a share of 50.01% for Rede D'Or, which will serve as the hospital operator and controller of the new Atlântica D'Or hospital network, and 49.99% for Atlântica Hospitais. This partnership encompasses all investments and assets, including real estate, related to the hospitals. As of March 31, 2025, the Company completed the contribution of assets and liabilities of Hospital São Luiz Campinas and Campinas Empreendimentos Imobiliários to "Atlântica D'Or". The Company received from Bradesco Seguros the amount of R\$383,393. As of September 30, 2025, the partnership encompasses four hospitals in operation (São Luiz Guarulhos, São Luiz Alphaville, Macaé D'Or and Hospital Campinas) and two other projects under development (located in Taubaté and Ribeirão Preto).

On September 1, 2025, the Company entered into an Investment, Purchase and Sale Agreement and Other Covenants with Atlântica Hospitais, for the purpose of contributing Hospital Glória D'Or, in the city of Rio de Janeiro, to the Atlântica D'Or hospital network. This is a joint venture held 50.01% by Rede D'Or and 49.99% by Atlântica Hospitais. On the closing date of the transaction, Atlântica Hospitais will pay the Company a purchase price of R\$440,879 for the acquisition of the shares representing a 49.99% interest in Hospital Glória D'Or. The consummation of the transaction is subject to the fulfillment of certain conditions precedent customary for transactions of this nature, including the necessary regulatory approvals.

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# 4. Cash and cash equivalents and marketable securities

### 4.1. Cash and cash equivalents

	Indivi	dual	Consol	idated
	09/30/2025	12/31/2024	09/30/2025	12/31/2024
Cash and cash equivalents				
Cash and banks	14,494	14,484	72,350	98,562
Short-term investments	1,632,780	394,427	5,462,591	6,472,189
Cash and cash equivalents	1,647,274	408,911	5,534,941	6,570,751

Financial investments classified as cash equivalents have maturities of less than three months from the date of acquisition and have an insignificant risk of changes in value.

#### 4.2. Marketable securities

Marketable securities are broken down in the table below, which shows their respective classifications, curve value and market value, as well as the contractual average rates:

	Fair value	_	Individual
	through profit or loss		09/30/2025
<b>.</b>	Market value/	Average interest	
Description	carrying amount	rate	Total
Fixed income securities - corporate bonds	9,631,484		9,631,484
Bank deposit certificates Floating rate CDI	9,481,040	101.61% CDI	9,481,040
Financial bills			
Floating rate CDI +	96,517	CDI+0.27% p.a.	96,517
Floating rate CDI %	53,927	105.00% CDI	53,927
Fixed income securities - government securities	522,492		522,492
Financial treasury bills	522,492	SELIC	522,492
Investment fund shares	26		26
Investment fund shares - other than funds-of-one	26	-	26
		_	10,154,002
		Current	10,154,002
		Noncurrent	-

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# 4. Cash and cash equivalents and marketable securities (Continued)

# 4.2. Marketable securities (Continued)

	Fair value	<u>-</u>	Individual
	through profit or loss Market value/	Average interest	12/31/2024
Description	carrying amount	rate	Total
Fixed income securities - corporate bonds Bank deposit certificates	9,164,455		9,164,455
Floating rate CDI Financial bills	9,164,455	103.09% CDI	9,164,455
Floating rate CDI	76,411	103.58% CDI	76,411
Fixed income securities - government			
securities	31,537		31,537
Financial treasury bills	31,537	SELIC	31,537
Investment fund shares	66		66
Investment fund shares – other than funds-of-one	66		66
			9,272,469
		Current =	9,272,469
		Noncurrent	-

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# 4. Cash and cash equivalents and marketable securities (Continued)

# 4.2. Marketable securities (Continued)

	Fair value through						Consolidated
	profit or loss	Fair value through oth	er comprehensive income	Amortized	l cost	_	09/30/2025
•	Market value/	-	Market value/	Curve value/carrying		Average	
Description	carrying amount	Curve value	carrying amount	amount	Market value	interest rate (a)	Total
Fixed income securities - corporate bonds	15,748,203	718,727	709,598	_	_	_	16,457,801
Bank deposit certificates							
Floating rate CDI +	59	-	-	-	-	CDI+1% p.a.	59
Floating rate CDI %	11,773,285	115,422	115,422	-	-	101.65% CDI	11,888,707
Debentures							
Fixed rate	70,676	-	-	-	-	12.98% p.a.	70,676
Floating rate CDI +	1,177,707	195,753	202,057	-	-	CDI+1.60% p.a.	1,379,764
Floating rate CDI %	3,171	624	569	-	-	114.6% CDI	3,740
Floating rate IPCA	586,839	-	-	-	-	IPCA+6.97% p.a.	586,839
Floating rate IGP-M	-	106,755	94,315	-	-	IGPM+5.84% p.a.	94,315
Financial bills						•	
Floating rate CDI +	1,974,995	-	-	-	-	CDI+0.44% p.a.	1,974,995
Floating rate CDI %	110,550	-	-	-	-	109.34% CDI	110,550
Floating rate IPCA	· -	269,689	266,298	-	-	IPCA+7.97% p.a.	266,298
Promissory notes	8,943	30,484	30,937	-	-	CDI+1.54% p.a.	39,880
Mortgage-backed Securities ("CRI")	1,944	<u>-</u>	-	-	-	16.4% p.a.	1,944
Time deposits with special guarantee (DPGE)	40,034	-	-	-	-	CDI+0.55% p.a.	40,034
Fixed income securities - government	40 400 000	0.004.054	0.007.404	0.700.770	0.570.000		40 400 447
securities	12,499,888	2,324,851	2,227,481	3,708,778	3,579,299		18,436,147
Financial treasury bills	11,661,999	123,210	123,257	-	-	SELIC	11,785,256
National treasury bills							
Fixed rate	358,256	-	-	-	-	13.39% p.a.	358,256
National treasury notes						•	
Series F - Fixed rate	331	19,678	18,053	-	-	9.27% p.a.	18,384
Series B – Floating rate IPCA	190,637	1,856,408	1,766,227	71,351	63,185	IPCA+6.53% p.a.	2,028,215
Series C – Floating rate IGP-M	77,864	325,555	319,944	1,740,216	1,618,904	IGPM+5.93% p.a.	2,138,024
Fixed income securities abroad	210,801	· -	· -	1,897,211	1,897,210	13.86% p.a.	2,108,012
Variable income securities	193,837	-	-	· · · · -	· · · -	· -	193,837
Shares	193,922	-	-	-	-	-	193,922
Impairment	(85)	-	-	-	-	-	(85)
Investment fund shares	4,326,852	-	-	-	-	-	4,326,852
Fixed income, equity and multi-market							
investment fund shares	4,300,665	-	-	-	-	-	4,300,665
Equity fund shares	26,187	-	-	-	-	-	26,187
Other investments	8,916	-	-	-	-	-	8,916
	•					_	39,423,553
						Current	37,653,030
						Noncurrent	1,770,523
						HOHOUHEIR	1,770,020

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# 4. Cash and cash equivalents and marketable securities (Continued)

# 4.2. Marketable securities (Continued)

	Fair value through profit or loss		other comprehensive ome	Amortiz	red cost		Consolidated 12/31/2024
	Market value/		Market value/	Curve		Average	
Description	carrying amount	Curve value	carrying amount	value/carrying amount	Market value	interest rate (a)	Total
Fixed income securities - corporate bonds	15,572,131	890,477	888,052	_	_		16,460,183
Bank deposit certificates	,	,	,				, ,
Floating rate CDI %	11,727,235	104,477	104,477	-	-	103.02% CDI	11,831,712
Debentures		•	•				
Floating rate CDI +	1,665,890	286,069	283,636	-	-	CDI+2.07% p.a.	1,949,526
Floating rate CDI %	10,932	15,703	15,145	-	_	125.95% CDI	26,077
Floating rate IPCA	240	-	-	-	-	IPCA+8.49% p.a.	240
Floating rate IGP-M	-	109,259	98,514	-	-	IGPM+5.84% p.a.	98,514
Financial bills			,-				
Floating rate CDI +	1,416,345	266,499	277,109	-	-	CDI+0.85% p.a.	1,693,454
Floating rate CDI %	682,335	77,185	77,400	-	-	108.35% CDI	759,735
Promissory notes	11,803	31,285	31,771	-	-	CDI+1.52% p.a.	43,574
Mortgage-backed Securities ("CRI")	2,805	- , <u>-</u>	- , <u>-</u>	-	_	17.13% p.a.	2,805
Time deposits with special guarantee (DPGE)	54,546	-	_	_	_	CDI+0.55% p.a.	54,546
Fixed income securities - government securities	7,935,249	1,833,904	1.719.803	1,908,808	1,821,597	-	11,563,860
Financial treasury bills	7,603,103	125,410	125,430	-	-,,	SELIC	7,728,533
National treasury bills	,,,,,,,,,	120,110	1=2,122				.,,
Fixed rate	201,123	-	_	_	_	15.94% p.a.	201,123
National treasury notes							
Series F - Fixed rate	311	33,869	30,841	_	_	8.86% p.a.	31,152
Series B – Floating rate IPCA	46,004	1,305,836	1,215,466	69,829	60,396	IPCA+5.44% p.a.	1,331,299
Series C – Floating rate IGP-M	84,708	368,789	348,066	1,838,979	1,761,201	IGPM+5.81% p.a.	2,271,753
Variable income securities	159,937	-		.,000,010	.,. 0.,20.		159,937
Shares	159,997	_	_	-	_	_	159,997
Impairment	(60)	_	_	_	_	_	(60)
Investment fund shares	5,730,397	_	_				5,730,397
Fixed income, equity and multi-market investment fund shares	5,710,028	_	_	_	_		5,710,028
Equity fund shares	20,369	_	_	_	_	_	20,369
Other investments	4,406	_	_				4,406
	4,400					•	33,918,783
						Current	32,067,003
						Noncurrent	1,851,780
						Noncurrent	1,001,700

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

### 5. Accounts receivable

		Indiv	ridual	Consolidated			
Description	Note	09/30/2025	12/31/2024	09/30/2025	12/31/2024		
Accounts receivable - hospital services	5.1	5,578,603	4,934,013	8,812,654	8,192,585		
Other accounts receivable	5.2	<del></del>	<del>-</del>	3,098,005	3,005,041		
	=	5,578,603	4,934,013	11,910,659	11,197,626		
Current		5,578,603	4,934,013	10,185,064	9,463,784		
Noncurrent		-	-	1,725,595	1,733,842		

### 5.1. Hospital services

Trade accounts receivable comprise receivables from healthcare companies and individuals, as follows:

	Indiv	/idual	Consc	olidated
	09/30/2025	12/31/2024	09/30/2025	12/31/2024
Accounts receivable from health insurance and health plans (a)	6,587,954	5.930.188	10,385,952	9,833,191
Accounts receivable from individuals Allowance for expected credit losses and	115,330	118,795	213,645	232,795
provision for disallowances	(1,124,681)	(1,114,970)	(1,786,943)	(1,873,401)
·	5,578,603	4,934,013	8,812,654	8,192,585

<sup>(</sup>a) Transfer from the net balance of accounts receivable to assets held for sale of in the amount of R\$240,491. Further details are presented in Note 26.

#### Changes in provision for disallowances and allowance for expected credit losses

	Indiv	/idual	Consc	olidated
	09/30/2025	09/30/2024	09/30/2025	09/30/2024
Balance at beginning of period	(1,114,970)	(946,225)	(1,873,401)	(1,647,717)
(Set up)/Reversal of provision for disallowances and allowance for expected credit losses Write-offs (a)	(576,884) 550,640	(575,538) -	(1,072,512) 1,105,628	(989,262) 278,584
Provision arising from the transfer of assets from Hospital Campinas	16,533	-	-	-
Transfer to available-for-sale assets Balance at end of period	(1,124,681)	(1,521,763)	53,342 (1,786,943)	(2,358,395)

<sup>(</sup>a) This includes the derecognition of uncollectible amounts and elimination of the provision for disallowances of the Group companies.

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

#### 5. Accounts receivable

### **5.1.** Hospital services (Continued)

<u>Changes in provision for disallowances and allowance for expected credit losses</u> (Continued)

At September 30, 2025 and December 31, 2024, the aging list of trade accounts receivable is as follows:

					Individual				
	,	_				Overdue			
			1 -	31 -	61 -	91 -	121 -	181 -	360 -
	Total	Falling due	30 days	60 days	90 days	120 days	180 days	360 days	720 days
09/30/2025	6,703,284	4,419,500	168,443	145,421	148,638	209,291	286,774	466,754	858,463
12/31/2024	6,048,983	3,757,285	142,631	204,249	118,674	186,389	226,633	622,224	790,898
				С	onsolidated				
						Overdue			
			1 -	31 -	61 -	91 -	121 -	181 -	360 -
	Total	Falling due	30 days	60 days	90 days	120 days	180 days	360 days	720 days

6,258,785 270,856 410,531 09/30/2025 10,599,597 578,064 274,879 259,477 868.596 1.678.409 12/31/2024 10,065,986 5,569,426 270,776 446,173 1,243,045 380,060 360,568 250,452 1.545.486 The Company's revenues arise from the provision of hospital services, including the use of

medicines and hospital materials. Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, i.e. upon rendering of medical services at an amount that reflects the consideration to which an entity expects to be entitled in exchange for providing services to a customer.

#### Changes in provision for disallowances and allowance for expected credit losses

The provision for disallowances and allowance for expected credit losses is presented reducing the balance of accounts receivable and recognized at an amount deemed sufficient by management to cover any expected losses on the realization of amounts billed.

The Company's criterion to recognize a provision for disallowances is to annually analyze the performance of notes overdue between 360 to 720 days, a period deemed sufficient for exhausting the collection process. The percentage reached is applied to the gross revenue recorded and recognized as a provision in current profit or loss, reflecting management's best expectation based on the analyzed history. The analysis is made individually by cash-generating unit, as well as the percentage recorded as a provision for disallowances in the year.

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

### 5. Accounts receivable (Continued)

#### **5.1.** Hospital services (Continued)

<u>Changes in provision for disallowances and allowance for expected credit losses</u> (Continued)

As a criterion for the recognition of an allowance for expected credit losses, an individual analysis of receivables is performed to identify specific counterparty risks. If necessary, an allowance for expected credit losses is recorded for the partial or total balance of receivables outstanding of these customers.

#### 5.2. Other accounts receivable

The receivables as at September 30, 2025 and December 31, 2024 presented in the consolidated financial statements are as follows:

		Consc	olidated
Description	Note	09/30/2025	12/31/2024
Other operating receivables	5.2.1	1,982,103	2,092,780
Consideration receivable - ASO health plans	5.2.2	908,229	786,391
Other (a)		207,673	125,870
		3,098,005	3,005,041
Current		1,372,410	1,271,199
Noncurrent		1,725,595	1,733,842

<sup>(</sup>a) This balance is represented mainly by receivables related to securities obligations and receivables not directly related to insurance operations, in subsidiaries that operate in this industry.

#### 5.2.1. Other operating receivables

	Consolidated			
	09/30/2025	12/31/2024		
Receivables from FCVS - SFH				
Principal (Note 5.2.1.1)	1,973,177	2,028,967		
Impairment (Note 5.2.1.1)	(221,281)	(227,873)		
Frozen funds (a)	103,690	80,601		
Other (b)	126,517	211,085		
Total	1,982,103	2,092,780		
Current	260,412	363,323		
Noncurrent	1,721,691	1,729,457		

<sup>(</sup>a) These refer to funds frozen in bank accounts and investment funds related to lawsuits.

<sup>(</sup>b) This balance is mainly represented by advances to suppliers.

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# **5. Accounts receivable** (Continued)

### **5.2. Other accounts receivable** (Continued)

### 5.2.1. Other operating receivables (Continued)

### 5.2.1.1. Receivables from FCVS - SFH

	Consolidated
Description	09/30/2025
Balance of receivables FCVS-SFH at 12/31/2024	2,028,967
Additions	168,894
Write-offs	(224,684)
Balance of receivables FCVS-SFH at 09/30/2025	1,973,177
Balance of impairment at 09/30/2025	(221,281)
Closing balance net of impairment at 09/30/2025	1,751,896
Current	123,680
Noncurrent	1,628,216
	0
<b>.</b>	Consolidated
Description	Consolidated 12/31/2024
•	12/31/2024
Balance of receivables FCVS-SFH at 12/31/2023	<b>12/31/2024</b> 1,963,933
Balance of receivables FCVS-SFH at 12/31/2023 Additions	1,963,933 212,433
Balance of receivables FCVS-SFH at 12/31/2023 Additions Write-offs	1,963,933 212,433 (147,399)
Balance of receivables FCVS-SFH at 12/31/2023 Additions Write-offs Balance of receivables FCVS-SFH at 12/31/2024	1,963,933 212,433 (147,399) 2,028,967
Balance of receivables FCVS-SFH at 12/31/2023 Additions Write-offs Balance of receivables FCVS-SFH at 12/31/2024 Balance of impairment at 12/31/2024	12/31/2024 1,963,933 212,433 (147,399) 2,028,967 (227,873)
Balance of receivables FCVS-SFH at 12/31/2023 Additions Write-offs Balance of receivables FCVS-SFH at 12/31/2024	1,963,933 212,433 (147,399) 2,028,967
Balance of receivables FCVS-SFH at 12/31/2023 Additions Write-offs Balance of receivables FCVS-SFH at 12/31/2024 Balance of impairment at 12/31/2024 Closing balance net of impairment at 12/31/2024	12/31/2024 1,963,933 212,433 (147,399) 2,028,967 (227,873) 1,801,094
Balance of receivables FCVS-SFH at 12/31/2023 Additions Write-offs Balance of receivables FCVS-SFH at 12/31/2024 Balance of impairment at 12/31/2024	12/31/2024 1,963,933 212,433 (147,399) 2,028,967 (227,873)

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

#### **5. Accounts receivable** (Continued)

#### **5.2.** Other accounts receivable (Continued)

#### 5.2.1. Other operating receivables (Continued)

#### 5.2.1.1. Receivables from FCVS - SFH (Continued)

As at September 30, 2025, there are lawsuits in progress related to the Housing Financial System (SH/SFH) in progress in which the Company has been summoned. Such lawsuits may give rise to future cash disbursement with the corresponding request for reimbursement to Caixa Econômica Federal (CAIXA), manager of the Wage Variation Compensation Fund (FCVS). In the cases in which the lawsuit is in the provisional enforcement phase to avoid early disbursement in cases for which decisions are not final and unappealable, the Company pledges in court surety bond policies. As at September 30, 2025, the total amount guaranteed through surety bond is R\$1,103,511 (R\$1,133,941 at 12/31/2024). The SH/SFH was created by article 14 of Law No. 4380/1964 and since 1967 has been guaranteed by the FCVS. Insurance companies have lawsuits filed against them because they are mischaracterized as representatives of the FCVS, which is the role of CAIXA, the manager of that Fund. In view of this role of FCVS representative in lawsuits, the insurance companies, which are the illegitimate parties, are entitled to receive reimbursements for all incurred expenditures. Law No. 12409/2011, amended by Law No. 13000/2014, as well as the CCFCVS Resolution No. 364 of March 28, 2014, expressly establish the responsibility of FCVS, through its manager CAIXA, for all lawsuits relating to the SH/SFH's public policy. In September 2018, the Federal Supreme Court (STF) recognized the general repercussion of the appeal to the Supreme Court filed by the Company to analyze the jurisdiction of the Federal Court in lawsuits of this nature. In June 2020, the merits of that appeal were judged and accepted to consolidate the interest of CAIXA, the FCVS administrator, in the SH/SFH-related lawsuits, and, consequently, establish the Federal Court's jurisdiction for processing and judging lawsuits of this nature. That appeal became final and unappealable on June 17, 2023. Currently, insurance companies are reimbursed by the FCVS for payments made in connection with SH/SFH-related lawsuits, based on the criteria established by CCFCVCS Resolution No. 448/2019 and restated by reference to the variation of the Referential Rate ("TR") between the date of payment of each expense and the date of effective reimbursement.

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

### **5.** Accounts receivable (Continued)

### **5.2. Other accounts receivable** (Continued)

### 5.2.2. Consideration receivable - ASO health plans

Administrative service only (ASO) health plans are plans in which the Company administers medical and hospital expenses on behalf of its customers, and is fully reimbursed by the customers, recording only its administration fee as revenue. The amounts related to consideration receivable by maturity are as follows:

	Consolidated				
	09/30/2025	12/31/2024			
Falling due	•				
Falling due from 1 to 30 days	813,621	703,766			
Falling due from 31 to 60 days	47,338	24,182			
Falling due from 61 to 180 days	14,893	12,400			
Total falling due	875,852	740,348			
Overdue	'				
Overdue from 1 to 30 days	31,931	44,947			
Overdue from 31 to 60 days	383	664			
Overdue from 61 to 180 days	641	730			
Overdue from 181 to 365 days	486	4			
Overdue for more than 365 days	3,021	3,000			
Total	36,462	49,345			
Provision for impairment	(4,085)	(3,302)			
Total overdue	32,377	46,043			
Total unearned premiums	912,314	789,693			
Total provision for impairment	(4,085)	(3,302)			
Total	908,229	786,391			

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

#### 6. Inventories

	Indiv	idual	Conso	lidated
	09/30/2025	12/31/2024	09/30/2025	12/31/2024
Medicines	134,736	138,042	305,143	328,274
Special materials	115,144	105,129	255,980	184,263
Disposable materials	105,201	95,787	251,377	172,967
Consumables	32,220	24,302	90,168	80,686
Laboratory materials	9,003	8,380	37,591	30,777
Surgical sutures	6,994	7,427	14,381	14,226
Dressing room materials	4,028	3,725	13,822	11,609
Food stuff	6,258	4,832	11,375	11,133
Other	36,768	42,632	83,484	78,942
	450,352	430,256	1,063,321	912,877

### 7. Transactions with related parties

Significant related-party transactions

The nature of significant related-party transactions is summarized below:

- (i) Leases the Company leases properties owned by the controlling shareholders, namely: properties of the hospitals Copa D'Or and Quinta D'Or, and the property of the administrative unit. Leases are at market value and generated an expense in profit or loss for the period ended September 30, 2025 of R\$21,845 (R\$23,141 at September 30, 2024) referring to interest and amortization of the right of use. Leases are annually restated by reference to the Extended Consumer Price Index (IPCA).
- (ii) Transfers of funds between companies to enhance the operations of certain investees and provide funds for expansion and/or acquisitions, management transfers funds between Group companies under current account remittance agreements entered into between the parties. These balances are substantially eliminated in the consolidated financial statements.
- (iii) Shared services these are centralized services rendered by the parent company, Rede D'Or, such as legal assistance, marketing, accounting, treasury, accounts payable and accounts receivable, which are shared among the other entities of the Group based on apportionment criteria that take into consideration the contribution of each entity to the consolidated gross revenue.
- (iv) *Debentures* certain subsidiaries issued nonconvertible debentures, which were acquired by the parent company. These debentures are intended to provide funds to the investees for investment in operations and expansion.
- (v) Book-entry trade notes certain subsidiaries carried out a private placement of book-entry nonconvertible commercial notes, in specific cases, convertible into shares, with all of these commercial notes being acquired by the parent company. These trade notes are intended to provide funds to the investees for investment in operations and expansion.

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

### 7. Transactions with related parties (Continued)

Significant related-party transactions (Continued)

(vi) Revenues and accounts receivable partially arise from commercial transactions conducted in the ordinary course of business relating to medical care provided to members of Sul América plans. These transactions have reference tables by type of service provided by the Company with Sul América and the maturities of these services are stipulated in a contract entered into between the parties.

In addition to the balances presented in the tables below, the Parent Company and subsidiary Rede D'Or Finance carried out three debenture issue and purchase transactions: i) on January 17, 2018, subsidiary Rede D'Or Finance issued senior notes totaling US\$500,000 thousand, and at the same time, the Parent Company issued debentures (10<sup>th</sup> issue), which were partially acquired by other investors and by subsidiary Rede D'Or Finance (Note 13); and ii) on January 22, 2020, subsidiary Rede D'Or Finance carried out the second issue of senior notes, in the total amount of US\$850,000 thousand. On February 13, 2020, Rede D'Or Finance reopened the second issue of senior notes and issued an additional US\$350 thousand in notes with the same characteristics as the initial issue. In addition, on April 17, 2020, the Parent Company issued debentures (17<sup>th</sup> issue – 1<sup>st</sup> series), which were acquired by subsidiary Rede D'Or Finance; and iii) on September 9, 2025, the subsidiary Rede D'Or Finance carried out its third issue of senior notes, for a total amount of US\$500 thousand. In addition, on September 30, 2025, the Parent Company issued debentures (37<sup>th</sup> issue), which were acquired by subsidiary Rede D'Or Finance. The respective debentures were issued through private placement efforts abroad, in compliance with applicable law.

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# 7. Transactions with related parties (Continued)

### Balances with related parties

					Individua	İ			
		09/30	)/2025				09/30/2024		
Company	Current assets	Noncurren assets	tNoncurrent liabilities	P&L	Current assets	Noncurren assets	tNoncurrent liabilities	P&L	P&L
Debentures Norte D'Or (j)	25,389	-	-	3,515	44,561	-	-	7,885	6,315
Debentures São Lucas (I)	399,000	-	-	31,922	-	-	-	2,217	2,217
Debentures Hospital Nossa Senhora das Neves (d)	364,305	-	-	42,227	335,528	-	-	49,827	37,504
Debentures Biocor (f)	90,466	-	-	10,016	62,450	-	-	5,649	3,865
Debentures São Carlos (k)	125,734	-	-	12,029	-	-	-	-	-
Debentures Proncor (m) Debentures Acreditar (n)	179,385 196,076	-	-	15,607 15,076	-	-	-	-	-
Debentures Onco Dor (o)	254,573	-	-	19,573	-	-	-	-	-
Debentures Clinp (q)	4,729	-	-	129	-	-	_	-	-
Debentures Clinivac (r)	2.570	_	_	70			_		
Debentures Oncologistas (s)	9.535	370.000	-	9.535			_		
Debentures São Rafael (t)	6,763		_	6,763	_	_	_	_	_
Book-entry trade notes Onco Star SP (g)	0,700	1,463,867	_	141.725	_	1,205,473	_	122.929	88.659
Book-entry trade notes Mediax (h)	6,008	1,400,007	_	721	5,287	1,200,470	_	632	444
Book-entry trade notes Cehon (p)	82,113	_	_	6.313	0,207	_	_	-	
Shared services	02,110			0,010					
Medise Medicina Diagnóstico e Serviços Ltda.	_	_	_	11,564	_	_	_	12,288	8,266
Hospital Esperança S.A.	_	_	_	37,751	-	_	_	42.404	27,500
Hospital São Marcos S.A.	_	_	_	6,419	-	_	_	6.259	4.614
Hospital Norte D'Or de Cascadura S.A.	_	2.866	_	10.062	-	3.020	_	11.854	8.404
J. Badim S.A.	_	25,579	_	2,711	-	22,868	_	4,225	3,575
Oncologia D'Or S.A.	_	9,727	_	72,609	-	13,479	_	85.267	58.053
Hospital Fluminense S.A.	_		_	16,064	-		_	18,006	12,980
Clínica São Vicente	-	-	-	14,769	-	-	-	16,356	11,367
Hospital Alpha-Med LTDA.	-	-	-	3,865	-	-	-	4,522	2,821
Hospital UDI	-	-	-	15,155	-	-	-	17,938	11,540
Onco Star SP	-	4,921	-	26,854	-	3,834	-	16,698	13,515
DF Star	-	· -	-	20,494	-	· -	-	24,613	13,922
Samer	-	-	-	6,887	-	-	-	7,832	5,068
São Lucas	-	1,745	-	14,965	-	5,449	-	16,497	10,594
São Rafael	-	4,280	-	35,776	-	11,114	-	42,877	29,635
Hospital Santa Cruz	-	-	-	12,451	-	-	-	14,356	9,591
Hospital Aliança	-	-	-	22,146	-	-	-	21,636	16,876
São Carlos	-	960	-	7,977	-	2,112	-	8,803	6,255
Glória D'Or	-	-	-	12,917	-	-	-	13,205	8,559
Cárdio Pulmonar	-	-	-	15,796	-	-	-	18,747	13,035
Hospital Brasil Mauá	-	-	-	12,585	-	-	-	13,463	9,408
Hospital Balbino	-	-	-	2,615	-	-	-	3,144	2,081
Biocor Hospital de Doenças Cardiovasculares	-	555	-	9,029	-	1,315	-	10,489	7,512
Proncor Unidade Intensiva Cardiorespiratória	-	434	-	3,725	-	1,445	-	4,368	2,797
Hospital Nossa Senhora das Neves	-	1,380	-	11,295	-	2,964	-	12,279	8,784
Hospital Novo Atibaia	-	-	-	9,208	-	-	-	12,470	8,971
Hospital Memorial Arthur Ramos	-	<del>-</del>	-	8,314	-		-	11,797	8,242
Hospital Alphaville	-	8,068	-	7,056	-	1,012	-	1,012	-
Hospital Macaé	-	6,213	-	5,995	-	219	-	219	-
Hospital Guarulhos	-	10,545	-	9,200	-	1,345	-	1,345	-
Hospital Campinas	-	9,595	-	9,595	-		-	-	-
Other	-	4,855	-	49,017	-	1,741	-	61,381	36,292
Unidade de Radiologia Clínica Ltda. (a)	-	8,239	-	-	-	14,742	-	-	-
Jenner S.A. (a)	-	2,000	-	-	-	2,000	-	-	-
JMJB Diagnósticos e Serviços Hospitalares S.A. (a)	-	10,609	-	-	-	12,021	-	-	-
J. Badim S.A. (a)	-	7,222	-		-	7,195	-	-	- 00.070
JM&AM Empreendimentos Imobiliários S.A. (b)	-	370	-	21,783	-	370	-	30,293	23,073
Onco Star SP (c)	-	262 004	-	-	-	29,598	-	-	-
Rede D'Or Finance	-	263,891	-	400	-	263,891	-	-	-
Other	4 740 040	93,677		129	447.000	198,857	-	755 700	-
	1,740,046	2,581,598	-	841,999	447,826	1,806,064	-	755,782	522,334

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

### 7. Transactions with related parties (Continued)

Balances with related parties (Continued)

						Consolidate	ed				
	09/30/2025						12/31/2024				09/30/2024
Company	Current assets	Noncurrent assets	Current liabilities	Noncurren t liabilities	P&L	Current assets	Noncurren t assets		Noncurren t liabilities	P&L	P&L
Debentures Mederi (e)	_	-	-	-	_	190,917	-	_	-	25,566	19,104
Debentures Biocor (f)	-	-	16,114	-	(1,883)		-	12,231	-	(331)	68
Book-entry trade notes Cenon (i)	584	-	-	-	150	1,234	-	-	-	204	138
Shared services											
J Badim S.A.	-	25,579	-	-	2,711	-	22,868	-	-	4,225	3,575
New Surgical Materiais Cirúrgicos (a) JMJB Diagnósticos e Serviços	-	23,361	-	-	· -	-	· -	-	-	-	, <u>-</u>
Hospitalares S.A. (a)	-	10,609	-	-	-	-	12,021	-	-	-	-
J Badim S.A. (a) JM&AM Empreendimentos Imobiliários	-	8,129	-	-	-	-	7,832	-	-	-	-
S.A. (b)	-	370	-	-	21,845	-	370	-	-	30,383	23,141
Other	_	23,770	-	4,677	-	-	18,912	-	3,769	-	-
	584	91,818	16,114	4,677	22,823	192,151	62,003	12,231	3,769	60,047	46,026

- (a) Transfers of funds for acquisition of companies, properties, expansion of operations, among others. These balances are substantially eliminated in the consolidated financial statements
- (b) Lease of properties owned by the controlling shareholders of Rede D'Or.
- (c) Onco Star SP: Rede D'Or provided funds for the acquisition of machinery and equipment as part of the operational routine.
- (d) On December 17, 2021, Hospital Nossa Senhora das Neves conducted a private issue of nonconvertible, single-series, registered debentures in the amount of R\$185,000, initially maturing on December 18, 2023, however this term was extended to December 18, 2025. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 2.9% p.a. until 12/18/2023 and 4.00% p.a. from 12/18/2023. Interest and the nominal value will be paid on the maturity date. There are no guarantees for the debentures.

On March 15, 2023, Hospital Nossa Senhora das Neves conducted the second private issue of nonconvertible, single-series, registered debentures in the amount of R\$158,200, initially maturing on March 15, 2025, however this term was extended to March 15, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 2.9% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.

On December 18, 2023, Hospital Nossa Senhora das Neves conducted the third private issue of nonconvertible, single-series, registered debentures in the amount of R\$16,900, which would mature on December 18, 2024, but this term was extended to December 18, 2025. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. and 2.90% p.a. from 03/17/2025. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.

On January 2, 2024, Hospital Nossa Senhora das Neves conducted the fourth private issue of nonconvertible, single-series, registered debentures in the amount of R\$16,900, initially maturing on January 2, 2025, however this term was extended to January 2, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. and 2.90% p.a. from 03/17/2025. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.

On February 6, 2025, Hospital Nossa Senhora das Neves conducted the sixth private issue of nonconvertible, single-series, registered debentures in the amount of R\$26,978, maturing on February 6, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.

On March 31, 2025, Hospital Nossa Senhora das Neves conducted the seventh private issue of nonconvertible, single-series, registered debentures in the amount of R\$10,000, maturing on March 31, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

### 7. Transactions with related parties (Continued)

#### Balances with related parties (Continued)

(e) On March 15, 2023, Mederi Distribuição e Importação de Produtos para Saúde S.A. conducted the third private issue of nonconvertible, single-series, registered debentures in the amount of R\$158,200, initially maturing on March 15, 2025, however this term was extended to March 15, 2026. The debentures may be fully or partially subscribed until the maturity date by Hospital Nossa Senhora das Neves. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 2.9% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.

On December 18, 2023, Mederi Distribuição e Importação de Produtos para Saúde S.A. conducted the fourth private issue of nonconvertible, single-series, registered debentures in the amount of R\$16,900, which would mature on December 18, 2024, but this term was extended to December 18, 2025. The debentures may be fully or partially subscribed until the maturity date by Hospital Nossa Senhora das Neves. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. and 2.90% p.a. from 03/17/2025. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.

On January 2, 2024, Mederi Distribuição e Importação de Produtos para Saúde S.A. conducted the fifth private issue of nonconvertible, single-series, registered debentures in the amount of R\$16,500, initially maturing on January 2, 2025, however this term was extended to January 2, 2026. The debentures may be fully or partially subscribed until the maturity date by Hospital Nossa Senhora das Neves S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. and 2.90% p.a. from 03/17/2025. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.

In the second quarter of 2025, Rede D'Or began consolidating Mederi Distribuição e Importação de Produtos para Saúde S.A. into its financial statements.

(f) On December 19, 2023, Biocor Hospital de Doenças Cardiovasculares S.A. conducted the first private issue of nonconvertible, single-series, registered debentures in the amount of R\$33,691, which would mature on December 19, 2024, but this term was extended to December 19, 2025. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.0% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.

On August 26, 2024, Biocor Hospital de Doenças Cardiovasculares S.A. conducted the second private issue of nonconvertible, single-series, registered debentures amounting to R\$10,000, maturing on August 30, 2025, however this term was extended to August 30, 2026. The debentures may be fully or partially subscribed until the maturity date, up to the limit of R\$5,100 by Rede D'Or São Luiz S.A. and R\$4,900 by Biocor Indústria e Pesquisa Ltda. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.0% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.

On November 14, 2024, Biocor Hospital de Doenças Cardiovasculares S.A. conducted the third private issue of nonconvertible, single-series, registered debentures in the amount of R\$15,000, maturing on November 14, 2025. The debentures may be fully or partially subscribed until the maturity date by up to R\$11,000 by Rede D'Or São Luiz S.A. and R\$4,000 by Biocor Indústria e Pesquisa Ltda. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.

On December 23, 2024, Biocor Hospital de Doenças Cardiovasculares S.A. conducted the fourth private issue of nonconvertible, single-series, registered debentures in the amount of R\$15,000, maturing on December 23, 2025. The debentures may be fully or partially subscribed until the maturity date by up to R\$12,000 by Rede D'Or São Luiz S.A. and R\$3,000 by Biocor Indústria e Pesquisa Ltda. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.

On February 26, 2025, Biocor Hospital de Doenças Cardiovasculares S.A. conducted the fifth private issue of nonconvertible, single-series, registered debentures amounting to R\$10,000, maturing on February 26, 2026. The debentures may be fully or partially subscribed until the maturity date, up to the limit of R\$8,000 by Rede D'Or São Luiz S.A. and R\$2,000 by Biocor Indústria e Pesquisa Ltda. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.

On May 28, 2025, Biocor Hospital de Doenças Cardiovasculares S.A. conducted the sixth private issue of nonconvertible, single-series, registered debentures amounting to R\$10,000, maturing on May 28, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rate asis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.

(g) On December 29, 2023, Onco Star SP Oncologia Ltda. carried out a private placement of single-series, book-entry convertible trade notes, without security interest or collateral security system, of first issue, in the amount of R\$1,082,544, maturing on December 29, 2030. The trade notes may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz. Trade notes not subscribed after this period will be automatically canceled. The trade notes earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 1.0% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees.

On December 29, 2024, Onco Star SP Oncologia Ltda. carried out a private placement of single-series, book-entry convertible trade notes, without security interest or collateral security system, of second issue, in the amount of R\$150,000, maturing on December 29, 2030. The trade notes may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz. Trade notes not subscribed after this period will be automatically canceled. The trade notes earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 1.0% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees.

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

### 7. Transactions with related parties (Continued)

### Balances with related parties (Continued)

- (h) On February 6, 2024, Memorial Imagem e Diagnóstico Ltda. (Mediax) carried out a private placement of single-series, book-entry convertible trade notes, without security interest or collateral security system, of first issue, in the amount of R\$4,655, initially maturing on February 6, 2025, however this term was extended to August 6, 2026. The trade notes may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz. Trade notes not subscribed after this period will be automatically canceled. The trade notes earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.0% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees.
- (i) On May 22, 2024, Instituto de Radioterapia do Vale do Paraíba Ltda. (CENON) carried out a private placement of single-series, book-entry nonconvertible trade notes, without security interest or collateral security system, of first issue, in the amount of R\$2,525, initially maturing on May 22, 2025, however this term was extended to May 22, 2026. The trade notes may be fully or partially subscribed until the maturity date by Centro Oncológico Do Vale Ltda. (IOV). Trade notes not subscribed after this period will be automatically canceled. The trade notes earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.0% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no quarantees.
- (j) On February 6, 2025, Hospital Norte D'Or conducted the seventh private issue of nonconvertible, single-series, registered debentures in the amount of R\$17,343, maturing on February 6, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. until April 10, 2025 and 10.03% p.a. from April 10, 2025. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
  - On April 30, 2025, Norte D'Or conducted the eighth private issue of nonconvertible, single-series, registered debentures in the amount of R\$5,430, initially maturing on October 30, 2025, however this term was extended to April 30, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 10.03% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
- (k) On January 15, 2025, São Lucas conducted the fifth private issue of nonconvertible, single-series, registered debentures amounting to R\$20,000, maturing on January 15, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
  - On February 06, 2025, São Carlos conducted the sixth private issue of nonconvertible, single-series, registered debentures amounting to R\$60,843, maturing on February 6, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
  - On May 20, 2025, São Carlos conducted the seventh private issue of nonconvertible, single-series, registered debentures amounting to R\$32,862, maturing on May 20, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
- (I) On February 6, 2025, São Lucas conducted the sixth private issue of nonconvertible, single-series, registered debentures amounting to R\$137,499, maturing on February 6, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
  - On March 27, 2025, São Lucas conducted the seventh private issue of nonconvertible, single-series, registered debentures amounting to R\$15,000, maturing on March 27, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
  - On May 13, 2025, São Lucas conducted the eighth private issue of nonconvertible, single-series, registered debentures amounting to R\$52,176, maturing on May 13, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the ODI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
  - On May 20, 2025, São Lucas conducted the ninth private issue of nonconvertible, single-series, registered debentures amounting to R\$142,403, maturing on May 20, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
  - On July 20, 2025, São Lucas conducted the tenth private issue of nonconvertible, single-series, registered debentures amounting to R\$20,000, maturing on July 20, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

### 7. Transactions with related parties (Continued)

### Balances with related parties (Continued)

(m) On February 6, 2025, Proncor conducted the ninth private issue of nonconvertible, single-series, registered debentures amounting to R\$106,988, maturing on February 6, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no quarantees for the debentures.

On March 28, 2025, Proncor conducted the tenth private issue of nonconvertible, single-series, registered debentures amounting to R\$5,000, maturing on March 28, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.

On May 13, 2025, Proncor conducted the eleventh private issue of nonconvertible, single-series, registered debentures amounting to R\$22,690, maturing on May 13, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no quarantees for the debentures.

On July 24, 2025, Proncor conducted the twelfth private issue of nonconvertible, single-series, registered debentures amounting to R\$366,600, maturing on July 24, 2026. Up to September 30, 2025, debentures were subscribed in the total amount of R\$29,100. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no quarantees for the debentures.

- (n) On April 17, 2025, Acreditar conducted the first private issue of nonconvertible, single-series, registered debentures amounting to R\$181,000, maturing on April 17, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
- (o) On April 17, 2025, Onco Dor Oncologia conducted the first private issue of nonconvertible, single-series, registered debentures amounting to R\$235,000, maturing on April 17, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
- (p) On April 17, 2025, Onco Dor BA Oncologia Ltda. (Cehon) carried out a private placement of book-entry nonconvertible trade notes, without security interest or collateral security system, in a single series, of second issue, in the amount of R\$75,800, maturing on April 17, 2026. The trade notes may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz. Trade notes not subscribed after this period will be automatically canceled. The trade notes earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.0% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees.
- (q) On August 06, 2025, CLINP Clínica Pediátrica S.A. conducted the second private issue of nonconvertible, single-series, registered debentures amounting to R\$4,600, maturing on August 10, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
- (r) On August 06, 2025, CLINIVAC Clínica Pediátrica S.A. conducted the second private issue of nonconvertible, single-series, registered debentures amounting to R\$2,500, maturing on August 10, 2026. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
- (s) On August 10, 2025, Oncologia Rede D'Or S.A. conducted the first private issue of nonconvertible, single-series, registered debentures amounting to R\$370,000, maturing on August 10, 2030. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.
- (t) On August 10, 2025, São Rafael conducted the first private issue of nonconvertible, single-series, registered debentures amounting to R\$270,000, maturing on August 10, 2030. The debentures any be fully or partially subscribed until the maturity date by Rede D'Or São Luiz. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 1.75% p.a. Interest and the nominal value will be paid on the maturity date, plus yield. There are no guarantees for the debentures.

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# 7. Transactions with related parties (Continued)

### Key management personnel compensation

The Company considers "Key management personnel" only the members of its Statutory Board and Board of Directors. At September 30, 2025 and 2024, key management personnel compensation is summarized as follows:

	09/30/2025	09/30/2024
Salaries and bonuses	99,329	106,933
Benefits	291	135
Share-based payment	16,689	29,289
	116,309	136,357

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

### 8. Investments

### Breakdown of and changes in investments - Individual

Company	12/31/2024	Equity pickup	Dividends	Capital increase/ Future capital contribution	Capital reduction /return of future capital contribution	Transfer to available-for- sale assets (a)	Transfers	Write-offs (b)	Other	09/30/2025
						, ,		. ,		
Medise Medicina Diagnóstico e Serviços S.A.	139,584	22,014	<u>-</u>	-	(29,146)	-		-	673	133,125
Hospital Esperança S.A.	5,175,670	258,626	(458,110)	-	(46,503)	-	(1,000)	-	-	4,928,683
PMJ Empreendimentos Imobiliários S.A.	889,825	15,738	(15,265)	26,397	-	-	(14,398)	-	-	902,297
Norte D'Or Participações S.A. (including goodwill)	133,602	(3,215)	-	510	-	-	-	-	-	130,897
Onco D'Or Oncologia S.A.	1,096,859	182,525	(895,593)	-	-	-	-	-	23,554	407,345
Jenner S.A. (including goodwill)	369,301	82,601	(346,276)	-	-	-	-	-	-	105,626
JMJB Diagnósticos e Serviços Hospitalares	44,811	(2,254)	-	-	-	-	-	-	-	42,557
Rodin Empreendimentos e Participações S.A.	447,492	(12,527)	-	30,553	-	-	-	(465,518)	-	-
Quinta Empreendimentos Imobiliários Ltda.	84,724	12,601	(16,482)	-	-	-	(22,918)	(57,925)	-	-
Hospital Fluminense S.A. (including goodwill)	317,729	32,548	(29,289)	3,525	-	-	-	-	-	324,513
Cardial Serviços Médicos (including goodwill)	137,980	49,692	(25,620)	-	-	-	-	-	-	162,052
TJK Empreendimentos Hospitalares	17,513	1,829	(1,950)	-	-	-	-	-	-	17,392
Villa Lobos Empreendimentos Imobiliários Ltda.	173,630	15,426	(1,770)	-	-	-	(34,322)	(152,964)	-	-
Santa Luzia II Empreendimentos Imobiliários Ltda.	61,572	(1,340)	-	-	-	-	-	-	-	60,232
Campinas Empreendimentos Imobiliários Ltda.	364,359	4,066	-	-	-	-	(363,197)	-	(5,228)	-
Sator Empreendimentos e Participações Ltda	4,089,079	186,724	(78,181)	-	(275,883)	-	-	-	•	3,921,739
Rede D'Or São Luiz Serviços Médicos S.A.	415,271	(11,792)	(76,673)	-	(85,141)	-	-	-	-	241,665
Olimpia Projeto Rua do Rocio 86 SPE S.A.	623,100	22,224	(3,504)	-	(37,421)	-	(31,037)	-	-	573,362
Laboratórios Richet	361,915	(8,839)	•	16,840	•	-	•	-	-	369,916
Santa Luzia III	306,751	16,728	-	5,513	-	-	(15,183)	(313,809)	-	-
Qualicorp Consultoria e Corretora de Seguros S.A.	484,640	(132)	(94)	-	-	-	-	•	(2)	484,412
Clínica Médica São Remo	58,453	(6,759)	-	11,269	-	-	-	-	-	62,963
Hospital Santa Cruz	433,842	20,495	(49,347)	17,082	-	-	-	-	-	422,072
Advance Plano de Saúde S.A.	40,419	(6,156)	•	´ <b>-</b>	-	-	-	-	-	34,263
Prisma Capital	1,604,880	`´(97)	-	-	-	-	-	-	-	1,604,783
RDSLGF Greenfields Ltda.	540,958	17,907	-	173,122	(186,774)	-	363,197	-	-	908,410
RDSL OH Operações Hospitalares Ltda.	114,943	72,652	-	232,219	(103,768)	-	´ -	-	-	316,046
Traditio Companhia de Seguros	5,002,876	867,903	-	136,641	•	-	-	-	(49,693)	5,957,727
Cia Saúde - SulAmérica	4,183,579	1,059,422	(211,439)	203,101	-	-	-	-	(51,849)	5,182,814
SAEPAR Serviços e Participações	2,183,881	373,931	• •	62,715	-	-	-	-	(39,480)	2,581,047
Other	1,779,914	106,837	(86,781)	450,109	(22,142)	(225,005)	118,858	(235,481)	33,990	1,920,299
	31,679,152	3,369,378	(2,296,374)	1,369,596	(786,778)	(225,005)	-	(1,225,697)	(88,035)	31,796,237

<sup>(</sup>a) Transfer to assets held for sale. Further details are presented in Note 26.
(b) The parent company carried out a corporate reorganization, involving the sale of interests in certain direct subsidiaries to another controlled entity within the Group.

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# **8. Investments** (Continued)

Breakdown of and changes in investments - Individual (Continued)

Company	12/31/2024	Equity pickup	Capital increase/ Future capital contribution	Capital reduction /return of future capital contributio n	Other	09/30/2025
Onco Star	(454,758)	(99,986)	-	-	(5,966)	(560,710)
Centro Hospitalar São Marcos S.A.	(8,911)	51	15	-	•	(8,845)
Hospital São Marcos (including goodwill)	(97,039)	(28,381)	-	(4,904)	(4,743)	(135,067)
Rede D'or Finance	(158,713)	(2,599)	-		•	(161,312)
	(719,421)	(130,915)	15	(4,904)	(10,709)	(865,934)
Equity pickup		3,238,463	_			

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# 8. Investments (Continued)

### Breakdown of and changes in investments - Individual (Continued)

		\	,	Capital increase/ Future capital	Capital			
Company	12/31/2023	Equity pickup	Dividends	contribution	reduction	Transfer	Other	09/30/2024
Medise Medicina Diagnóstico e Serviços S.A.	247,261	26,097	(29,967)	-	-	-	_	243,391
Hospital Esperança S.A.	4.350.628	343,725	(69,196)	474,769	-	-	(7,605)	5,092,321
PMJ Empreendimentos Imobiliários S.A.	902,254	11,616	(33,662)	3,477	-	-	-	883,685
Norte D'Or Participações S.A. (including goodwill)	126,956	8,775		20	-	-	-	135,751
Onco D'Or Oncologia S.A.	892,114	153,590	-	-	-	-	-	1,045,704
Jenner S.A. (including goodwill)	290,265	59,891	-	-	-	-	-	350,156
JMJB Diagnósticos e Serviços Hospitalares	45,287	439	-	-	-	-	-	45,726
Rodin Empreendimentos e Participações S.A.	283,335	(4,969)	-	139,700	-	-	-	418,066
Quinta Empreendimentos Imobiliários Ltda.	93,925	14,304	(28,059)	· -	-	-	-	80,170
Hospital Fluminense S.A. (including goodwill)	294,761	20,110	(35,021)	20,472	-	-	-	300,322
Cardial Serviços Médicos (including goodwill)	117,990	26,839	(16,800)	· -	-	-	-	128,029
TJK Empreendimentos Hospitalares	17,478	1,452	(1,915)	-	-	-	-	17,015
Villa Lobos Empreendimentos Imobiliários Ltda.	221,265	18,755	(46,342)	-	-	-	-	193,678
Santa Luzia II Empreendimentos Imobiliários Ltda.	63,408	(1,310)	•	-	-	-	-	62,098
Campinas Empreendimentos Imobiliários Ltda.	369,075	13,587	-	2,589	(25,069)	-	-	360,182
Sator Empreendimentos e Participações Ltda	3,540,316	185,454	-	243,285	•	-	-	3,969,055
Rede D'Or São Luiz Serviços Médicos S.A.	316,878	75,265	-	3,000	-	-	-	395,143
Olimpia Projeto Rua do Rocio 86 SPE S.A.	617,864	26,269	(31,673)	1,238	-	-	-	613,698
Proncordis Pronto Atendimento Cardiológico Ltda.	451	(3)		´ -	-	-	-	448
Laboratórios Richet	328,103	(11,39 <sup>4</sup> )	-	52,221	-	-	-	368,930
Santa Luzia III	308,411	<b>`15,116</b>	(22,067)	234	-	-	-	301,694
Qualicorp Consultoria e Corretora de Seguros S.A.	485,204	(1,710)	•	-	-	-	473	483,967
Clínica Médica São Remo	50,285	(7,362)	-	13,368	-	-	-	56,291
Hospital Santa Cruz	429,179	24,486	(53,503)	10,509	-	-	-	410,671
Advance Plano de Saúde S.A.	35,201	5,701	•		-	-	-	40,902
Prisma Capital	1,608,020	(5,399)	-	30	-	-	-	1,602,651
RDSLGF Greenfields Ltda. (a)	<u>-</u>	252	-	490,855	(414,906)	439,597	-	515,798
RDSL OH Operações Hospitalares Ltda. (a)	-	651	-	82,538	. , ,	6,083	-	89,272
Traditio Companhia de Seguros	4,276,157	410,518	(99,034)	´ -	-	´ <b>-</b>	132,365	4,720,006
Cia Saúde – SulAmérica	3,351,225	506,015	(148,638)	13,658	-	-	153,154	3,875,414
SAEPAR Serviços e Participações	1,630,657	163,120	(357)	267,247	-	-	54,391	2,115,058
Other	2,002,422	37,188	(19,941)	153,397	-	(445,680)	(3,098)	1,724,288
	27,296,375	2,117,068	(636,175)	1,972,607	(439,975)	-	329,680	30,639,580

<sup>(</sup>a) On August 16, 2024, the Company closed the Partnership with Atlântica Hospitais e Participações S.A. ("Atlântica Hospitais") - a company focused on hospital investments, indirectly controlled by Bradseg Participações S.A., which in turn is the parent of Bradesco Seguros Group - for the creation of the new hospital network "Atlântica D'Or, which will be the hospital operator and controlling shareholder of the new hospital network Atlântica D'Or, and 49.99% for Atlântica Hospitais. The Company received R\$690,004 from Bradesco Seguros, R\$603,768 as reimbursement and supplementary construction budget, and R\$86,236 referring to inflation adjustment. On November 12, 2024, considering the inaugurations after the third quarter, the partnership encompassed three hospitals in operation (São Luiz Guarulhos, São Luiz Alphaville and Macaé D'Or) and two other projects under development (located in Taubaté and Ribeirão Preto).

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# **8. Investments** (Continued)

Breakdown of and changes in investments - Individual (Continued)

Company	12/31/2023	Equity pickup	Capital increase/ Future capital contribution	Other	09/30/2024
Onco Star	(322,217)	(61,585)	1	(38,312)	(422,113)
Centro Hospitalar São Marcos S.A.	(8,581)	(329)	-	· · ·	(8,910)
Hospital São Marcos (including goodwill)	(107,717)	(2,779)	4,614	-	(105,882)
Rede D'or Finance	(175,045)	4,417	•	_	(170,628)
	(613,560)	(60,276)	4,615	(38,312)	(707,533)
Equity pickup		2,056,792		-	

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 8. Investments (Continued)

### Breakdown of and changes in investments - Consolidated

Company	12/31/2024	Equity pickup	Acquisition of control	Dividends	Other	Transfer	09/30/2025
JMJB Diagnósticos e Serviços Hospitalares S.A.	44,811	(2,254)	-	-	-	-	42,557
Instituto de Radioterapia do Vale do Paraíba Ltda.	16,686	661	-	-	(250)	-	17,097
Qualicorp Consultoria e Corretora de Seguros S.A. (a)	2,087,272	(568)	-	(404)	(9)	-	2,086,291
Eldorado do Sul Participações Ltda.	35,791	6,883	-	(28,853)	(47)	-	13,774
Other	298,996	24,077	1,666	(15,814)	•	(17,471)	291,454
	2,483,556	28,799	1,666	(45,071)	(306)	(17,471)	2,451,173

<sup>(</sup>a) Based on the shareholders' agreement entered into in November 2019, considering the nominations to the Executive Board and Board of Directors that the Company is entitled to, it was concluded that Rede D'Or has significant influence over Qualicorp; therefore, it records the investment using the equity method. The Company recognized equity pickup until June 30, 2025, considering the provisions of IAS 28 (CPC 18) - Investment in associates and joint ventures.

		Equity		Capital increase/ Future capital		
Company	12/31/2023	pickup	Dividends	contribution	Other	09/30/2024
JMJB Diagnósticos e Serviços Hospitalares S.A.	45,287	439	-	_	-	45,726
Instituto de Radioterapia do Vale do Paraíba Ltda.	15,874	714	-	-	(111)	16,477
Qualicorp Consultoria e Corretora de Seguros S.A. (a)	2,089,698	(7,366)	-	-	2,039	2,084,371
Eldorado do Sul Participações Ltda.	29,205	4,990	-	-		34,195
Sharecare Brasil Serviços de Consult.Ltda.	(218)	•	-	-	218	
Sul América Investimentos Distribuidora de Títulos e						
Valores Mobiliários S.A. (SAMI) (b)	88,108	21,398	-	-	(109,506)	-
Other	295,914	13,968	(14,966)	10,650	(3,834)	301,732
	2,563,868	34,143	(14,966)	10,650	(111,194)	2,482,501

<sup>(</sup>a) Based on the shareholders' agreement entered into in November 2019, considering the nominations to the Executive Board and Board of Directors that the Company is entitled to, it was concluded that Rede D'Or has significant influence over Qualicorp; therefore, it records the investment using the equity method. The Company recognized equity pickup until June 30, 2024.

<sup>(</sup>b) On April 30, 2024, the Central Bank of Brazil - BCB approved the transfer of corporate control of Sul América Investimentos DTVM S.A. ("SAMI"), in the context of the merger of Sul América S.A. ("SASA") into Rede D'Or ("Company").

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# **8. Investments** (Continued)

## Summary of information on main subsidiaries

_				09/30/2025				09/30/2024
						Operating		
	% Total	% Voting	A	Liebilitiee	Faurite.	income	P&L for the	P&L for the
Discrete and in discrete substitutions	% i otai	capital	Assets	Liabilities	Equity	(expenses)	period	period
Direct and indirect subsidiaries  Medica Medicina Diagrafetica a Services S.A. ("Medica")	400.00	400.00	202 EZC	247 200	420.207	22.007	24 500	20.422
Medise Medicina Diagnóstico e Serviços S.A. ("Medise")	100.00	100.00 100.00	383,576	247,209	136,367 6,014,638	33,697	24,509 230,504	29,122
Hospital Esperança S.A. ("Esperança")	100.00 100.00	100.00	10,450,127	4,435,489		462,698		191,497
PMJ Empreendimentos Imobiliários S.A.			1,159,009	256,049	902,960	20,060	15,753	11,627
Norte D'Or Participações S.A.	100.00	100.00	102,791	251	102,540	(3,243)	(3,218)	8,784
Onco D'Or Oncologia S.A.	98.87	98.87	722,162	303,814	418,348	205,993	187,513	129,831
Jenner S.A.	91.24	91.24	123,996	2,021	121,975	165,098	150,730	104,809
JMJB Diagnósticos e Serviços Hospitalares S.A.	50.00	50.00	95,520	9,788	85,732	(4,508)	(2,254)	439
Rodin Empreendimentos e Participações S.A.	100.00	100.00	490,897	25,408	465,489	(12,277)	(12,528)	(4,969)
Quinta Empreendimentos Imobiliários Ltda.	100.00	100.00	59,100	1,061	58,039	13,715	12,602	14,306
Hospital Fluminense S.A.	100.00	100.00	439,673	128,423	311,250	45,269	32,581	20,130
Cardial Serviços Médicos Ltda.	89.44	89.44	200,340	68,189	132,151	68,436	49,692	26,839
TJK Empreendimentos Imobiliários Ltda.	100.00	100.00	17,412	10	17,402	1,785	1,829	1,452
Villa Lobos Empreendimentos Imobiliários S.A.	100.00	100.00	154,649	1,422	153,227	17,676	15,427	18,757
Santa Luzia II Emp. Imobiliários Ltda.	100.00	100.00	64,031	3,750	60,281	(1,623)	(1,340)	(1,310)
Campinas Empreendimentos Imob.	100.00	100.00	-	-	-	4,343	4,066	13,589
Sator Empreendimentos e Participações Ltda.	100.00	100.00	3,681,428	138,977	3,542,451	186,453	186,743	185,472
Rede D'Or Finance	100.00	100.00	10,026,204	10,187,515	(161,311)	10	(2,599)	4,417
Rede D'Or São Luiz Serviços Médicos S.A.	100.00	100.00	505,585	161,748	343,837	(22,299)	(11,793)	75,273
Olimpia Projeto Rua do Rocio 86 SPE S.A.	100.00	100.00	578,048	3,994	574,054	24,630	22,246	26,296
Proncordis Pronto Atendimento Cardiológico Ltda.	100.00	100.00	6,954	251	6,703	(240)	(240)	(251)
Laboratórios Richet	100.00	100.00	580,521	158,226	422,295	(13,680)	(8,847)	(12,945)
Onco Star SP Oncologia Ltda.	84.00	84.00	1,358,882	2,027,129	(668,247)	(18,936)	(99,986)	(61,585)
Centro Hospitalar São Marcos S.A	100.00	100.00	21	3,532	(3,511)	51	51	(329)
Santa Luzia III Empreendimentos Imobiliários Ltda.	100.00	100.00	317,222	3,107	314,115	19,589	16,729	15,117
Hospital São Marcos	100.00	100.00	241,734	387,914	(146,180)	(26,061)	(28,410)	(2,779)
Clínica Médica São Remo	100.00	100.00	84,244	23,322	60,922	(5,594)	(6,760)	(7,363)
Hospital Santa Cruz	100.00	100.00	972,152	285,345	686,807	48,827	31,058	24,347
Advance Plano de Saúde S.A.	100.00	100.00	46,256	12,002	34,254	(8,051)	(6,157)	5,701
Prisma Capital	100.00	100.00	1,607,411	57	1,607,354	(437)	(97)	(5,404)
RDSLGF Greenfields Ltda.	100.00	100.00	908,418	1	908,417	17,905	17,907	382
RDSL OH Operações Hospitalares Ltda.	100.00	100.00	316,065	19	316,046	72,581	72,652	661
Traditio Companhia de Seguros	100.00	100.00	8,663,028	217,252	8,445,776	1,166,962	1,214,226	561,812
Cia Saúde - SulAmérica	100.00	100.00	29,379,919	18,206,020	11,173,899	2,606,174	2,261,009	1,064,398
SAEPAR Serv. E Partic	100.00	100.00	2,799,326	218,279	2,581,047	361,616	373,931	163,120

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 8. Investments (Continued)

## Summary of the associates' and joint ventures' information

	09/30/2025							09/30/2024
	% Total	% Voting capital	Assets	Liabilities	Equity	Operating income (expenses)	P&L for the period	P&L for the period
Companies recognized by the equity method in the consolidated								
financial statements								
JMJB Diagnósticos e Serviços Hospitalares S.A.	50.00	50.00	95,520	9,788	85,732	(4,508)	(2,254)	439
Instituto de Radioterapia do Vale do Paraíba Ltda.	50.00	50.00	41,796	11,959	29,837	16,984	14,571	9,155
Eldorado do Sul Participações Ltda.	33.33	33.33	15.247		15.247	20.650	6,883	4,990
Qualicorp Consultoria e Corretora de Seguros S.A. (a)	25.85	25.85	3,801,619	2,470,256	1,331,363	(a)	(a)	(b)

<sup>(</sup>a) The Company recognized equity pickup until June 30, 2025, and 2024.

#### **Impairment**

The recoverable amount of a CGU is determined based on the calculation of value in use. These calculations use cash flow projections based on financial budgets approved by management covering a five to seven years' period. Assumptions are described in Note 10.

There is no indication of impairment of investments to date.

Notes to interim financial statements (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# 9. Property and equipment

## Balance breakdown

		Individual							
			09/30/2025			12/31/2024			
Description	Depreciation rate	Cost	Accumulated depreciation	Net amount	Cost	Accumulated depreciation	Net amount		
Hospital machinery and equipment	12% to 20%	2,013,166	(1,577,858)	435,308	1,843,976	(1,473,756)	370,220		
Surgical instruments	20%	154,498	(98,979)	55,519	146,112	(86,720)	59,392		
Machinery and equipment	7% to 10%	1,103,288	(734,067)	369,221	1,057,171	(650,215)	406,956		
Buildings	2.5% to 4%	893,711	(336,358)	557,353	892,674	(308,517)	584,157		
Improvements in own buildings	4%	509,192	(204,362)	304,830	488,456	(190,572)	297,884		
Leasehold improvements	3% to 4%	3,679,659	(875,563)	2,804,096	3,382,389	(769,766)	2,612,623		
Furniture and fixtures	10%	296,481	(238,491)	57,990	279,474	(218,689)	60,785		
Vehicles	20%	5,907	(4,910)	997	5,907	(4,812)	1,095		
Facilities	10%	204,673	(115,313)	89,360	170,881	(103,611)	67,270		
Land	-	147,698		147,698	147,698	-	147,698		
Construction in progress	-	1,124,793	-	1.124.793	1.097.248	-	1,097,248		
Other	5% to 10%	15,190	(7,722)	7,468	14,800	(7,348)	7,452		
		10,148,256	(4,193,623)	5,954,633	9,526,786	(3,814,006)	5,712,780		

		Consolidated							
			09/30/2025			12/31/2024			
	Depreciation		Accumulated	Net		Accumulated	Net		
Description	rate	Cost	depreciation	amount	Cost	depreciation	amount		
Hospital machinery and equipment	2% to 20%	4,126,718	(2,741,867)	1,384,851	3,710,404	(2,470,553)	1,239,851		
Surgical instruments	20%	371,498	(217,357)	154,141	341,803	(188,909)	152,894		
Machinery and equipment	7% to 10%	1,723,871	(1,105,774)	618,097	1,631,824	(1,018,232)	613,592		
Buildings	5% to 4%	5,859,797	(1,021,820)	4,837,977	4,773,617	(862,555)	3,911,062		
Improvements in own buildings	4%	1,009,138	(299,048)	710,090	854,783	(265,916)	588,867		
Leasehold improvements	3% to 4%	5,988,872	(1,271,290)	4,717,582	5,251,827	(1,129,152)	4,122,675		
Furniture and fixtures	10%	567,848	(394,006)	173,842	548,445	(366,340)	182,105		
Vehicles	20%	29,279	(25,732)	3,547	30,666	(26,822)	3,844		
Facilities	10%	465,805	(217,226)	248,579	455,622	(204,747)	250,875		
Land	_	1,287,978	-	1,287,978	1,270,421	-	1,270,421		
Construction in progress	_	2,202,448	-	2,202,448	2,590,389	-	2,590,389		
Other	5% to 10%	58,875	(9,332)	49,543	61,736	(9,853)	51,883		
		23,692,127	(7,303,452)	16,388,675	21,521,537	(6,543,079)	14,978,458		

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 9. Property and equipment (Continued)

## Changes - Individual

	12/31/2024	Additions	Transfers (a)	09/30/2025
Cost				
Hospital machinery and equipment	1,843,976	227,112	(57,922)	2,013,166
Surgical instruments	146,112	9,569	(1,183)	154,498
Machinery and equipment	1,057,171	52,184	(6,067)	1,103,288
Buildings	892,674	1,037	-	893,711
Improvements in own buildings	488,456	12,764	7,972	509,192
Leasehold improvements	3,382,389	220,791	76,479	3,679,659
Furniture and fixtures	279,474	17,814	(807)	296,481
Vehicles	5,907	-	-	5,907
Facilities	170,881	33,856	(64)	204,673
Land	147,698	-	-	147,698
Construction in progress	1,097,248	122,807	(95,262)	1,124,793
Other	14,800	395	(5)	15,190
	9,526,786	698,329	(76,859)	10,148,256
Depreciation				
Hospital machinery and equipment	(1,473,756)	(121,996)	17,894	(1,577,858)
Surgical instruments	(86,720)	(12,645)	386	(98,979)
Machinery and equipment	(650,215)	(84,505)	653	(734,067)
Buildings	(308,517)	(27,841)	-	(336,358)
Improvements in own buildings	(190,572)	(13,790)	-	(204,362)
Leasehold improvements	(769,766)	(105,827)	30	(875,563)
Furniture and fixtures	(218,689)	(19,914)	112	(238,491)
Vehicles	(4,812)	(98)	-	` (4,910)
Facilities	(103,611)	(11,708)	6	(115,313)
Other	(7,348)	(374)	-	(7,722)
	(3,814,006)	(398,698)	19,081	(4,193,623)
Property and equipment, net	5,712,780	299,631	(57,778)	5,954,633

<sup>(</sup>a) Transfer of assets of Hospital Campinas from the parent company to "Atlântica D'Or".

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 9. Property and equipment (Continued)

Changes - individual (Continued)

	12/31/2023	Additions	Transfers (a)	09/30/2024
Cost				
Hospital machinery and equipment	1,678,455	124,781	(5,021)	1,798,215
Surgical instruments	136,301	5,438	-	141,739
Machinery and equipment	875,363	126,840	(1,602)	1,000,601
Buildings	887,453	5,202	(2)	892,653
Improvements in own buildings	445,826	748	30,548	477,122
Leasehold improvements	2,857,531	148,543	359,960	3,366,034
Furniture and fixtures	256,789	14,108	-	270,897
Vehicles	5,907	-	-	5,907
Facilities	151,249	7,872	(597)	158,524
Land	169,698	-	(22,000)	147,698
Construction in progress	1,140,363	462,024	(639,977)	962,410
Other	14,605	173	-	14,778
	8,619,540	895,729	(278,691)	9,236,578
Depreciation				
Hospital machinery and equipment	(1,321,300)	(114,435)	-	(1,435,735)
Surgical instruments	(69,778)	(12,624)	-	(82,402)
Machinery and equipment	(552,059)	(71,930)	-	(623,989)
Buildings	(271,507)	(27,705)	-	(299,212)
Improvements in own buildings	(172,642)	(13,513)	-	(186,155)
Leasehold improvements	(642,186)	(93,543)	-	(735,729)
Furniture and fixtures	(193,709)	(18,507)	-	(212,216)
Vehicles	(4,606)	(155)	-	(4,761)
Facilities	(90,749)	(9,508)	-	(100,257)
Other	(6,881)	(347)	=	(7,228)
	(3,325,417)	(362,267)	-	(3,687,684)
Property and equipment, net	5,294,123	533,462	(278,691)	5,548,894

<sup>(</sup>b) The amount of R\$278,691 refers to property and equipment items that were transferred to subsidiaries through future capital contributions.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# 9. Property and equipment (Continued)

## Changes - Consolidated

			Transfer to assets			
	12/31/2024	Additions	Transfers	held for sale (a)	09/30/2025	
Cost						
Hospital machinery and equipment	3,710,404	445,445	-	(29,131)	4,126,718	
Surgical instruments	341,803	29,695	-	-	371,498	
Machinery and equipment	1,631,824	195,104	-	(103,057)	1,723,871	
Buildings	4,773,617	792,056	294,124	-	5,859,797	
Improvements in own buildings	854,783	70,623	83,732	-	1,009,138	
Leasehold improvements	5,251,827	378,954	402,808	(44,717)	5,988,872	
Furniture and fixtures	548,445	29,873	-	(10,470)	567,848	
Vehicles	30,666	-	-	(1,387)	29,279	
Facilities	455,622	70,778	-	(60,595)	465,805	
Land	1,270,421	20,899	-	(3,342)	1,287,978	
Construction in progress	2,590,389	397,334	(780,664)	(4,611)	2,202,448	
Other	61,736	1,043	-	(3,904)	58,875	
	21,521,537	2,431,804	-	(261,214)	23,692,127	
Depreciation						
Hospital machinery and equipment	(2,470,553)	(284,838)	-	13,524	(2,741,867)	
Surgical instruments	(188,909)	(28,448)	-	-	(217,357)	
Machinery and equipment	(1,018,232)	(135,466)	-	47,924	(1,105,774)	
Buildings	(862,555)	(159,265)	-	-	(1,021,820)	
Improvements in own buildings	(265,916)	(33,132)	-	-	(299,048)	
Leasehold improvements	(1,129,152)	(165,889)	-	23,751	(1,271,290)	
Furniture and fixtures	(366,340)	(34,274)	-	6,608	(394,006)	
Vehicles	(26,822)	(288)	-	1,378	(25,732)	
Facilities	(204,747)	(25,997)	-	13,518	(217,226)	
Other	(9,853)	(1,655)	-	2,176	(9,332)	
	(6,543,079)	(869,252)	-	108,879	(7,303,452)	
Property and equipment, net	14,978,458	1,562,552	-	(152,335)	16,388,675	

<sup>(</sup>a) Transfer to assets held for sale. Refer to Note 26 for more details.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 9. Property and equipment (Continued)

## **Changes - Consolidated** (Continued)

	12/31/2023	Additions	Sales/disposals (a)	Transfers	Business combinations	09/30/2024
Cost	12/01/2020	Additions	(u)	Transiers	COMBINATIONS	03/00/2024
Hospital machinery and						
equipment	3,133,364	331,465	(25)	(5,041)	213	3,459,976
Surgical instruments	305,903	19,054	(=0)	-	-	324,957
Machinery and equipment	1,363,779	146,583	(12,956)	(1,667)	47,861	1,543,600
Buildings	3,839,290	47,510	(485)	(27,199)	-	3,859,116
Improvements in own buildings	679,784	3,155	(371)	101,322	-	783,890
Leasehold improvements	4,415,681	382,609	(3,856)	385,212	1,759	5,181,405
Furniture and fixtures	490,374	34,157	(1,956)	(36)	3,322	525,861
Vehicles	29,373	· -	(3)	-	1,296	30,666
Facilities	326,015	61,169	(13 <del>7</del> )	(11,943)	44,546	419,650
Land	1,181,599	59,790	` <u>-</u>	27,197	3,273	1,271,859
Construction in progress	2,625,219	1,077,518	(2,665)	(467,845)	2,127	3,234,354
Other	60,099	216	(24)	· -	1,200	61,491
	18,450,480	2,163,226	(22,478)	-	105,597	20,696,825
Depreciation						
Hospital machinery and						
equipment	(2,146,769)	(238,054)	25	-	(213)	(2,385,011)
Surgical instruments	(155,494)	(24,426)	-	-	-	(179,920)
Machinery and equipment	(854,475)	(100,245)	7,081	-	(26,331)	(973,970)
Buildings	(695,809)	(119,482)	-	-	-	(815,291)
Improvements in own buildings	(232,594)	(24,432)	28	-	-	(256,998)
Leasehold improvements	(930,721)	(144,611)	18	-	(13)	(1,075,327)
Furniture and fixtures	(324,193)	(31,496)	1,043	-	(836)	(355,482)
Vehicles	(26,295)	(269)	3	-	(32)	(26,593)
Facilities	(165,516)	(22,476)	34	-	(8,241)	(196,199)
Other	(9,211)	(473)	1	-	-	(9,683)
	(5,541,077)	(705,964)	8,233	-	(35,666)	(6,274,474)
Property and equipment, net	12,909,403	1,457,262	(14,245)	-	69,931	14,422,351

<sup>(</sup>a) Sales/disposals refer to the property and equipment items of D'Or Consultoria's companies.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## **9. Property and equipment** (Continued)

Significant changes for the periods ended September 30, 2025 and 2024 were as follows:

#### 2025

- (i) Investments in the expansion works of hospital facilities such as Hospital Assunção, São Vicente, Onco Star and the new tower of UDI Hospital.
- (ii) Expenses with improvements for the growth and expansion of hospitals and clinics, primarily hospitals São Lucas, Assunção, Morumbi and UDI.
- (iii) Purchases of hospital machinery and equipment for the Hospitals new Barra D'Or, Anália, Hospital Assunção, Onco Star, Aliança and São Vicente.
- (iv) Investments in construction works of Hospitals Taubaté and Ribeirão Preto.

#### 2024

- (i) Investments in the construction of the new hospitals São Luiz Alphaville and Guarulhos, in São Paulo, the new Hospital Macaé, and the new tower of Hospital new Barra D'Or, in Rio de Janeiro.
- (ii) Expansions of Hospital Vila Nova Star, in the city of São Paulo, the new building of Hospital Aliança in the city of Salvador, and of Hospital Assunção;
- (iii) Purchases of hospital machinery and equipment for the ventures of new hospitals São Luiz Alphaville, Guarulhos, Macaé, and new Barra D'Or. Also, investments for the new tower of Vila Nova Star, Aliança, and the update of imaging equipment of hospitals Copa D'Or and Copa Star.

#### Capitalized borrowing costs

The Company capitalizes borrowing costs attributable to qualifying assets. At September 30, 2025, R\$134,944 in interest on loans and financing were capitalized in Property and equipment (R\$128,827 at September 30, 2024).

#### Impairment testing of property and equipment

Management has assessed the existence of events or changes in economic, operational or technological circumstances and has not identified any evidence that could indicate deterioration or impairment of property and equipment.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# 10. Intangible assets

	Annual	Individual		Consolidated		
	amortization rate	09/30/2025	12/31/2024	09/30/2025	12/31/2024	
Finite useful life						
Software	20%	207,389	218,292	673,006	698,722	
Customer portfolio - SASA	11% to 20%	109,040	135,929	109,040	135,929	
Exclusive agreements (b)	20%	15,776	18,923	105,610	244,129	
Other (b)		-	-	5,337	59,476	
Indefinite useful life						
Goodwill						
Acquisition of Copa D'Or		80,058	80,058	80,058	80,058	
Acquisition of HMSL		668,339	668,339	668,339	668,339	
Acquisition of Hospital Brasil		121,398	121,398	121,398	121,398	
Acquisition of Hospital Prontolinda		30,595	30,595	30,595	30,595	
Acquisition of Vivalle		38,692	38,692	38,692	38,692	
Acquisition of São Marcos		-	-	10,807	10,807	
Acquisition of Santa Luzia		199,333	199,333	199,333	199,333	
Acquisition of Sinisgalli		156,646	156,646	156,646	156,646	
Acquisition of Hospital Esperança		-	-	108,408	108,408	
Acquisition of Norte D'Or				28,450	28,450	
Acquisition of IFOR		85,724	85,724	85,724	85,724	
Acquisition of Sino Brasileiro		241,947	241,947	241,947	241,947	
Acquisition of Villa-Lobos		136,074	136,074	136,074	136,074	
Acquisition of Bartira		105,584	105,584	105,584	105,584	
Acquisition of Onco ABC/Cardeal/JLD		-	-	55,414	55,414	
Acquisition of Oncoholding		-	-	159,445	159,445	
Acquisition of Hospital Fluminense				10,658	10,658	
Acquisition of Hospital Santa Helena		125,802	125,802	125,802	125,802	
Acquisition of Acreditar		-	-	155,720	155,720	
Acquisition of Memorial São José		112,528	112,528	112,528	112,528	
Acquisition of Alpha-Med		-	-	43,815	43,815	
Acquisition of CEHON				68,757	68,757	
Acquisition of Maximagem		46,742	46,742	46,742	46,742	
Acquisition of Ribeirão Pires		129,739	129,739	129,739	129,739	
Acquisition of NEOH		-	-	33,422	33,422	
Acquisition of Salus		-	-	8,956	8,956	
Acquisition of Prontimagem		-	-	6,220	6,220	
Acquisition of Sator		-	-	163,089	163,089	
Acquisition of Hospital São Rafael		-	-	509,363	509,363	
Acquisition of Laboratório Richet		-	-	184,232	184,232	
Acquisition of UDI		-	-	335,883	335,883	
Acquisition of Samer		-	-	70,939	70,939	
Acquisition of Hospital Rio Mar		-	-	94,833	94,833	
Acquisition of Hospital São Lucas		<del>-</del>	<del>-</del>	223,079	223,079	
Acquisition of Hospital Aviccena		60,476	60,476	60,476	60,476	
Acquisition of Perinatal		655,580	655,580	655,580	655,580	
Acquisition of Hospital Santa Cruz		-	-	299,583	299,583	
Acquisition of Aliança		-	-	925,555	925,555	
Acquisition of Salute		-	-	15,475	15,475	
Acquisition of São Carlos		-	-	160,139	160,139	
Acquisition of Clínica São Lucas		-	-	45,673	45,673	
Acquisition of Clivalle		-	-	40,786	40,786	
Acquisition of HCP/Cárdio Pulmonar		-	-	146,894	146,894	
Acquisition of Guaianases		-	-	115,751	115,751	
Acquisition of Antônio Afonso		-	-	16,782	16,782	

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 10. Intangible assets (Continued)

	Annual	al Individual		Conso	lidated
	amortization rate	09/30/2025	12/31/2024	09/30/2025	12/31/2024
Indefinite useful life	-				
Acquisition of Balbino		-	-	77,500	77,500
Acquisition of América		-	-	456,511	456,511
Acquisition of Serra Mayor		-	-	68,981	68,981
Acquisition of Biocor		-	-	620,347	620,347
Acquisition of Proncor		-	-	202,929	202,929
Acquisition of Santa Emilia		-	-	121,991	121,991
Acquisition of Hospital Nossa Senhora das				200.004	
Neves		-	-	326,634	326,634
Acquisition of HNSN Empreendimentos		-	-	34,790	34,790
Acquisition of Orthoservice		-	-	33,705	33,705
Acquisition of HNA Emp. E Participações		-	-	12,401	12,401
Acquisition of Hospital Novo Atibaia		-	-	173,020	173,020
Acquisition of Hospital Arthur Ramos		-	-	272,686	272,686
Acquisition of Hospital Santa Isabel		-	-	243,287	243,287
Acquisition of Hospital Aeroporto		-	-	171,511	171,511
Acquisition of Paraná Clínicas		-	-	284,701	284.701
Acquisition of Sompo Saúde		-	-	199,384	199,384
Acquisition of Prodent		-	-	106,681	106,681
Acquisition of SASA		1,820,625	1,820,625	1,820,625	1,820,625
Other goodwill (b)		48,650	48,650	436,076	580,766
Trademark - SASA		2,068,575	2,068,575	2,068,575	2,068,575
Trademarks and patents (a)		190,810	190,810	194,433	193,999
	_	7,456,122	7,497,061	15,853,146	16,242,665

<sup>(</sup>a) This mainly refers to the Hospital São Luiz trademark registered upon its acquisition in 2010.

#### Software development costs and licenses

These refer mainly to expenditures incurred with the development of technological infrastructure, applications, improvements in the companies' website and in operations of Sul América S.A., development of own systems, and acquisition of software licenses used in operations.

#### **Impairment**

Goodwill is allocated to the Cash-Generating Units (CGU) identified by management, i.e. each hospital, as shown in the table above.

The recoverable amount of a CGU is determined based on the calculation of value in use. Value in use calculations use cash flow projections based on financial budgets approved by management covering a five-year period.

<sup>(</sup>b) This balance reduction mainly refers to the transfer to available-for-sale assets. Refer to Note 26 for more details.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 10. Intangible assets (Continued)

#### Impairment (Continued)

Discount rates represent the current market assessment of the risks specific to each CGU, taking into consideration the time value of money and individual risks of the underlying assets that have not been incorporated in the cash flow estimates. The discount rate calculation is based on the specific circumstances of the Company and is derived from its weighted average cost of capital (WACC). The WACC takes into consideration both debt and equity. The cost of equity is derived from the expected return on investment by the investors. The cost of debt is based on the interest-bearing financing the Company is obliged to service. Segment-specific risk is incorporated by applying individual beta factors. The beta factors are evaluated annually based on publicly available market data.

There is no indication of impairment of intangible assets to date.

## 11. Right of use

#### Balance breakdown

			Indivi	dual		
		09/30/2025			12/31/2024	
Description	Cost	Amortization	Net balance	Cost	Amortization	Net balance
Properties	3,829,881	(1,400,969)	2,428,912	3,668,297	(1,218,118)	2,450,179
·	3,829,881	(1,400,969)	2,428,912	3,668,297	(1,218,118)	2,450,179
			Consoli	dated		
		09/30/2025			12/31/2024	
Description	Cost	Amortization	Net balance	Cost	Amortization	Net balance
Hospital machinery and						
equipment	-	-	-	885	(818)	67
Properties	5,023,521	(1,934,400)	3,089,121	4,731,845	(1,679,650)	3,052,195
Vehicles	1,397	(1,089)	308	1,471	(710)	761
	5,024,918	(1,935,489)	3,089,429	4,734,201	(1,681,178)	3,053,023

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## **11. Right of use** (Continued)

## Changes - Individual

	12/31/2024	Additions (a)	Amortization	Transfers (c)	09/30/2025
Cost					
Properties	3,668,297	279,206	-	(117,622)	3,829,881
	3,668,297	279,206	-	(117,622)	3,829,881
Amortization					
Properties	(1,218,118)	-	(211,317)	28,466	(1,400,969)
	(1,218,118)	-	(211,317)	28,466	(1,400,969)
Right of use, net	2,450,179	279,206	(211,317)	(89,156)	2,428,912
	12/31/2023	Additions (a)	Amortization	Transfers	09/30/2024
Cost					,
Properties	3,108,775	360,913	-	-	3,469,688
·	3,108,775	360,913	-	-	3,469,688
Amortization					
Properties	(950,269)	-	(193,771)	-	(1,144,040)
	(950,269)	-	(193,771)	-	(1,144,040)
Right of use, net	2,158,506	360,913	(193,771)	=	2,325,648

## Changes - Consolidated

	12/31/2024	Additions (a)	Write-offs (b)	s Amortization	Transfer to assets held for sale (d)	09/30/2025
Cost						
Hospital machinery and equipment	885	-	(885)	-	-	-
Properties	4,731,845	367,262	-	-	(75,586)	5,023,521
Vehicles	1,471	-	(74)	-	-	1,397
	4,734,201	367,262	(959)	-	(75,586)	5,024,918
Amortization						
Hospital machinery and equipment	(818)	-	885	(67)	-	-
Properties	(1,679,650)	-	-	(281,801)	27,051	(1,934,400)
Vehicles	(710)	-	74	(453)	-	(1,089)
	(1,681,178)	-	959	(282,321)	27,051	(1,935,489)
Right of use, net	3,053,023	367,262	-	(282,321)	(48,535)	3,089,429
	12/31/2023	Additio	ns (a)	Write-offs (b)	Amortization	09/30/2024
Cost						
Hospital machinery and equipment	2,531		-	(1,646)	-	885
Properties	4,024,562	481,2		-	-	4,505,824
Vehicles	3,684	1,4	471	(3,684)	-	1,471
	4,030,777	482,	733	(5,330)	-	4,508,180
Amortization						
Hospital machinery and equipment	(1,646)		-	1,646	(616)	(616)
Properties	(1,344,985)		-	-	(243,586)	(1,588,571)
Vehicles	(3,684)			3,684	(545)	(545)
	(1,350,315)		-	5,330	(244,747)	(1,589,732)
Right of use, net	2,680,462	482,	733	-	(244,747)	2,918,448
-		<u> </u>			*	

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 11. Right of use (Continued)

- (a) Additions referring to new agreements and renewals due to maturities.
- (b) Write-offs referring to contract termination.
- (c) Transfers of assets of Hospital Campinas to Atlântica D'or.
- (d) Transfer to assets available for sale. Refer to Note 26 for more details.

The rights of use are amortized during the lease contract term and take into consideration the expected renewal, when management intends to exercise this right, and in accordance with the terms of the contracts.

#### 12. Insurance contract assets and liabilities

	09/30/202			1/2024
Insurance contracts	Assets	Liabilities	Assets	Liabilities
Long-term contracts (BBA/VFA)	40,497	15,561,428	22,647	17,423,448
Short-term contracts (PAA)	3,235	3,879,862	34,382	2,866,005
Total	43,732	19,441,290	57,029	20,289,453
Current Noncurrent	24,855 18,877	7,208,933 12,232,357	8,715 48,314	7,099,761 13,189,692

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 12. Insurance contract assets and liabilities (Continued)

### 12.1. Changes in assets or liabilities for remaining coverage and incurred claims relating to insurance contracts

## Short-term contracts (PAA)

				Consolidated		
		Asset/liability for	Liabilit			·
		remaining coverage	incurred	claims	_	
		Excluding loss component	Estimated future cash flows at present value	Risk adjustment	Assets for insurance acquisition costs	Total
Insurance contract liabilities at 12/31/2024		(635,185)	5,178,280	167,428	(1,844,518)	2,866,005
Insurance contract assets at 12/31/2024		(50,259)	40,701	72	(24,896)	(34,382)
Total insurance contracts at 12/31/2024		(685,444)	5,218,981	167,500	(1,869,414)	2,831,623
Insurance revenue	Note 18.2	(22,099,905)	-	-	-	(22,099,905)
Insurance costs	Note 19.2/ (f)	2,546,101	10,644,472	13,684	-	13,204,257
Insurance service result		(19,553,804)	10,644,472	13,684	-	(8,895,648)
Finance income (costs) from insurance operations	Note 22	-	775,304	17,366	-	792,670
Changes in other comprehensive income		-	(6,076)	(85)	-	(6,161)
Total changes that impact P&L or other comprehensive income		(19,553,804)	11,413,700	30,965	-	(8,109,139)
Premiums and other cash flows received from policyholders	(a)	22,162,042	-	-	-	22,162,042
Claims and other benefits paid to policyholders or their beneficiaries	(f)	-	(10,506,205)	-	-	(10,506,205)
Acquisition cash flows paid	(b)	(1,161,797)	-	-	(539,022)	(1,700,819)
Other expenses allocated to the insurance service	(c)	(820,618)	-	-	-	(820,618)
Total cash flows		20,179,627	(10,506,205)	-	(539,022)	9,134,400
Allocation of acquisition costs prepaid to insurance cash flows	(d)	(206,103)	-	-	206,103	-
Other	(e)	(26,027)	45,770	-	-	19,743
Total insurance contracts at 09/30/2025		(291,751)	6,172,246	198,465	(2,202,333)	3,876,627
Insurance contract liabilities at 09/30/2025 Insurance contract assets at 09/30/2025	·	(286,696) (5,055)	6,170,484 1,762	198,407 58	(2,202,333)	3,879,862 (3,235)

<sup>(</sup>a) Any premium reimbursements were included in this line.

<sup>(</sup>b) Insurance acquisition cash flows paid before initial recognition of the respective group are adjusted to the liability/asset for remaining coverage only when these groups are recognized. Insurance acquisition cash flows paid before the related group is recognized are included in cash flows from assets for acquisition until the group is recognized.

<sup>(</sup>c) Other changes within insurance assets or liabilities that affect other statement of financial position lines, as well as expenses allocated to insurance contracts not directly related to claims (such as contract issue and maintenance costs, costs to comply with regulatory requirements, among others) and acquisition cash flows, which are not recorded in assets/liabilities from insurance and reinsurance contracts and were included in the Insurance Costs line.

<sup>(</sup>d) Other changes in acquisition cash flows include the reclassification to liabilities of insurance acquisition cash flows that have been recognized before the group recognition by applying another CPC/IFRS.

<sup>(</sup>e) Refers to the elimination of transactions between group companies.

<sup>(</sup>f) Includes the eliminations of incurred claims and other expenses to be allocated to insurance contracts between the Group companies.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 12. Insurance contract assets and liabilities (Continued)

### 12.1. Changes in assets or liabilities for remaining coverage and incurred claims relating to insurance contracts (Continued)

Short-term contracts (PAA) (Continued)

			C	onsolidated		
	_	Asset/liability for remaining coverage	Liability i		Assets for	
	_	Excluding loss component	Estimated future cash flows at present value	Risk adjustme nt	insurance acquisition costs	Total
Insurance contract liabilities at 12/31/2023		(742,794)	3,752,308	144,542	(1,794,552)	1,359,504
Insurance contract assets at 12/31/2023	_	(61,658)	28,477	79	(43,245)	(76,347)
Total insurance contracts at 12/31/2023	_	(804,452)	3,780,785	144,621	(1,837,797)	1,283,157
Insurance revenue	Note 18.2	(26,602,196)	-	-	-	(26,602,196)
Insurance costs	Note 19.2/ (f)	3,093,801	14,610,172	6,070	-	17,710,043
Insurance service result	_	(23,508,395)	14,610,172	6,070	-	(8,892,153)
Finance income (costs) from insurance operations	Note 22	-	713,235	18,213	-	731,448
Changes in other comprehensive income	_	-	(53,370)	(1,404)	-	(54,774)
Total changes that impact P&L or other comprehensive income		(23,508,395)	15,270,037	22,879	-	(8,215,479)
Premiums and other cash flows received from policyholders	(a)	26,705,065	-	-	-	26,705,065
Claims and other benefits paid to policyholders or their beneficiaries	(f)	-	(13,861,128)	-	-	(13,861,128)
Acquisition cash flows paid	(b)	(1,441,236)	•	-	(662,377)	(2,103,613)
Other expenses allocated to the insurance service	(c)	(988,345)	-	-	-	(988,345)
Total cash flows		24,275,484	(13,861,128)	-	(662,377)	9,751,979
Allocation of acquisition costs prepaid to insurance cash flows	(d)	(630,760)	-	-	630,760	-
Other	(e)	(17,321)	29,287	-	-	11,966
Total insurance contracts at 12/31/2024		(685,444)	5,218,981	167,500	(1,869,414)	2,831,623
Insurance contract liabilities at 12/31/2024	_	(635,185)	5,178,280	167,428	(1,844,518)	2,866,005
Insurance contract assets at 12/31/2024		(50,259)	40,701	72	(24,896)	(34,382)

<sup>(</sup>a) Any premium reimbursements were included in this line.

<sup>(</sup>b) Insurance acquisition cash flows paid before initial recognition of the respective group are adjusted to the liability/asset for remaining coverage only when these groups are recognized. Insurance acquisition cash flows paid before the related group is recognized are included in cash flows from assets for acquisition until the group is recognized.

<sup>(</sup>c) Other changes within insurance assets or liabilities that affect other statement of financial position lines, as well as expenses allocated to insurance contracts not directly related to claims (such as contract issue and maintenance costs, costs to comply with regulatory requirements, among others) and acquisition cash flows, which are not recorded in assets/liabilities from insurance and reinsurance contracts and were included in the Insurance Costs line.

<sup>(</sup>d) Other changes in acquisition cash flows include the reclassification to liabilities of insurance acquisition cash flows that have been recognized before the group recognition by applying another CPC/IFRS.

<sup>(</sup>e) Refers to the elimination of transactions between group companies.

<sup>(</sup>f) Includes the eliminations of incurred claims and other expenses to be allocated to insurance contracts between the Group companies.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 12. Insurance contract assets and liabilities (Continued)

### 12.1. Changes in assets or liabilities for remaining coverage and incurred claims relating to insurance contracts (Continued)

#### Long-term contracts (BBA/VFA)

		Consolidated				
	•	Asset/liab		Liabili		
		remaining	coverage	incurred	claims	_
		Forting Programme		Estimated future	Dist.	
		Excluding loss	Loss	cash flows at	Risk	Tatal
	,	component	component	present value	adjustment	Total
Insurance contract liabilities at 12/31/2024		15,809,964	942,256	650,640	20,588	17,423,448
Insurance contract (assets) at 12/31/2024		(28,331)	-	5,681	3	(22,647)
Total insurance contracts at 12/31/2024	•	15,781,633	942,256	656,321	20,591	17,400,801
Insurance revenue	Note 18.2	(2,160,575)	-	-	-	(2,160,575)
Insurance costs	Note 19.2 (d)	108,900	(95,012)	1,617,222	794	1,631,904
Investment component	(e)	(6,163,543)	-	6,163,543	-	-
Insurance service result		(8,215,218)	(95,012)	7,780,765	794	(528,671)
Finance income (costs) from insurance operations	Note 22	1,558,704	52,634	74,026	1,642	1,687,006
Changes in other comprehensive income		208,175	24,237	(12,525)	(293)	219,594
Total changes that impact P&L or other comprehensive income		(6,448,339)	(18,141)	7,842,266	2,143	1,377,929
Premiums and other cash flows received from policyholders	(a)	4,514,906	-	=	-	4,514,906
Claims and other benefits paid to policyholders or their beneficiaries	(d)	-	-	(7,783,760)	-	(7,783,760)
Acquisition cash flows paid	(b)	(47,840)	-	-	-	(47,840)
Provision for social security amounts to be regularized		72,288	-	-	-	72,288
Other expenses allocated to the insurance service	(c)	(13,393)	-	-	-	(13,393)
Total cash flows		4,525,961		(7,783,760)		(3,257,799)
Total insurance contracts at 09/30/2025		13,859,255	924,115	714,827	22,734	15,520,931
Insurance contract liabilities at 09/30/2025		13,904,008	924,115	710,574	22,731	15,561,428
Insurance contract assets at 09/30/2025		(44,753)	-	4,253	3	(40,497)

<sup>(</sup>a) Any premium reimbursements were included in this line.

<sup>(</sup>b) Insurance acquisition cash flows paid before initial recognition of the respective group are adjusted to the liability/asset for remaining coverage only when these groups are recognized. Insurance acquisition cash flows paid before the related group is recognized are included in cash flows from assets for acquisition until the group is recognized.

<sup>(</sup>c) Other changes within insurance assets or liabilities that affect other statement of financial position lines, as well as expenses allocated to insurance contracts not directly related to claims (such as contract issue and maintenance costs, costs to comply with regulatory requirements, among others) and acquisition cash flows, which are not recorded in assets/liabilities from insurance and reinsurance contracts and were included in the Insurance Costs line. Cash flows related to investment and redemptions of non-separable pension investment components (VGBL/PGBL) were also included in this line.

<sup>(</sup>d) Includes the eliminations of incurred claims and other expenses to be allocated to insurance contracts between the Group companies.

<sup>(</sup>e) In the long-term products, the investment component of Asset/Liability for remaining coverage was transferred to Liability for incurred claims relating to the payment of benefits (annual fees), redemptions and pension portability.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 12. Insurance contract assets and liabilities (Continued)

#### 12.1. Changes in assets or liabilities for remaining coverage and incurred claims relating to insurance contracts (Continued)

Long-term contracts (BBA/VFA) (Continued)

				Consolidated		
		Asset/liability for remaining coverage		Liability incurred cl		
	<u>-</u>	Excluding loss component	Loss component	Estimated future cash flows at present value	Risk adjustment	Total
Insurance contract liabilities at 12/31/2023 Insurance contract (assets) at 12/31/2023		14,304,162 (8,519)	936,095	522,426 2,849	20,336	15,783,019 (5,667)
Total insurance contracts at 12/31/2023	-	14,295,643	936,095	525,275	20,339	15,777,352
Insurance revenue	Note 18.2	(2,852,631)	-	-		(2,852,631)
Insurance costs	Note 19.2 (d)	156,921	33,586	2,217,971	(2,006)	2,406,472
Investment component	(e)	(2,722,808)	-	2,722,808	-	-
Insurance service result	•	(5,418,518)	33,586	4,940,779	(2,006)	(446,159)
Finance income (costs) from insurance operations	Note 22	1,183,350	86,930	97,017	2,412	1,369,709
Changes in other comprehensive income	_	(929,789)	(114,355)	(6,495)	(154)	(1,050,793)
Total changes that impact P&L or other comprehensive income		(5,164,957)	6,161	5,031,301	252	(127,243)
Premiums and other cash flows received from policyholders	(a)	6,762,939	-	-	-	6,762,939
Claims and other benefits paid to policyholders or their beneficiaries	(d)	-	-	(4,900,255)	-	(4,900,255)
Acquisition cash flows paid	(b)	(74,168)	-	-	-	(74,168)
Provision for social security amounts to be regularized		(1,130)	-	-	-	(1,130)
Other expenses allocated to the insurance service	(c)	(36,694)	-	-	-	(36,694)
Total cash flows	_	6,650,947	-	(4,900,255)	•	1,750,692
Total insurance contracts at 12/31/2024	-	15,781,633	942,256	656,321	20,591	17,400,801
Insurance contract liabilities at 12/31/2024		15,809,964	942,256	650,640	20,588	17,423,448
Insurance contract assets at 12/31/2024		(28,331)	-	5,681	3	(22,647)

<sup>(</sup>a) Any premium reimbursements were included in this line.

<sup>(</sup>b) Insurance acquisition cash flows paid before initial recognition of the respective group are adjusted to the liability/asset for remaining coverage only when these groups are recognized. Insurance acquisition cash flows paid before the related group is recognized are included in cash flows from assets for acquisition until the group is recognized.

<sup>(</sup>c) Other changes within insurance assets or liabilities that affect other statement of financial position lines, as well as expenses allocated to insurance contracts not directly related to claims (such as contract issue and maintenance costs, costs to comply with regulatory requirements, among others) and acquisition cash flows, which are not recorded in assets/liabilities from insurance and reinsurance contracts and were included in the Insurance Costs line. Cash flows related to investment and redemptions of non-separable pension investment components (VGBL/PGBL) were also included in this line.

<sup>(</sup>d) Includes the eliminations of incurred claims and other expenses to be allocated to insurance contracts between the Group companies.

<sup>(</sup>e) In the long-term products, the investment component of Asset/Liability for remaining coverage was transferred to Liability for incurred claims relating to the payment of benefits (annual fees), redemptions and pension portability.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 12. Insurance contract assets and liabilities (Continued)

## 12.2. Contracts held showing cash flow estimate at present value, risk adjustment, and contractual service margin

	Consolidated				
	Estimated present				
	value of future cash		Contractual		
	flows	Risk adjustment	service margin	Total	
Insurance contract liabilities at 12/31/2024	16.228.704	544,145	650.599	17,423,448	
Insurance contract assets at 12/31/2024	(8,748)	33	(13,932)	(22,647)	
Total insurance contracts at 12/31/2024	16,219,956	544,178	636,667	17,400,801	
Changes that relate to contractual services	(183,109)	(48,270)	(60,485)	(291,864)	
Contractual service margin recognized for services provided	(103,109)	(40,270)	(60,485)	(60,485)	
Risk adjustment recognized for the risk expired		(48,270)	(00,403)	(48,270)	
Experience adjustments	(183,109)	(40,270)	_	(183.109)	
Changes that relate to future services	(18,026)	(47,158)	43,326	(21,858)	
Contracts initially recognized in the period (a)	(70,836)	608	70.228	(21,000)	
Changes in estimates that adjust the contractual service margin	32.795	(5,893)	(26,902)		
Changes in estimates that do not adjust the contractual service margin	20,015	(41,873)	(20,002)	(21,858)	
Changes that relate to past services	(262,977)	48,028	-	(214,949)	
Adjustments to liabilities for incurred claims	(262,977)	48,028	-	(214,949)	
Income (loss) from insurance service	(464,112)	(47,400)	(17,159)	(528,671)	
Insurance finance costs	1,634,920	46,646	5,440	1,687,006	
Effects of changes in interest rates	199,424	20,170	-	219,594	
Total	1,370,232	19,416	(11,719)	1,377,929	
Premiums received	4,514,906	-	-	4,514,906	
Other expenses paid	(7,724,865)	-	_	(7,724,865)	
Insurance acquisition cash flows	(47,840)	-	-	(47,840)	
Net insurance contract (assets)/liabilities at 09/30/2025	14,332,389	563,594	624,948	15,520,931	
Insurance contract liabilities at 09/30/2025	14,345,920	563,568	651,940	15,561,428	
Insurance contract assets at 09/30/2025	(13,531)	26	(26,992)	(40,497)	

<sup>(</sup>a) The estimates of the present value of future cash flows for the contracts initially recognized in the period includes an estimate of R\$1,375,446 in net written premiums, R\$1,292,401 in claims and other insurance service expenses, and R\$12,209 in acquisition cash flows.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 12. Insurance contract assets and liabilities (Continued)

## 12.2. Contracts held showing cash flow estimate at present value, risk adjustment, and contractual service margin (Continued)

	Consolidated					
	Estimated present value of future cash flows	Risk adjustment	Contractual service margin	Total		
1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	44.507.000	700 700	450.000	15 700 010		
Insurance contract liabilities at 12/31/2023	14,587,203	739,783	456,033	15,783,019		
Insurance contract assets at 12/31/2023	(2,619)	50	(3,098)	(5,667)		
Total insurance contracts at 12/31/2023	14,584,584	739,833	452,935	15,777,352		
Changes that relate to contractual services	(248,809)	(70,900)	(48,003)	(367,712)		
CSM recognized for services provided	-	-	(48,003)	(48,003)		
Risk adjustment recognized for the risk expired		(70,900)	-	(70,900)		
Experience adjustments	(248,809)	-	-	(248,809)		
Changes that relate to future services	87,653	(171,129)	226,624	143,148		
Contracts initially recognized in the period (a)	(57,780)	708	57,072	-		
Changes in estimates that adjust CSM	(166,060)	(3,488)	169,552	4		
Changes in estimates that do not adjust CSM	311,493	(168,349)	-	143,144		
Changes that relate to past services	(288,793)	67,198	-	(221,595)		
Adjustments to liabilities for incurred claims	(288,793)	67,198	-	(221,595)		
Income (loss) from insurance service	(449,949)	(174,831)	178,621	(446,159)		
Insurance finance costs	1,285,455	79,143	5,111	1,369,709		
Effects of changes in interest rates	(950,826)	(99,967)	-	(1,050,793)		
Total	(115,320)	(195,655)	183,732	(127,243)		
Premiums received	6,762,939	-	-	6,762,939		
Other expenses paid	(4,938,079)	-	-	(4,938,079)		
Insurance acquisition cash flows	(74,168)	-	-	(74,168)		
Total insurance contracts at 12/31/2024	16,219,956	544,178	636,667	17,400,801		
Insurance contract liabilities at 12/31/2024	16,228,704	544,145	650,599	17,423,448		
Insurance contract assets at 12/31/2024	(8,748)	33	(13,932)	(22,647)		

<sup>(</sup>a) The estimates of the present value of future cash flows for the contracts initially recognized in the period includes an estimate of R\$2,796,542 in net written premiums, R\$2,717,506 in claims and other insurance service expenses, and R\$21,257 in acquisition cash flows.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 12. Insurance contract assets and liabilities (Continued)

## 12.3. Expected recognition of contractual service margin (CSM) in future years

		Consolidated						
		Long-term contr	acts (BBA/VFA)					
	2025	2026 to 2030	After 2030	09/30/2025				
Release of CSM	12,073	188,492	424,383	624,948				
		Consol						
		Long-term contr	acts (BBA/VFA)					
	2025	2026 to 2030	After 2030	12/31/2024				
Release of CSM	37,239	176,113	423,315	636,667				

## 12.4. Expected recognition of acquisition cash flows in future years

		Conso	lidated	
		Short-term co	ntracts (PAA)	
			Above	
	1 year	5 years	5 years	09/30/2025
Release of assets for acquisition cash flows	728,087	1,407,247	66,999	2,202,333
		Conso	lidated	
		Short-term co	ntracts (PAA)	
			Above	
	1 year	5 years	5 years	12/31/2024

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 12. Insurance contract assets and liabilities (Continued)

#### 12.5. Guarantee for technical reserves

The subsidiaries regulated by Brazil's Private Insurance Supervisory Office ("SUSEP") and the Brazilian Regulatory Agency for Private Health Insurance and Plans ("ANS"), based on the regulatory guidance established by these agencies, have to keep assets offered as guarantee for their technical reserves (liabilities representing the obligations of these companies to the policyholders/beneficiaries), measured based on accounting standards defined by such regulators, which differ materially from CPC 50/IFRS 17.

The assets offered as guarantee for such technical reserves are recorded in clearinghouses in the technical reserve account. SUSEP and ANS may authorize the free movement of assets offered as guarantee by the regulated companies, provided that all financial requirements regarding the coverage of technical reserves and sufficiency of capital, as well as all accounting obligations, are met.

As at September 30, 2025, the subsidiaries regulated by SUSEP and ANS were compliant with the requirements for coverage of technical reserves.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# 13. Loans, financing and debentures

				Principal	B				Indiv	ridual	Consc	lidated
Transaction/Instrument	Index	Spread	Curren cy	(R\$)	Beginni ng	Maturity	Amortization	Guarantees	09/30/2025	12/31/2024	09/30/2025	12/31/2024
Citibank III (a)	SOFR	0.99%	US\$	304,158	Apr/23	Apr/27	Annual	n/a	328,848	371,948	328,848	371,948
BofA II (a)	Fixed rate	0.88%	EUR€	400.520	Jun/21	Jun/25	Bullet	n/a	-	425,221	-	425,221
BofA III (b) / (d)	Fixed rate	4.93%	US\$	900,000	Jan/25	Feb/28	Bullet	n/a	-	-	823,282	-
JP Morgan II (a)	Fixed rate	1.58%	US\$	520,000	Jul/20	Jul/25	Bullet	n/a	-	606,665	-	606.665
CCB Bank of China	100% of DI	1.20%	R\$	85,000	May/20	May/26	Bullet	n/a	90,185	86,096	90,185	86,096
Other (f)	Fixed rate/IPCA	-	R\$	n/a	n/a	Mar/28	Monthly	Surety	-	-	3,946	30,809
Debentures – 5 <sup>th</sup> issue - Esperança	100% of DI	1.35%	R\$	1,100,000	Dec/24	Nov/34	Bullet	n/a ´	-	-	1,156,720	1,105,033
Debentures – 10 <sup>th</sup> issue (a)	Fixed rate	11.82%	R\$	1,628,100	Jan/18	Jan/28	Bullet	n/a	1,552,044	1,476,975	32,460	33,397
Commercial paper (b) / (g)	104.52% of DI	_	R\$	900,000	Aug/25	Sept/28	Bullet	n/a	· · ·	-	913,581	· -
Debentures – 14th issue (b)	106% of DI	-	R\$	500,000	Oct/18	Oct/26	Annual	Property	265,727	254,145	265,727	254,145
Debentures – 17 <sup>th</sup> issue 3 <sup>rd</sup> series (b)	100% of DI	0.79%	R\$	1,000,000	Jun/19	Jun/29	Annual	n/a	1,038,852	998,592	1,038,852	998,592
Debentures – 17 <sup>th</sup> issue 2 <sup>nd</sup> series (c)	100% of DI	1.25%	R\$	2,500,000	Dec/19	Dec/26	Annual	n/a	· · ·	1,747,726	· · · · -	1,747,726
Debentures – 17th issue 1st series (a)	Fixed rate	8.75%	R\$	3,198,350	Apr/20	Jan/30	Bullet	n/a	2,474,369	2,229,774	-	· · · · -
Debentures – 19th issue 2nd series	100% of DI	1.90%	R\$	2,500,000	Aug/21	Aug/31	Annual	n/a	2,536,094	2,602,930	2,536,094	2,602,930
Debentures – 19th issue 3rd series	100% of DI	1.90%	R\$	1,500,000	Sept/21	Aug/31	Annual	n/a	1,521,656	1,561,758	1,521,656	1,561,758
Debentures - 23 <sup>rd</sup> issue 2 <sup>nd</sup> series	100% of DI	1.90%	R\$	850,000	May/22	May/32	Annual	n/a	899,566	858,913	899,566	858,913
Debentures - 23 <sup>rd</sup> issue 3 <sup>rd</sup> series	100% of DI	1.90%	R\$	625,000	May/22	May/32	Annual	n/a	661,445	631,554	661,445	631,554
Debentures – 25th issue 1st series	100% of DI	2.00%	R\$	450,000	Oct/22	Oct/32	Bullet	n/a	481,959	459,870	481,959	459,870
Debentures – 25 <sup>th</sup> issue 2 <sup>nd</sup> series	100% of DI	1.95%	R\$	150,000	Oct/22	Oct/32	Annual	n/a	160,617	153,274	160,617	153,274
Debentures – 27th issue	100% of DI	1.70%	R\$	1,100,000	Feb/23	Feb/30	Annual	n/a	1,115,629	1,144,468	1,115,629	1,144,468
Debentures – 29th issue	100% of DI	2.25%	R\$	1,000,000	Aug/23	Jul/31	Annual	n/a	1,026,586	1,051,540	1,026,586	1,051,540
Debentures – 31st issue	100% of DI	2.00%	R\$	500,000	Oct/23	Oct/31	Annual	n/a	537,453	512,441	537,453	512,441
Debentures – 33rd issue	100% of DI	1.70%	R\$	2,000,000	May/24	May/34	Bullet	n/a	2,125,251	2,028,319	2,125,251	2,028,319
Debentures - 34th issue 1st series	100% of DI	0.65%	R\$	2,750,000	Oct/24	Sept/27	Bullet	n/a	2,756,967	2,804,995	2,756,967	2,804,995
Debentures – 34th issue 2nd series	100% of DI	1.10%	R\$	1,500,000	Oct/24	Sept/31	Bullet	n/a	1,504,093	1,531,460	1,504,093	1,531,460
Debentures – 34th issue 3rd series	100% of DI	1.30%	R\$	1.650.000	Oct/24	Sept/34	Bullet	n/a	1.654.645	1,685,320	1.654.645	1,685,320
Debentures – 35th issue (e)	100% of DI	0.90%	R\$	1,000,000	Jun/25	Jun/33	Annual	n/a	1,041,581	-	1,041,581	-
Debentures – 36th issue 1st series (i)	100% of DI	1.00%	R\$	1,155,520	Aug/25	Aug/32	Bullet	n/a	1,168,934	-	1,168,934	-
Debentures – 36th issue 2nd series (i)	100% of DI	1.15%	R\$	531,419	Aug/25	Aug/35	Annual	n/a	537,670	-	537,670	-
Debentures – 36th issue 3rd series (i)	100% of DI	1.55%	R\$	558,500	Aug/25	Aug/40	Annual	n/a	565,300	_	565,300	-
Debentures – 37 <sup>th</sup> issue (a) / (h)	Fixed rate	15.40%	R\$	2,740,100	Sept/25	Sept/35	Bullet	n/a	2,812,054	-		-
Debentures (SULA) - 9 <sup>th</sup> issue 2 <sup>nd</sup> series	100% of DI	1.70%	R\$	750,000	Nov/21	Nov/28	Annual	n/a	818,151	781,036	818,151	781.036
Debentures GGSH (f)	100% of DI	2.20%	R\$	100.000	Dec/23	Dec/28	Semiannual	n/a	-	-	-	100,677
Debentures GGSH (f)	100% of DI	1.70%	R\$	500,000	Apr/24	Apr/29	Annual	n/a	_	_	_	503,385
CCB GGSH (f)	100% of DI	2.42%	R\$	125,000	Aug/23	Aug/28	Semiannual	Surety	_	_	_	129,347
Senior Notes I (a)	Fixed rate	4.95%	US\$	1,596,400	Jan/18	Jan/28	Bullet	n/a	-	_	2,587,803	2,900,649
Senior Notes II (a)	Fixed rate	4.50%	US\$	5,062,504	Jan/20	Jan/30	Bullet	n/a	-	-	3,485,640	3,745,843
Senior Notes III (a) / (j)	Fixed rate	6.45%	US\$	2,740,100	Sept/25	Sept/35	Bullet	n/a	-	-	2,687,372	-
Mortgage-backed Securities (CRI) – 2 <sup>nd</sup> issue Mortgage-backed Securities (CRI) – 3 <sup>rd</sup> issue	IPCA	6.06%	R\$	300,000	Jul/18	Jul/25	Bullet	n/a	-	431,574	-	431,574
2 <sup>nd</sup> series Mortgage-backed Securities (CRI) – 4 <sup>th</sup> issue	IPCA	4.66%	R\$	372,949	Dec/18	Dec/25	Bullet	n/a	553,867	517,624	553,867	517,624
2 <sup>nd</sup> series	IPCA	3.93%	R\$	30,100	Feb/19	Feb/26	Bullet	n/a	43,082	41,233	43,082	41,233
Mortgage-backed Securities (CRI) – 5 <sup>th</sup> issue Mortgage-backed Securities (CRI) – 6 <sup>th</sup> issue (a)	IPCA	3.45%	R\$	538,328	Sept/19	Aug/29	Annual	n/a	742,129	721,601	742,129	721,601
(4)	IPCA	4.93%	R\$	1,500,000	May/21	May/36	Annual	n/a	1,367,823	1,251,080	1,367,823	1,251,080

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# 13. Loans, financing and debentures (Continued)

				Principal					Indiv	ridual	Consol	idated
Transaction/Instrument	Index	Spread	Curren cy	(R\$)	Beginn ing	Maturity	Amortization	Guarantees	09/30/2025	12/31/2024	09/30/2025	12/31/2024
Mortgage-backed Securities (CRI) – 7 <sup>th</sup> issue 1 <sup>st</sup> series (a)	IPCA	5.58%	R\$	400,000	Dec/21	Dec/31	Annual	n/a	420,150	391,767	420,150	391,767
Mortgage-backed Securities (CRI) – 7 <sup>th</sup> issue 2 <sup>nd</sup> series (a) Mortgage-backed Securities (CRI) – 8 <sup>th</sup> issue	IPCA	6.10%	R\$	600,000	Dec/21	Dec/36	Annual	n/a	583,328	541,243	583,328	541,243
2 <sup>nd</sup> series (a)  Mortgage-backed Securities (CRI) – 8 <sup>th</sup> issue	IPCA	5.83%	R\$	798,634	Jun/22	Jun/29	Bullet	n/a	830,883	775,219	830,883	775,219
3 <sup>rd</sup> series (a)  Mortgage-backed Securities (CRI) – 9 <sup>th</sup> issue 1 <sup>st</sup>	IPCA	6.01%	R\$	341,867	Jun/22	Jun/32	Annual	n/a	344,679	322,852	344,679	322,852
series (a) Mortgage-backed Securities (CRI) – 9 <sup>th</sup> issue	IPCA	6.38%	R\$	30,000	Aug/22	Jul/29	Bullet	n/a	31,557	30,538	31,557	30,538
2 <sup>nd</sup> series (a) Mortgage-backed Securities (CRI) – 9 <sup>th</sup> issue	IPCA	6.54%	R\$	70,000	Aug/22	Jul/32	Bullet	n/a	71,220	69,346	71,220	69,346
3 <sup>rd</sup> series (a) Mortgage-backed Securities (CRI) – 10 <sup>th</sup> issue 1 <sup>st</sup> series	IPCA 100% of DI	6.77%	R\$	400,000	Aug/22	Jul/37	Bullet	n/a	396,628	386,124	396,628	386,124
Mortgage-backed Securities (CRI) – 10 <sup>th</sup> issue 2 <sup>nd</sup> series	100% of DI	0.75% 1.00%	R\$ R\$	86,186 176,323	Dec/22 Dec/22	Dec/27 Dec/29	Bullet Bullet	n/a n/a	87,549 246.735	83,985 220.960	87,549 246,735	83,985 220,960
Mortgage-backed Securities (CRI) – 10 <sup>th</sup> issue 3 <sup>rd</sup> series (a)	IPCA	6.79%	R\$	82.487	Dec/22	Dec/29	Bullet	n/a	86.181	80.247	86,181	80,247
Mortgage-backed Securities (CRI) – 10 <sup>th</sup> issue 4 <sup>th</sup> series (a)	IPCA	6.94%	R\$	55,004	Dec/22	Dec/32	Annual	n/a	55,975	52,203	55,975	52,203
Mortgage-backed Securities (CRI) – 11 <sup>th</sup> issue 1 <sup>st</sup> series	100% of DI	1.00%	R\$	429,340	Aug/23	Aug/28	Bullet	n/a	425,516	434,531	425,516	434,531
Mortgage-backed Securities (CRI) – 11 <sup>th</sup> issue 2 <sup>nd</sup> series (a)  Mortgage-backed Securities (CRI) – 11 <sup>th</sup> issue	IPCA	6.20%	R\$	557,457	Aug/23	Aug/30	Bullet	n/a	541,193	523,380	541,193	523,380
3 <sup>rd</sup> series (a)  Mortgage-backed Securities (CRI) – 11 <sup>th</sup> issue	IPCA	6.55%	R\$	524,038	Aug/23	Aug/33	Annual	n/a	495,175	478,712	495,175	478,712
1 <sup>st</sup> series (a)  Mortgage-backed Securities (CRI) – 12 <sup>th</sup> issue	IPCA	6.69%	R\$	250,000	Dec/23	Dec/33	Annual	n/a	242,976	227,625	242,976	227,625
2 <sup>nd</sup> series (a) Mortgage-backed Securities (CRI) – 13 <sup>th</sup> issue	IPCA	6.95%	R\$	500,000	Dec/23	Dec/38	Annual	n/a	472,649	441,344	472,648	441,344
1 <sup>st</sup> series (k)	IPCA	7.22%	R\$	115,114	Sept/25	Sept/35	Bullet	n/a	-	-	108,754	-
Mortgage-backed Securities (CRI) – 13 <sup>th</sup> issue 2 <sup>nd</sup> series (k)	IPCA	7.10%	R\$	214,886	Sept/25	Sept/45	Bullet	n/a		-	203,010	
								Current Noncurrent	37,714,971 1,819,800 35,895,171	34,028,208 3,920,516 30,107,692	42,879,071 1,877,425 41,001,646	38,870,599 3,915,191 34,955,408

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 13. Loans, financing and debentures (Continued)

- (a) As mentioned in Note 24, the Group enters into derivative financial instruments to hedge foreign exchange differences and interest rate (Fixed rate, SOFR and IPCA) at a floating interest rate in Brazilian reais indexed to the CDI, and has adopted the fair value hedge accounting as accounting practice; therefore, these debts are recorded at fair value through profit or loss.
- (b) As mentioned in Note 24, the Group enters into derivative financial instruments to hedge interest rate or foreign exchange difference at a fixed interest rate in Brazilian reais and has adopted the cash flow hedge accounting as accounting practice; therefore, these debts are recorded at amortized cost and derivatives at fair value. The effective portion of the debt is recorded at fair value through other comprehensive income and any ineffective portion and interest at fair value through profit or loss.
- (c) On January 13, 2025, Rede D'Or carried out the optional early redemption of its 2<sup>nd</sup> series of the 17<sup>th</sup> Debenture Issue of Rede D'Or São Luiz S.A. in the principal amount of R\$1,750,000.
- d) On January 31, 2025, through its subsidiary Sul América Companhia de Seguro Saúde, Rede D'Or paid in a foreign currency loan in the amount of US\$154 million, maturing on February 3, 2028 with an interest rate of 4.93% p.a., payable semiannually. Concomitantly, a derivative financial instrument was entered into to hedge against exchange rate fluctuations and foreign currency interest, for R\$900 million, at a fixed interest rate in Brazilian reais of 14.86% p.a.
- (e) On June 13, 2025, Rede D'Or paid in the 35<sup>th</sup> issue of Debentures in a single series, in the total amount of R\$1,000 million, maturing on June 10, 2033. This issue is indexed to the CDI + 0.90% p.a., to be paid semiannually. There are no quarantees.
- (f) This balance reduction mainly refers to the transfer to available-for-sale liabilities. Refer to Note 26 for more details.
- (g) On August 25, 2025, Sul América Companhia de Seguro Saúde paid in the first issue of Commercial Papers, totaling R\$900 million, maturing on September 5, 2028 with interest equivalent to 104.52% of the interbank deposit rate (DI) p.a., to be paid semiannually. There are no quarantees.
- (h) On September 30, 2025, Rede D'Or paid in the 37th issue of debentures in a single series, in the total amount of R\$2,740 million, maturing on September 05, 2035 with a fixed interest rate of 15.40% p.a. to be paid semiannually. There are no guarantees. Concomitantly, the Company entered into a hedging transaction to hedge interest rate at a cost of CDI + 2.07% p.a. (fixed to floating rate).
- (i) On August 25, 2025, Rede D'Or paid in the 36th issue of debentures in three series, in the total amount of R\$2,245 million, maturing on August 20, 2032, August 20, 2035 and August 20, 2040. The first series is indexed to the CDI + 1.00% p.a., the second series to the CDI + 1.15% p.a., and the third series to the CDI + 1.55% p.a., to be paid semiannually. There are no guarantees.
- j) On September 9, 2025, through its wholly-owned subsidiary Rede D'Or Finance, a privately-held corporation located in Luxembourg, Rede D'Or conducted the 3<sup>rd</sup> issue of Senior Notes, in the total amount of US\$500 million, adjusted at an interest rate of 6.45% p.a., maturing on September 10, 2035, with semiannual interest payments from March 9, 2026 and lump-sum payment of principal on September 10, 2035. Concomitantly, a derivative financial instrument was entered into to hedge against exchange rate fluctuations and foreign currency interest, for R\$2,740 million, at a fixed interest rate in Brazilian reais of 15.40% p.a.
- (k) On September 25, 2025, GNI64 RJ Empreendimentos Imobiliários Ltda. through a securitization company, has completed the placement of two series of registered, book-entry Real Estate Receivables Certificates ("CRI") totaling R\$ 330 million, maturing on September 17, 2035, and September 17, 2045, to securitize the purchase price of real estate acquired by GNI64 RJ Empreendimentos Imobiliários Ltda. The first series of the CRI is remunerated by IPCA + 7.2182% per year, and the second series is remunerated by IPCA + 7.0959% per year, to be paid semi-annually. There are no guarantees.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 13. Loans, financing and debentures (Continued)

Significant loans, financing and debentures were taken out for general corporate purposes, in order to acquire companies, expand hospitals and build new units.

Total costs related to the issues of loans, financing and debentures, in the amount of R\$321,683 at September 30, 2025 (R\$334,027 at December 31, 2024), were recorded as a reduction of the balances and have been amortized over the term of the agreements, as established by CPC 08 - Transactions Costs and Premiums on Issue of Marketable Securities.

Before the SASA business combination, the Company did not have covenants relating to debt ratios, nor corresponding ratios based on net debt, EBITDA and finance costs rather than the guarantees listed above. Since as a result of the merger, the Company is the successor, there are covenants whose application is suspended, as shown in Note 13.1. below.

At September 30, 2025, the maturity of noncurrent balances is as follows:

09/30/2025							
Ind	ividual	Cons	solidated				
Year	Amount	Year	Amount				
2026	110 100	2026	110 100				
2026	112,423		112,423				
-	3,911,232	2027	3,911,232				
2028	2,865,664	2028	5,665,908				
2029	4,281,412	2029	4,281,412				
2030	6,099,745	2030	7,134,369				
2031 to 2045	18,624,695	2031 to 2045	19,896,302				
	35,895,171		41,001,646				

#### 13.1. Covenants

The Company is exempt from the obligation to meet any financial ratios (financial covenants) until the quarters stated below, per transaction, as approved at the general meeting of debenture holders held on August 18, 2022.

Issue	Exempt until
Ninth issue of debentures of Sul América S.A.	3 <sup>rd</sup> quarter of 2025

The Company may settle in advance the respective issues before the covenants mentioned above become applicable.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 13. Loans, financing and debentures (Continued)

### 13.1. Covenants (Continued)

From the quarters above, and in accordance with the early maturity clauses contained in the debenture indentures of the Ninth Issue of Debentures of Sul América S.A., the Company will have to maintain certain financial ratios within the previously established thresholds (financial covenants). The table below presents the financial covenants to which the Company will be subject.

Covenant	Ratio
Financial ratio I - net financial debt/casl	1
generation	Equal to or lower than 2 times the cash generation
Financial ratio II - cash generation/net	Equal to or higher than 4 times the net finance
finance income (cost)	income (cost)
Financial ratio III - cash generation	Equal to or higher than zero

<u>Net financial debt</u>: financial obligations less cash, cash equivalents and short-term investments, net of technical reserves to be covered.

<u>Cash generation</u>: profit or loss before income taxes, less depreciation and amortization.

### 14. Provision for contingencies and judicial deposits

The Company and its subsidiaries are parties to various tax, civil and labor claims. The judicial deposits will only be released in the event of a decision favorable to the Company. Based on the opinion of its internal and external legal advisors, management recognized a provision for losses that is deemed sufficient to cover probable losses, as follows:

		Indi	ividual	
	09/30/2025		12/31/2	2024
	Provision for contingencies	Judicial deposits	Provision for contingencies	Judicial deposits
Tax and social security	347,045	(374,076)	462,784	(323,131)
Labor	128,599	(32,416)	145,772	(47,037)
Civil	123,202	(6,263)	134,858	(6,045)
	598,846	(412,755)	743,414	(376,213)

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# 14. Provision for contingencies and judicial deposits (Continued)

		Consolidated				
	09/30/	/2025	12/31/	2024		
	Provision for contingencies	Judicial deposits	Provision for contingencies	Judicial deposits		
Tax and social security	1,282,154	(1,801,396)	1,686,457	(2,062,120)		
Labor Civil	295,190 1,503,556	(121,480) (685,465)	299,832 1.372.527	(132,617) (575,349)		
	3,080,900	(2,608,341)	3,358,816	(2,770,086)		

## 14.1. Proceedings assessed as probable loss

Changes in provisions for contingencies for the periods ended September 30, 2025 and 2024 were as follows:

	Individual			
	Tax and social security	Labor	Civil	Total
Balances at December 31, 2023	526,597	136,284	157,304	820,185
Additions, net of reversals Monetary restatement Payments	(64,869) 1,289 (3)	4,763 (9,955)	2,086 (1,774)	(64,869) 8,138 (11,732)
Balances at September 30, 2024	463,014	131,092	157,616	751,722
Balances at December 31, 2024	462,784	145,772	134,858	743,414
Additions, net of reversals Monetary restatement Payments	(118,770) 3,031 -	3,430 8,747 (29,350)	3,998 4,578 (20,232)	(111,342) 16,356 (49,582)
Balances at September 30, 2025	347,045	128,599	123,202	598,846

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 14. Provision for contingencies and judicial deposits (Continued)

## 14.1. Proceedings assessed as probable loss (Continued)

	Consolidated				
	Tax and social				
	security	Labor	Civil	Total	
Balances at December 31, 2023	1,714,567	293,306	1,260,481	3,268,354	
Additions, net of reversals	(64,438)	2,585	326,639	264,786	
Monetary restatement	44,882	14,061	90,334	149,277	
Payments	(319)	(26,463)	(285,935)	(312,717)	
Additions from business combinations	2,970	-	-	2,970	
Balances at September 30, 2024	1,697,662	283,489	1,391,519	3,372,670	
Balances at December 31, 2024	1,686,457	299,832	1,372,527	3,358,816	
Additions, net of reversals	(117,451)	20,388	346,990	249,927	
Monetary restatement	42,650	18,964	116,412	178,026	
Payments (a)	(329,502)	(42,302)	(332,370)	(704,174)	
Transfer to held-for-sale liabilities	•	(1,692)	(3)	(1,695)	
Balances at September 30, 2025	1,282,154	295,190	1,503,556	3,080,900	

<sup>(</sup>a) Of the total payments made in the period, R\$328,740 refers to settlement of the proceedings with the transformation of the judicial deposit into definitive payment.

#### 14.2. Proceedings assessed as possible loss

The proceedings assessed as possible loss by the Company and its legal advisors, for which no provisions have been recorded, are summarized below:

	Indiv	ridual	Conso	lidated
	09/30/2025	12/31/2024	09/30/2025	12/31/2024
Tax and social security (a)	1,043,399	972,718	2,807,346	2,659,709
Labor (b)	412,727	307,328	801,937	614,114
Civil (c)	504,830	556,926	857,120	962,733
	1,960,956	1,836,972	4,466,403	4,236,556

<sup>(</sup>a) As of September 30, 2025, of the total amount of R\$ 2,807,346 (R\$ 2,659,709 as of December 30, 2024). The unprovisioned portion consists of tax disputes, among which the most relevant relate to the following issues: (i) tax assessments issued against the subsidiaries CIA. SAÚDE and TRADITIO, questioning the deductibility of amortization of goodwill arising from the merger of the parent companies SLT Participações S.A. and STA Participações S.A., respectively, in the calendar years 2005, 2006 and 2007; (ii) non-approval of tax offsets in the administrative sphere; (iii) disallowance of tax loss carryforwards and negative tax base; (iv) proceedings seeking to collect ISS debts arising from alleged failure to pay the tax on services rendered in the Municipality of São Paulo, currently under appeal, following a favorable ruling in the Execution Objections filed by SulAmérica.

In addition, the Company is a party to various tax proceedings involving PIS, COFINS, ISS and Real Estate Tax (IPTU). There are no individually significant proceedings.

<sup>(</sup>b) Proceedings largely derived from overtime payment, 13th monthly salary, 30-day resignation notice, vacation pay and Unemployment Compensation Fund (FGTS). There are no individually significant proceedings.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 14. Provision for contingencies and judicial deposits (Continued)

#### **14.2. Proceedings assessed as possible loss** (Continued)

(c) Proceedings related to compensation for alleged property and pain and suffering damages. There are no individually significant proceedings.

Considering the complexities of the lawsuits, as well as of the Brazilian legal system, the Company cannot estimate with reasonable accuracy a timeframe for the judgment to take place and whether any amounts will be disbursed in connection with these legal proceedings.

#### 15. Leases

	Indiv	idual	
	09/30/2025	12/31/2024	
Nominal value of future payments	6,906,363	6,968,840	
Present value adjustment	(3,954,379)	(4,041,120)	
_	2,951,984	2,927,720	
Current	622,778	627,124	
Noncurrent	2,329,206	2,300,596	
_	Consolidated		
_	09/30/2025	12/31/2024	
Nominal value of future payments	9,401,621	9,392,666	
Present value adjustment	/ <del>-</del>		
	(5,711,740)	(5,790,193)	
	(5,711,740) 3,689,881	(5,790,193) 3,602,473	
-			
Current			

The liabilities were measured at the present value of the remaining lease payments discounted at the average rate of 14.59% at September 30, 2025.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

### 15. Leases (Continued)

At September 30, 2025, the maturity of noncurrent balances is as follows:

Individua	I	Consolidat	ted
Year	Amount	Year	Amount
2026	140.318	2026	173.928
2027	549,798	2027	663,612
2028	497,584	2028	601,065
2029	470,068	2029	561,227
2030	451,682	2030	524,089
2031 to 2059	4,174,135	2031 to 2082	6,052,481
Undiscounted amounts	6,283,585	Undiscounted amounts	8,576,402
Embedded interest	(3,954,379)	Embedded interest	(5,711,740)
Balance at 09/30/2025	2,329,206	Balance at 09/30/2025	2,864,662

## 16. Equity

#### a) Capital

The Company's capital is broken down as follows:

	09/30	0/2025	12/31/2024		
Shareholders	Number of shares	Equity interest	Number of shares	Equity interest	
Controlling shareholders Outstanding shares Treasury shares Total common shares	1,088,604,826 1,118,138,582 82,549,182 2,289,292,590	47.55% 48.84% 3.61% 100%	1,087,728,526 1,132,391,070 69,172,994 2,289,292,590	47.51% 49.46% 3.02% 100%	

Subscribed and paid-in capital at September 30, 2025 amounts to R\$15,711,360 represented by 2,289,292,590 no-par-value registered common shares (R\$15,711,360 at December 31, 2024 represented by 2,289,292,590 no-par-value registered common shares). As approved in the Company's Articles of Incorporation, the limit of authorized capital is up to 8 billion shares (units).

Under the Company's Articles of Incorporation, each common share is entitled to a vote at the Company's general meetings.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## **16. Equity** (Continued)

### a) Capital (Continued)

The premium reserve on issue of shares derived substantially from capital contributions made (i) on March 31, 2015, by the former shareholder BTG Pactual Saúde Fundo de Investimento em Participações, in the amount of R\$600,000, of which R\$147,664 were recorded as capital increase and R\$452,336 as premium reserve on the subscription of shares; and (ii) on April 27, 2015, by HPT Participações S.A. (Carlyle Group investee), in the amount of R\$1,819,435, of which R\$181,943 for capital increase and R\$1,637,491 as premium reserve on the subscription of shares.

At the Special General Meeting (SGM) held on September 24, 2020, shareholders approved the Company's capital increase in the amount of R\$1,600,000, without issue of new shares, through capitalization of part of the capital reserve. In connection with the IPO, on December 8, 2020 the Company carried out a capital increase of R\$ 4,218,820 and an increase in the capital reserve of R\$ 4,218,820. At December 31, 2020, the net effect on the capital reserve was R\$ 2,618,820.

In connection with the follow-on offering, on May 26, 2021 the Company carried out a capital increase of R\$ 888,920 and an increase in the capital reserve of R\$ 888,920. Other events occurred in 2021 and 2022 and reduced the capital reserve.

#### b) Allocations of income

Changes in the balances of dividends and interest on equity payable in the periods ended September 30, 2025 and 2024 were as follows:

	2025	2024
Balance payable at December 31	69,192	99,769
Allocation of dividends and IOE	1,350,000	1,000,000
Reinvested dividends	-	(25,066)
Additions from business combination	-	17,604
Allocation of dividends and IOE - noncontrolling interests	203,032	65,263
Payment of dividends and IOE	(1,025,557)	(712,412)
Withholding income tax	(132,373)	(114,005)
Balance payable at September 30	464,294	331,153

The distribution and payments of dividends and interest on equity were approved at the Board of Directors' Meeting held on March 21, 2025, June 11, 2025 and September 18, 2025, ad *referendum* of the Company's Annual General Meeting (AGM).

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 16. Equity (Continued)

#### c) Treasury shares

Changes in treasury shares are as follows:

	09/30/2025			09/30/2024		
	Number of shares	Share value (in reais)	Total	Number of shares	Share value (in reais)	Total
Balance at December 31	69,172,994	21.09	1,458,602	34,685,880	14.97	519,418
Share buyback (a) Disposals of shares (b) Return of shares	13,393,000 (37,700) 20,888	27.70 21.27 -	370,933 (802) -	12,912,900 (512,226) 121,909	26.46 14.97 -	341,739 (7,671)
Balance at September 30	82,549,182	22.15	1,828,733	47,208,463	18.08	853,486

<sup>(</sup>a) On December 13, 2024, the second buyback program was approved for shares issued by the Company, to be held in treasury and subsequently cancelled or disposed of. The settlement of share buyback transactions will be carried out within a maximum period of 12 months, starting on December 16, 2024 and concluding on December 15, 2025.

#### d) Share-based payment (Restricted shares)

#### Restricted Stock Option Plan

The plan establishes the terms and conditions for the granting of common shares issued by the Company, subject to certain restrictions, to managing officers, employees and service providers of the Company, or of other companies under its control.

#### 1st Restricted Stock Option Program

In 2020, the Company's Board of Directors approved the 1<sup>st</sup> Restricted Stock Option Program and established the conditions for the granting of the Company's no-par-value registered common shares to managing officers and employees.

The rights of beneficiaries in relation to restricted shares will only be fully vested if their contract with the Company or with any entity under its control, as the case may be, is not terminated for a certain period, subject to the conditions for the release of trading restrictions, as defined by the Board of Directors, with specific conditions in case of termination.

<sup>(</sup>b) Shares purchased and sold substantially refer to the share-based payment plan, as described below.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## **16. Equity** (Continued)

d) Share-based payment (restricted shares) (Continued)

Restricted Stock Option Plan (Continued)

<u>1<sup>st</sup> Restricted Stock Option Program</u> (Continued)

The total restricted shares delivered through the Restricted Stock Option Plan cannot exceed the maximum limit of 5% (five percent) of shares issued by the Company, which at September 30, 2025 was equivalent to a total of 114,464,630 shares.

In the nine-month period ended September 30, 2025, a total of 52,000 Restricted Shares was granted to the elected beneficiaries, referring exclusively to the 1<sup>st</sup> Restricted Stock Option Program, at the weighted average price of R\$19.63. All restricted shares granted in the ninemonth period ended September 30, 2025 were vested immediately on January 2, 2025, and there are no restricted shares already granted that have not been vested.

Of the total shares mentioned above, for purposes of measuring shareholder dilution, the total amount of shares effectively vested for the beneficiaries under the 1<sup>st</sup> Restricted Stock Option Program was 52,000 shares, referring exclusively to the Restricted Stock Option Plan, in accordance with item 33-E of Accounting Pronouncement CPC 10 - Share-Based Payment.

For the purpose of calculating the expenses to be allocated, a projected cancellation rate of 7.14% was used, based on the average historical cancellations of the Company's plans.

### 2<sup>nd</sup> Restricted Stock Option Program

Within the scope of the Restricted Stock Option Plan, the Company's Board of Directors approved the 2<sup>nd</sup> Restricted Stock Option Program, beginning January 2022, which established the specific conditions for receiving a certain amount of units of reference that will entitle to the settlement of awards provided for in the individual grant agreements, which can be settled with no-par-value registered common shares of the Company to its managing officers, employees and service providers, or in cash, at the Company's discretion, depending, in that case, on the appreciation of the RDOR3 share price in a certain period of time, or on the variation of the Company's EBITDA, under the terms of the individual agreements.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## **16. Equity** (Continued)

d) Share-based payment (restricted shares) (Continued)

Restricted Stock Option Plan (Continued)

2<sup>nd</sup> Restricted Stock Option Program (Continued)

In the nine-month period ended September 30, 2025, 3,939,375 Units of Reference in total were granted to the elected beneficiaries, related exclusively to the 2<sup>nd</sup> Restricted Stock Option Program, which is not yet fully vested.

The 2<sup>nd</sup> Restricted Stock Option Program is measured and recognized at fair value, using the Company's valuation identification model (Market cap) and deducting the reference value agreed with each executive officer, duly restated by reference to the IPCA or by the variation of the Company's EBITDA, according to Accounting Pronouncement CPC 10 - Share-Based Payment.

The rights of the beneficiaries in relation to the restricted shares will only be fully vested if their contract with the Company or any entity under its control, as the case may be, is not terminated for a certain period and if the result of the award arising from the exercise of their units of reference is positive in the specific settlement windows provided for in the individual agreements, which implies the RDOR3 share price at the time of the settlement window, or that there has been progress in the result of the formula for the variation of EBITDA, for the Beneficiary to be entitled to receive it, under specific conditions in case of termination. The Company pays all taxes and charges levied on the award at the time of its settlement in shares, or in cash, at its sole discretion.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## **16. Equity** (Continued)

d) Share-based payment (restricted shares) (Continued)

Restricted Stock Option Plan (Continued)

2<sup>nd</sup> Restricted Stock Option Program (Continued)

For the purpose of calculating the expenses to be allocated, a cancellation rate of 1.28% was used, based on the average historical cancellations of the Company's plans.

Like previous plans, the 1<sup>st</sup> Restricted Stock Option Program was measured and recognized at fair value using the Black, Scholes & Merton (1973) model, according to Accounting Pronouncement CPC 10 - Share-Based Payment, whose main assumptions are described below.

The 2<sup>nd</sup> Restricted Stock Option Program is measured and recognized at fair value, using the Company's valuation identification model (Market cap) and deducting the reference value agreed with each executive officer, duly restated by reference to the IPCA, according to Accounting Pronouncement CPC 10 - Share-Based Payment.

Program	Year	Vesting period	Number of shares	Annual volatility	Risk-free rate	Weighted average of fair value of shares (in reais)	Vesting status	Options canceled
1 <sup>st</sup> program	2020	05/29/2020 to 05/29/2027	46.591.300	26.36%	4.66%	7.45	Partially vested	-
1st program	2021	04/01/2021 to 04/01/2028	5,361,026	28.81%	5.98%	25.50	Partially vested	-
1 <sup>st</sup> program	2022	01/01/2022 to 01/01/2028	3,577,793	32.75%	11.55%	15.03	Partially vested	-
2 <sup>nd</sup> program	2022	01/01/2022 to 12/31/2028	2,392,730	-	-	29.16	Partially vested	75,002
1 <sup>st</sup> program	2023	01/01/2023 to 12/31/2028	2,371,279	44.56%	11.64%	12.95	Partially vested	· -
2 <sup>nd</sup> program	2023	01/01/2023 to 12/31/2029	2,731,014	-	-	19.15	Partially vested	3,572
1st program	2024	01/01/2024 to 12/31/2028	706,519	43.61%	9.77%	11.07	Partially vested	· -
2 <sup>nd</sup> program	2024	01/01/2024 to 12/31/2030	3,451,522	-	-	22.70	Partially vested	15,715
1st program	2025	01/01/2025 to 12/31/2028	52,000	39.73%	14.97%	7.98	Partially vested	· -
2 <sup>nd</sup> program	2025	01/01/2025 to 12/31/2030	3,939,375	-	-	22.21	Partially vested	15,715

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## **16. Equity** (Continued)

#### d) Share-based payment (restricted shares) (Continued)

Restricted Stock Option Plan (Continued)

The effects of the share-based payment plans, covering all granted and outstanding options, on equity and profit or loss for the year, are as follows:

	Fair value of	Effect on P&L for		Cumulative effect on liabilities and
	options per year	the year	Changes - RSU	equity
2011	1,457	1,457	-	1,457
2012	16,234	16,234	-	17,691
2013	20,656	20,656	-	38,347
2014	27,363	27,363	-	65,710
2015	51,949	51,949	-	117,659
2016	30,864	30,864	-	148,523
2017	32,599	32,599	-	181,122
2018	40,662	40,662	-	221,784
2019	40,656	40,656	-	262,440
2020	80,071	80,071	(80,071)	-
2021	120,427	120,427	(120,427)	-
2022	124,276	124,276	(70,623)	53,653
2023	78,400	78,400	(42,769)	37,179
2024	77,907	77,907	(18,944)	58,976
2025	68,195	68,195	(14,198)	53,997
2026	11,670			
2027	11,670	_		
	835,056	-		

#### e) Other comprehensive income

In the nine-month period ended September 30, 2025, the effects of the cash flow hedge taken out for debt hedging purposes were recognized as other comprehensive income, reducing equity for the period by R\$69,610, as well as net finance income (costs) from insurance and reinsurance contracts, reducing equity for the period by R\$128,281.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 17. Current and deferred taxes

Income and social contribution tax expenses for the nine-month periods ended September 30, 2025 and 2024 are as follows:

	Indiv	ridual	Consolidated		
	09/30/2025	09/30/2024	09/30/2025	09/30/2024	
Deferred					
Income tax	322,392	110,298	375,688	198,882	
Social contribution tax	116,323	40,449	125,950	69,369	
	438,715	150,747	501,638	268,251	
Current				_	
Income tax	1,876	1,060	(859,972)	(697,867)	
Social contribution tax	273	421	(432,286)	(328,143)	
	2,149	1,481	(1,292,258)	(1,026,010)	
Income and social contribution tax expenses	440,864	152,228	(790,620)	(757,759)	

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 17. Current and deferred taxes (Continued)

Changes in deferred income and social contribution tax assets and liabilities for nine-month periods ended September 30, 2025 and 2024 were as follows:

			Individual			Cons	solidated		
	12/31/2024	Additional benefits (expenses) recorded	Other comprehensiv e income	09/30/2025	12/31/2024	Additional benefits (expenses)	Other comprehensiv e income	Transfer to available-for-sale assets	09/30/2025
Assets									
Income tax losses	595,545	342,942	-	938,487	1,128,997	352,289	-	(16,269)	1,465,017
Social contribution tax losses	249,677	123,459	-	373,136	401,535	114,599	-	(5,857)	510,277
Allowance for expected credit losses and provision for disallowances	364,296	23,897	-	388,193	812,962	84,654	-	(9,987)	887,629
Provision for contingencies	89,430	(8,304)	-	81,126	944,730	42,144	-	-	986,874
Provision for bonuses	86,720		-	86,720	86,771	22,069	-	-	108,840
Deferred gain on property sales	20,576	(1,000)	-	19,576	15,205	(1,000)	-	-	14,205
Amortization of right of use (IFRS 16)	435,553	71,848	-	507,401	717,591	146,377	-	-	863,968
PVA allocation (IFRS 16)	706,178	106,571	-	812,749	1,007,429	184,835	-	-	1,192,264
Actuarial gain/loss on defined benefit pension plans	-	-	-	-	9,345	-	-	-	9,345
Impairment of tax credits	-	-	-	-	42,954	(1,462)	-	-	41,492
Insurance contracts - IFRS 17	-	-	-	-	1,189,957	(49,813)	85,499	-	1,225,643
Gain/loss on market value adjustment	-	-	-	-	9,757	(10,329)	1,543	-	971
Other provisions	64,401	5,456	-	69,857	25,421	43,093	-	(18,440)	50,074
Total deferred tax assets	2,612,376	664,869	-	3,277,245	6,392,654	927,456	87,042	(50,553)	7,356,599
Liabilities									
Differences between accounting and tax bases of goodwill	(795,498)	(45,314)	-	(840,812)	(1,332,015)	(184,091)	-	530	(1,515,576)
Gain on acquisition in stages	(99,040)	-	-	(99,040)	(124,003)	-	-	-	(124,003)
Swap difference	(273,634)	46,506	-	(227,128)	(240,551)	103,352	-	-	(137,199)
Foreign exchange differences	64,767	(42,568)	_	22,199	65,099	(42,604)	-	_	22,495
Leases (IFRS 16)	(957,927)	(153,071)	_	(1,110,998)	(1,462,644)	(270,768)	_	_	(1,733,412)
Cash flow hedge	(91,802)	(100,011,	35,859	(55,943)	(91,800)	(=::,:::,	35,859	_	(55,941)
Revaluation surplus - business combinations	(564,454)	(31,707)		(596,161)	(564,454)	(31,707)	-	_	(596,161)
Total deferred tax liabilities	(2,717,588)	(226,154)	35,859	(2,907,883)	(3,750,368)	(425,818)	35,859	530	(4,139,797)
Net offert and (link lite)	/F4 0FC)	420.745		207.450	2.462.002	E04 C20		(50.022)	2 044 500
Net effect - asset (liability)	(51,256)	438,715	-	387,459	3,162,893	501,638	-	(50,023)	3,614,508
Net effect - deferred PIS/COFINS	25,041		05.050	26,331	498,984		400.004		593,417
Effect on equity	(53,956)	•	35,859	(18,097)	(520,607)	•	122,901	-	(397,706)
Assets as per statement of financial position	-			395,693	3,509,725				4,221,925
Liabilities as per statement of financial position	(80,171)			-	(368,455)				(411,706)

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 17. Current and deferred taxes (Continued)

			Individual					Cons	olidated		
	12/31/2023	Additional benefits (expenses) recorded	Other comprehensive income	Other (1)	09/30/2024	12/31/2023	Additional benefits (expenses)	Other comprehensiv e income	Other (1)	Additions from business combinations	09/30/2024
Assets											
Income tax losses	625,977	15,152	-	(138,524)	502,605	1,213,641	(59,066)	-	(140,992)	33	1,013,616
Social contribution tax losses	225,352	6,196	-	(15,330)	216,218	427,944	(46,095)	-	(15,913)	20	365,956
Allowance for expected credit losses and											
provision for disallowances	329,421	195,683	-	-	525,104	675,202	271,237	-	-	-	946,439
Provision for contingencies	76,002	(1,222)	-	-	74,780	847,002	81,013	-	-	1,060	929,075
Provision for bonuses	30,416	42,228	-	-	72,644	31,873	60,739	-	-	-	92,612
Deferred gain on property sales	21,909	(1,000)	-	-	20,909	16,538	(1,000)	-	-	-	15,538
Amortization of right of use (IFRS 16)	344,484	65,882	-	-	410,366	576,645	97,274	-	-	-	673,919
PVA allocation (IFRS 16)	571,059	100,849	-	-	671,908	803,240	152,289	-	-	-	955,529
Actuarial gain/loss on defined benefit											
pension plans	-	-	-	-	-	11,910	-	-	-	-	11,910
Impairment of tax credits	-	-	-	-	-	76,559	(31,282)	-	-	-	45,277
Insurance contracts - IFRS 17	-	-	-	-	-	1,524,585	159,055	(189,530)	-	-	1,494,110
Other provisions	74,311	6,822	-	-	81,133	(10,137)	43,406	-	-	2,685	35,954
Total deferred tax assets	2,298,931	430,590	=	(153,854)	2,575,667	6,195,002	727,570	(189,530)	(156,905)	3,798	6,579,935
Liabilities											
Differences between accounting and tax											
bases of goodwill	(735,080)	(45,314)	-	-	(780,394)	(1,119,531)	(157,215)	-	-	-	(1,276,746)
Gain on acquisition in stages	(99,040)		-	-	(99,040)	(124,003)		-	-	-	(124,003)
Swap difference	(82,804)	(121,569)	-	-	(204,373)	(49,721)	(121,569)	-	-	-	(171,290)
Foreign exchange differences	(34,791)	50,066	-	-	15,275	(34,791)	50,287	-	-	-	15,496
Leases (IFRS 16)	(755,084)	(150,113)	-	-	(905,197)	(1,151,821)	(220,415)	-	-	-	(1,372,236)
Cash flow hedge	(61,744)	-	(4,358)	-	(66,102)	(82,637)	-	(441)	-	-	(83,078)
Deferred revenue	(2,666)	_	-	-	(2,666)	(7,601)	-	-	-	-	(7,601)
Variable income investment	-	_	-	-	-	(6,812)	-	-	-	-	(6,812)
Revaluation surplus - business						(					(-,- ,
combinations	(537,114)	(12,913)	-	-	(550,027)	(537,114)	(12,913)	-	-	-	(550,027)
Gain/loss on market value adjustment	-	(,,	-	-	(,,	(26,358)	2,506	7,473	-	-	(16,379)
Total deferred tax liabilities	(2,308,323)	(279,843)	(4,358)	-	(2,592,524)	(3,140,389)	(459,319)	7,032	-	-	(3,592,676)
Net effect - asset (liability)	14,506	150,747	_	(153,854)	11,399	3,154,935	268,251	_	(156,905)	3,798	3,270,079
Net effect - desert (liability)	21.614	130,747	_	(100,004)	41,919	376.838	200,231	_	(130,303)	3,730	498,904
Effect on equity	(23,898)		(4,358)		(28,256)	(100,322)	_	(182,498)		<u> </u>	(282,820)
Enection equity	(23,090)	-	(4,330)	-	(20,230)	(100,322)	-	(102,430)	-	-	(202,020)
Assets as per statement of financial position Liabilities as per statement of financial position	12,222				25,062	3,600,118 (168,667)					3,720,803 (234,640)

<sup>(1)</sup> The reduction in the balance of tax credits recognized on income and social contribution tax loss derived notably from the use of this total within the scope of the tax self-regularization program set forth by the Brazilian IRS.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 17. Current and deferred taxes (Continued)

The reconciliation of income and social contribution taxes to the amount determined at the statutory rate as at September 30, 2025 and 2024 is as follows:

	Individual		Conso	lidated
	09/30/2025	09/30/2024	09/30/2025	09/30/2024
Income before income and social contribution taxes	3,075,110	2,769,692	4,443,286	3,757,095
Income and social contribution tax expenses at statutory rates Social contribution tax rate difference (a)	1,045,537	941,695 -	1,510,717 134,362	1,277,412 69,588
Adjustments to determine the effective rate: Equity pickup, net of any gains earned abroad Interest on equity IOE income	(1,101,077) (459,000) 71,889	(699,309) (340,000)	(9,792) (459,000) -	(11,609) (340,000)
Accrual (reversal) of tax credit on temporary differences Restatement of judicial deposits Unduly paid taxes computed Deduction from programs under tax incentive	- - -	- - - (51,741)	(121,315) (22,574) (13,297)	2,168 (13,808) (14,745) (53,225)
First-time adoption - SUSEP Circular No. 678/2022	-	(31,741)	-	(49,323)
Impact on companies taxed due to rate difference Workers' Meal Program (PAT) and tax	-	-	(65,212)	(38,153)
incentives Tax-exempt income or income subject to	-	-	(29,846)	(17,011)
withholding tax  Tax benefit - Technological innovation	-	-	(60,311) (17,681)	- (22,514)
Permanent losses on receivables Other	1,787	(2,873)	(20,991) (34,440)	(31,021)
Expenses (credit) recorded in the statement of profit or loss	(440,864)	(152,228)	790,620	757,759

<sup>(</sup>a) Refers to the difference in the social contribution tax rate between financial and similar companies (15%) and non-financial subsidiaries (9%).

Accumulated income and social contribution tax losses may be carried indefinitely; however, offsetting is limited to 30% of taxable profit generated in each fiscal year.

The Company expects that deferred tax credits over its tax loss carryforwards will be realized within 1 or 5 years, except for the deferred gain related to the sale of real estate, whose realization will occur over the contractual rent period.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

#### 18. Net revenue

		Indiv	vidual	Conso	lidated
Description	Note	09/30/2025	09/30/2024	09/30/2025	09/30/2024
Hospital services	18,1	11,710,778	10,855,502	17,231,070	16,106,060
Insurance revenue	18,2	, , , <u>-</u>	· · · · -	24,037,180	21,548,407
Revenue from asset management		-	-	81,166	67,830
		11.710.778	10.855.502	41.349.416	37.722.297

#### 18.1. Hospital services

	Indiv	Individual		lidated
	09/30/2025	09/30/2024	09/30/2025	09/30/2024
Gross revenue (a) Deductions from revenue	13,011,903	12,109,767	19,903,143	18,482,512
Cancellations and rebates (a)	(592,976)	(577,306)	(1,118,706)	(1,004,909)
Taxes on revenues	(708,149)	(676,959)	(1,553,367)	(1,371,543)
Net revenue from hospital services	11,710,778	10,855,502	17,231,070	16,106,060

<sup>(</sup>a) Includes eliminations of Gross Revenue and Cancellations and rebates between the Group companies in the net amount of R\$ 6,070,237 at September 30, 2025 (R\$4,654,118 at September 30, 2024).

#### 18.2. Insurance revenue

Breakdown of total insurance revenue recognized in the period per measurement model is as follows:

		Consolidated	Consolidated
		09/30/2025	09/30/2024
Amounts relating to changes in liability/asset for remaining coverage			
Expected insurance expenses	(a)	2,063,308	2,063,583
Changes in the risk adjustment for non-financial risk	(b)	1,035	1,267
CSM recognized in profit or loss for the period	(c)	60,485	31,120
Allocation of the portion of premiums that relate to the recovery of	. ,		
insurance acquisition cash flows	(d)	35,747	35,623
Insurance revenue - Long-term products (BBA/VFA)		2,160,575	2,131,593
Premium release due to provision of insurance services	(e)	22,099,905	19,606,818
Insurance revenue - Short-term products (PAA)		22,099,905	19,606,818
Gross insurance revenue		24,260,480	21,738,411
Taxes on insurance revenues		(223,300)	(190,004)
Net insurance revenue		24,037,180	21,548,407

<sup>(</sup>a) Expected expenses for the period due to the provision of insurance services that comprise claims and other expenses that the Company expects to incur to cover insured events that occurred during the period.

(b) The change in risk adjustment shows the amount of risk that expired during the period.

(e) Amount recognized as insurance revenue for services rendered in the period.

 <sup>(</sup>c) CSM is recognized in profit or loss over the coverage period of the corresponding group of contracts based on coverage units.
 (d) Premiums relating to acquisition cash flows are systematically allocated, on a straight-line basis, based on the passage of time over the coverage period of the group of contracts or according to the portfolio's permanence curve.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 19. Cost of services

		Indiv	idual	Consolidated		
Description	Note	09/30/2025	09/30/2024	09/30/2025	09/30/2024	
Hospital services	19,1	(7,952,990)	(7,483,323)	(17,514,340)	(15,464,426)	
Insurance costs	19,2	-	-	(14,836,161)	(15,190,305)	
Asset management costs		-	-	(4,627)	(3,323)	
		(7,952,990)	(7,483,323)	(32,355,128)	(30,658,054)	

## 19.1. Hospital services

	Indiv	idual	Conso	lidated
	09/30/2025	09/30/2024	09/30/2025	09/30/2024
Personnel	(3,091,887)	(2,810,764)	(6,327,104)	(5,497,691)
Materials and medicines	(2,123,775)	(2,020,586)	(5,083,996)	(4,505,342)
Third-party services	(1,985,237)	(1,940,587)	(4,497,361)	(4,092,926)
Utilities and services	(161,905)	(162,206)	(368,070)	(325,220)
Rents	(8,059)	(7,661)	(78,022)	(76,156)
Depreciation and amortization	(582,127)	(541,519)	(1,159,787)	(967,091)
	(7,952,990)	(7,483,323)	(17,514,340)	(15,464,426)

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 19. Cost of services (Continued)

#### 19.2. Insurance costs

Incurred claims and other expenses allocated to insurance contracts

Amortization of acquisition cash flows

Amortization of allocation of consideration paid in business combinations to the insurance portfolios

Losses or reversal of losses on onerous contracts

Reclassification of the investment component

Incurred claims and other expenses allocated to insurance contracts
Amortization of acquisition cash flows
Amortization of allocation of consideration paid in business combinations to the insurance portfolios
Losses or reversal of losses on onerous contracts
Reclassification of the investment component

			Consolidated		
	Long-term p	roducts			
	(BBA/V	FA)	Short-term pro	ducts (PAA)	
		Liability			
	Liability for	for	Liability for	Liability for	
	remaining	incurred	remaining	incurred	
	coverage	claims	coverage	claims	09/30/2025
(a)	(73,153)	(1,618,016)	(820,618)	(10,658,156)	(13,169,943)
(b)	(35,747)	-	(1,355,086)	-	(1,390,833)
(c)	-	-	(370,397)	-	(370,397)
(d)	95,012	-	-	-	95,012
(e)	6,163,543	(6,163,543)	-	-	-
	6,149,655	(7,781,559)	(2,546,101)	(10,658,156)	(14,836,161)

Long-term products (BBA/VFA) Short-term products (PAA)  Liability Liability for Liability for	
Liability	
•	
Liability for for Liability for remaining incurred remaining incurred	10004
coverage claims coverage claims 09/30/	2024
	51,013)
(b) (35,623) - (1,074,789) - (1,11	10,412)
(470.070)	
	70,278)
(d) (58,602) (5	58,602)
(e) 2,043,669 (2,043,669)	-
1,866,633 (3,707,596) (2,277,118) (11,072,224) (15,19	205)

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

### 19. Cost of services (Continued)

#### 19.2. Insurance costs (Continued)

- (a) The most significant expenses are linked to incurred claims. This balance also includes expenses related to loss adjustments, issue, maintenance and collection of premiums, compliance with regulatory requirements, among other requirements necessary for the fulfillment of the Company's obligations linked to insurance contracts. Includes the elimination of claims incurred and other expenses to be allocated to insurance contracts between the Group companies in the amount of R\$6,070,237 as of September 30, 2025 (R\$4,654,118 as of September 30, 2024).
- (b) Acquisition cash flows are systematically allocated, on a straight-line basis, based on the passage of time over the coverage period of the group of contracts or according to the portfolio's permanence curve.
- (c) Amortization of the asset fair value computed by means of acquisition Purchase Price Allocation (PPA) allocated to the insurance contract portfolios, which was systematically and rationally allocated to the liability for remaining coverage, a portion of the contracts in force, and to the assets for acquisition cash flows, portion of futures contracts (renewals).
- (d) Amortization of part of the liability fair value determined in the acquisition PPA allocated to the insurance contract portfolios as a loss component, experience adjustments, changes in estimated cash flows, and one
- (e) In the long-term products, the investment component of Asset/Liability for remaining coverage is transferred to Liability for incurred claims relating to the payment of benefits (annual fees), redemptions and pension portability.

## 20. General and administrative expenses

	Indiv	idual	Consolidated		
	09/30/2025	09/30/2024	09/30/2025	09/30/2024	
Personnel	(642,590)	(593,345)	(769,196)	(709,313)	
Third-party services	(135,974)	(122,517)	(258,955)	(210,897)	
Travel and lodging	(36,014)	(33,376)	(65,091)	(56,692)	
Depreciation and amortization	(135,207)	(153,829)	(244,894)	(231,748)	
Reversal of/provision for contingencies	111,342	64,869	(249,927)	(264,786)	
•	(838,443)	(838,198)	(1,588,063)	(1,473,436)	

## 21. Other operating income (expenses), net

	iiidi	viduai	Oonsonaatea		
	09/30/2025	09/30/2024	09/30/2025	09/30/2024	
Taxes, charges and penalties	(72,873)	(65,561)	(142,330)	(126,206)	
Gain on disposal of properties	2,940	2,940	2,940	2,940	
Lease of machinery and equipment	(13,380)	(14,445)	(49,901)	(36,306)	
Freight expenses	(13,079)	(10,371)	(57,901)	(44,197)	
Legal fees	(444)	(539)	(3,194)	(3,310)	
Gain on divestiture	` <u>-</u>	354,103	-	354,103	
Other income and costs	30,450	(46,314)	75,398	(62,669)	
	(66,386)	219,813	(174,988)	84,355	
	<u> </u>				

Individual

Consolidated

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

### 22. Finance income (costs), net

Finance income (costs) for the nine-month periods ended September 30, 2025 and 2024 are broken down as follows:

	Individual		Consc	olidated
	09/30/2025	09/30/2024	09/30/2025	09/30/2024
Short-term investment yield	686,554	647,424	4,000,236	2,675,169
Net foreign exchange differences on financing	125,085	(146,245)	1,389,823	(912,955)
Fair value of debt	(603,463)	903,529	(740,136)	674,119
Fair value of derivatives (swaps)	94,944	(878,818)	(1,206,944)	5,170
Interest and monetary difference on financing and				
debentures	(3,197,180)	(2,526,058)	(3,407,848)	(2,607,238)
Interest on lease liabilities	(313,444)	(296,616)	(380,227)	(346,107)
Taxes on finance income (costs)	(69,880)	(48,747)	(94,700)	(67,644)
Finance income (costs) from insurance contracts	-	-	(2,479,676)	(1,639,159)
Other income and costs	266,209	320,205	136,552	296,314
	(3,011,175)	(2,025,326)	(2,782,920)	(1,922,331)
				_
Total finance income	2,423,503	1,804,135	8,191,258	5,537,007
Total finance costs	(5,434,678)	(3,829,461)	(10,974,178)	(7,459,338)
	(3,011,175)	(2,025,326)	(2,782,920)	(1,922,331)

### 23. Earnings per share

Basic earnings per share are calculated by dividing the profit attributable to the shareholders of the Company by the weighted average number of common shares issued over the period, excluding common shares purchased by the Company and held as treasury shares. For the periods presented, the Company's basic and diluted earnings per share are equal, considering that the Company and its subsidiaries do not hold any instruments with a potential dilutive effect. The weighted average number of common shares used in the calculation corresponds to the average number of shares outstanding for the periods presented.

Drofit attributable to the Company's controlling aboveholders
Profit attributable to the Company's controlling shareholders
Weighted average number of common shares issued (in thousands)
Basic and diluted earnings per share - in reais (R\$)

09/30/2025	09/30/2024
3,515,974	2.921.920
2,206,743	2,242,084
1.5933	1.3032

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management

### 24.1. Financial instruments by category

#### Fair value hierarchy

The financial instruments recognized at fair value are measured at levels from 1 to 3, based on the fair value measurement, as follows:

Level 1: fair value measurement derives from quoted (unadjusted) prices in active markets for identical assets or liabilities.

Level 2: fair value measurement derives from other inputs included in Level 1, which are quoted through an asset or liability directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3: fair value measurement derives from valuation techniques that include an asset or liability that is not included in an active market.

The following tables present breakdown of financial assets and liabilities at September 30, 2025 and December 31, 2024:

Individual							
Fair value Book balance							
Financial assets	Classification by category	hierarchy	09/30/2025	12/31/2024			
Cash and cash equivalents Marketable securities (shares	Fair value through profit or loss	Level 2	1,647,274	408,911			
and government securities) Marketable securities (corporate bonds and	Fair value through profit or loss	Level 1	522,492	31,537			
investment fund shares)	Fair value through profit or loss	Level 2	9,631,510	9,240,932			
Accounts receivable	Amortized cost	-	5,578,603	4,934,013			
Dividends receivable	Amortized cost	-	516,456	563,310			
Judicial deposits	Amortized cost Fair value through profit or loss	-	412,755	376,213			
Derivatives	and other comprehensive income	Level 2	482,072	555,277			
			18,791,162	16,110,193			

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

## **24.1. Financial instruments by category** (Continued)

Fair value hierarchy (Continued)

Individual						
		Fair value	Book b	alance		
Financial liabilities	Classification by category	hierarchy	09/30/2025	12/31/2024		
Trade accounts payable Loans, financing and	Amortized cost	-	780,345	666,543		
debentures Salaries, accruals and social	Amortized cost (a)	Level 2	37,714,971	34,028,208		
charges	Amortized cost Fair value through profit or loss and	-	647,042	491,097		
Derivatives	other comprehensive income	Level 2	1,680,030	2,114,447		
		_	40,822,388	37,300,295		

<sup>(</sup>a) The debt portion recorded as hedge accounting (fair value hedge) is measured at fair value through profit or loss, totaling R\$13,246,245 at September 30, 2025 (R\$10,835,902 at December 31, 2024).

Consolidated							
	Fair value	Book balance					
Financial assets	Classification by category	hierarchy	09/30/2025	12/31/2024			
Cash and cash equivalents Marketable securities (shares	Fair value through profit or loss	Level 2	5,534,941	6,570,751			
and government securities) Marketable securities (government securities, corporate bonds and investment fund	Fair value through profit or loss	Level 1	12,482,924	8,095,186			
shares)	Fair value through profit or loss Fair value through profit or loss	Level 2	20,294,772	21,306,934			
Marketable securities (government securities)	and other comprehensive income Fair value through profit or loss	Level 1	2,227,481	1,719,803			
Marketable securities (corporate bonds)  Marketable securities	and other comprehensive income	Level 2	709,598	888,052			
(government securities)	Amortized cost	-	3,708,778	1,908,808			
Accounts receivable	Amortized cost	-	11,954,391	11,327,808			
Judicial deposits	Amortized cost Fair value through profit or loss	-	2,608,341	2,770,086			
Derivatives	and other comprehensive income	Level 2	2,898,716	3,725,265			
		_	62,419,942	58,312,693			

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

### 24. Financial instruments and financial risk management (Continued)

#### 24.1. Financial instruments by category (Continued)

Fair value hierarchy (Continued)

Consolidated Book balance Fair value Financial liabilities Classification by category hierarchy 09/30/2025 12/31/2024 Trade accounts payable Amortized cost 1,784,099 1,534,698 Loans, financing and 42,879,071 debentures Amortized cost (a) Level 2 38,870,599 Salaries, accruals and social charges Amortized cost 1,366,601 1,109,208 Fair value through profit or loss and other 2,176,222 Derivatives comprehensive income Level 2 2,206,799 48,205,993 43,721,304

Financial assets and liabilities accounted for at amortized cost approximate their respective fair values, as they are adjusted by provisions, present value and/or restated at floating market rates.

#### 24.2. Risk management

The Company's financial transactions are conducted by the financial function in accordance with the strategy previously approved by the executive board and shareholders. The Company's risk management strategies and the corresponding effects on the individual and consolidated interim financial information can be summarized as follows:

#### a) Capital management

The main purpose of capital management is to ensure the Company's ability to continue as a going concern and maximize return to shareholders.

The Company uses own and third-party capital to finance its activities, and the use of third-party capital seeks to optimize its capital structure. The Company monitors its capital structure and makes adjustments in light of changes in economic conditions. At September 30, 2025 and December 31, 2024, the Company has the following capital structure:

<sup>(</sup>a) The debt portion recorded as hedge accounting (fair value hedge) is measured at fair value through profit or loss, totaling R\$15,437,126 at September 30, 2025 (R\$13,823,628 at December 31, 2024).

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

#### 24.2. Risk management (Continued)

#### a) Capital management (Continued)

	Individual		Consolidated		
	09/30/2025	12/31/2024	09/30/2025	12/31/2024	
Cash and cash equivalents Marketable securities Derivatives Technical reserves	1,647,274 10,154,002 -	408,911 9,272,469 -	5,534,941 39,423,553 (3,733)	6,570,751 33,918,783 -	
Insurance (b) Private pension (b)	-	-	(8,422,320) (11,215,892)	(7,137,782) (13,536,474)	
. , ,	11,801,276	9,681,380	25,316,549	19,815,278	
Loans, financing and debentures Derivatives Cash flow hedge	(37,714,971) (1,197,958) (164,536)	(34,028,208) (1,559,170) (270,005)	(42,879,071) 726,227 (139,439)	(38,870,599) 1,518,466 (270,005)	
Net debt (a) Total equity	(27,276,189) 26.332.327	(26,176,003) 24,702,627	(16,975,734) 28,802,268	(17,806,860) 26,701,868	
Total net debt and equity	(943,862)	(1,473,376)	11,826,534	8,895,008	
Leverage ratio	1.04	1.06	0.59	0.67	

<sup>(</sup>a) The net debt corresponds to the sum of the balances of loans, financing and debentures, derivative financial instruments, net (current and noncurrent) plus the cash flow hedge effect of other comprehensive income (the Company has swaps accounted for in accordance with the fair value and cash flow hedge accounting, for purposes of hedging the Company against fluctuations in foreign currency and interest rates, respectively) deducted of the balance of cash and cash equivalents and marketable securities.

#### b) Interest rate risk

The Company has loans, financing and debentures in local currency subject particularly to the fluctuation of the CDI and IPCA rates. The risk inherent to these liabilities arises from the possibility of fluctuations in these rates that impact the Company's cash flows.

The sensitivity analysis of interest on loans, financing and debentures, net of short-term yields, considered as probable scenario (Scenario I) the reference rates obtained with BM&FBOVESPA at September 30, 2025, and Scenarios II and III take into consideration a rate increase by 25% and 50%, respectively. The results, in nominal values, are as follows:

<sup>(</sup>b) Technical reserve balances recorded in the subsidiaries regulated by SUSEP and ANS, based on regulatory guidance established by these agencies, which includes eliminations upon consolidation.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

### 24. Financial instruments and financial risk management (Continued)

#### 24.2. Risk management (Continued)

#### b) Interest rate risk (Continued)

Scenarios	Scenario I current	Scenario II + 25%	Scenario III + 50%
CDI rate (p.a.)	14.90%	18.63%	22.35%
IPCA rate (p.a.)	5.17%	6.46%	7.76%
Projected interest expenses (in millions)	8,593	10,502	12,410

## c) Credit risk

Credit risk is the risk that a counterparty to a business arrangement will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Company is exposed to credit risk from its operating activities (primarily trade accounts receivable) and from its financing activities, including deposits with banks and financial institutions, foreign exchange transactions and other financial instruments. In the case of identification of imminent risk of non-realization of these assets, the Company records provisions to bring them to their probable realizable value.

#### d) Liquidity risk

Liquidity risks arise from the possibility of lack of readily available resources to honor commitments made on a timely basis due to the mismatch between payment and receipt flows.

SulAmérica's Investment Policy provides for and describes minimum amounts that must be invested in highly liquid assets to mitigate the risk of non-payment of claims and benefits.

Daily cash projections and stress tests are carried out to anticipate any abnormal situation, having a daily control over liquidity risk.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

## **24.2. Risk management** (Continued)

#### d) <u>Liquidity risk</u> (Continued)

Daily cash projections and stress tests are carried out to anticipate any abnormal situation, having a daily control over liquidity risk.

The amounts disclosed below are projected considering inflation and interest through to maturity.

	Individual - 09/30/2025					
	Within 1 year	From 1 to 2 years	From 2 to 5 years	Over 5 years	Total financial liabilities	
Trade accounts payable	780,345	-	-	-	780,345	
Loans, financing and debentures Salaries, accruals and social	1,895,731	3,798,399	15,434,938	23,241,725	44,370,793	
charges	647,042	-	-	-	647,042	
Derivatives	(615,794)	(414,914)	(855,528)	1,988,995	102,759	
	2,707,324	3,383,485	14,579,410	25,230,720	45,900,939	
	Consolidated - 09/30/2025					
	Within 1	From	From	Over	Total financial	
	year	1 to 2 years	2 to 5 years	5 years	liabilities	
Trade accounts payable	1,784,099	-	-	-	1,784,099	
Loans, financing and debentures	1,955,762	3,789,727	19,852,691	24,819,119	50,417,299	
Insurance liabilities Salaries, accruals and social	10,453,464	2,382,025	3,849,043	7,258,086	23,942,618	
charges	1,366,601	-	-	_	1,366,601	
Derivatives	(1,082,387)	(836,274)	2,458,755	4,368,757	4,908,851	
	14,477,539	5,335,478	26,160,489	36,445,962	82,419,468	

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

#### **24.2. Risk management** (Continued)

#### d) Liquidity risk (Continued)

	Individual - 12/31/2024						
	Within 1 year	From 1 to 2 years	From 2 to 5 years	Over 5 years	Total financial liabilities		
Trade accounts payable Loans, financing and	666,543	-	-	-	666,543		
debentures	4,081,452	1,205,590	12,505,438	22,144,716	39,937,196		
Salaries, accruals and social charges	491,097	- (604.734)	- (4.402.500)	- 2 652 400	491,097		
Derivatives	(425,283) 4,813,809	(694,731) 510,859	(1,193,589) 11,311,849	2,653,109 24,797,825	339,506 41,434,342		
	Consolidated - 12/31/2024						
		_	_	_	Total		
	Within	From 1 to 2 years	From	Over	financial liabilities		
	1 year	1 to 2 years	Z to 5 years	5 years	nabilities		
Trade accounts payable Loans, financing and	1,534,698	-	-	-	1,534,698		
debentures	4,075,909	1,285,713	14,931,573	25,403,252	45,696,447		
Insurance liabilities	10,699,763	2,464,724	4,501,946	7,579,614	25,246,047		
Salaries, accruals and social							
charges	1,109,208	-	-	-	1,109,208		
	(500,000)	(757 570)	4 00 4 4 40	0.707.004	0 744 504		
Derivatives	(522,960) 16,896,618	(757,579) 2,992,858	1,284,149 20,717,668	6,707,981 39,690,847	6,711,591 80,297,991		

#### e) Foreign currency

The Company has loans and financing and trade accounts payable in foreign currency (mainly the US dollar). The risk related to these assets and liabilities arises from the possibility of the Company incurring losses due to fluctuations in exchange rates. Liabilities in foreign currency represent 21.0% of total gross debt at September 30, 2025 (16.6% at December 31, 2024). The Company has derivative financial instruments to hedge loans and financing against foreign exchange rate fluctuation (see topic below). Management understands that the risk of exposure to foreign currency is not significant in relation to its financial position.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## **24. Financial instruments and financial risk management** (Continued)

#### **24.2. Risk management** (Continued)

#### f) Derivatives

At September 30, 2025, the Company has swaps recorded based on fair value and cash flow hedge accounting, in order to hedge the Company against fluctuations in foreign currency and interest rate, respectively. The swaps exchange: (i) the flow of interest and principal in foreign currency for Brazilian reais plus a percentage of CDI or CDI + spread; (ii) floating interest rate for fixed interest rate; and (iii) inflation rate IPCA + spread for a percentage of CDI or CDI + spread.

The fair value of those instruments at the reporting date is as follows:

				Indiv	ridual
	Maturity	Referen	ce value	09/30/2025	12/31/2024
Description	month/year	(notiona	l amount)	Fair va	alue
Swap (currency)	06/30/2025				
Long position	EUR/BRL + 1.0366%	EUR	_		
Short position	CDI+1.35%	R\$	-	-	55,609
Swap (currency)	04/27/2027				
Long position	USD SOFR + 0.99%	US\$	61,385		
Short position	CDI + 1.63%	R\$	326,480	3,734	61,310
Swap (currency)	07/01/2025				
Long position	USD/BRL + 1.8588%	US\$	100,786		
Short position	CDI + 1.323%	R\$	549,997	-	24,497
Swap (index)	01/18/2028				
Long position	BRL Fixed rate (11.82%)	R\$	1,634,663		
Short position	CDI + 2.01%	R\$	1,634,663	(131,029)	(245,419)
Swap (index)	01/22/2030				
Long position	BRL Fixed rate (8.80%)	R\$	2,135,109		
Short position	CDI + 2.125%	R\$	2,135,109	(538,200)	(750,302)
Swap (index)	01/22/02030				
Long position	BRL Fixed rate (8.65%)	R\$	1,116,094	(044.000)	(400,400)
Short position	CDI + 2.40%	R\$	1,116,094	(311,268)	(426,196)
Swap (index)	09/09/2035				
Long position	BRL Fixed rate (15.40%)	R\$	2,740,100		
Short position	CDI + 2.04%	R\$	2,740,100	45,836	-
Swap (index)	06/20/2029				
Long position	CDI + 0.79%	R\$	1,042,823		
Short position	BRL Fixed rate (7.71%)	R\$	1,042,823	175,572	244,621
Swap (index)	10/26/2026				
Long position	106.0% CDI	R\$	266,743		
Short position	BRL Fixed rate (6.765%)	R\$	266,743	19,641	28,717

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

## 24.2. Risk management (Continued)

				Indiv	
	Maturity	Refer	ence value	09/30/2025	12/31/2024
Description	month/year	(notion	nal amount)	Fair va	lue
0 ( 1 )	05/45/0000				
Swap (index)	05/15/2036	БФ.	4 500 440		
Long position	IPCA + 4.9347%	R\$	1,536,118	(400.044)	(004 504)
Short position	CDI + 1.35%	R\$	1,536,118	(180,211)	(224,591)
Swap (index)	12/15/2031				
Long position	IPCA + 5.5758%	R\$	407,874		
Short position	CDI + 0.56%	R\$	407,874	13,788	1,983
Swap (index)	12/15/2036				
Long position	IPCA + 6.1017%	R\$	612,902		
Short position	CDI + 1.403%	R\$	612,902	(27.742)	(42.620)
Short position	CDI + 1.403%	ĽΦ	612,902	(27,743)	(43,629)
Swap (index)	06/15/2029				
Long position	IPCA + 5.83%	R\$	814,129		
Short position	102.7% CDI	R\$	814,129	19,996	(2,941)
Swap (index)	06/15/2032				
Long position	IPCA + 6.01%	R\$	348,700		
Short position	104.1% CDI	R\$	348,700	(2,633)	(10,272)
Swap (index)	07/16/2029				
Long position	IPCA + 6.3828%	R\$	30,464		
Short position	103.65% CDI	R\$	,	1.436	(FG)
Short position	103.05% CDI	KΦ	30,464	1,430	(56)
Swap (index)	07/15/2032				
Long position	IPCA + 6.5445%	R\$	71,110		
Short position	104.8% CDI	R\$	71,110	913	(2,079)
Swap (index)	07/15/2037				
Long position	IPCA + 6.7692%	R\$	406,556		
Short position	107.9% CDI	R\$	406,556	(5,506)	(22,630)
Swap (index)	12/17/2029				
Long position	IPCA + 6.7947%	R\$	84,339		
Short position	108.1% CDI	R\$	84,339	2,244	(145)
	40/45/0000				
Swap (index)	12/15/2032	DΦ	50.004		
Long position	IPCA + 6.9354%	R\$	56,264	(40)	(4.400)
Short position	110.1% CDI	R\$	56,264	(43)	(1,409)
Swap (index)	08/15/2030				
Long position	IPCA + 6.20%	R\$	562,147		
Short position	106.6% CDI	R\$	562,147	(80,871)	(68,791)
Swap (index)	08/15/2033				
Long position	IPCA + 6.55%	R\$	528,689		
Short position	109.3% CDI	R\$	528,689	(89,605)	(78,328)
poomon	.00.070 001	, .ψ	320,000	(55,000)	(10,020)
Swap (index)	12/15/2033				
ong position	IPCA + 6.6941%	R\$	255,286		
Short position	CDI + 0.73%	R\$	255,286	(33,310)	(28,330)
Swap (index)	12/15/2038				
ong position	IPCA + 6.9527%	R\$	510,970		
Short position	CDI + 1.02%	R\$	510,970	(80,699)	(70,789)
z podition	OD: 1 1.02/0	ινψ	0.0,070	(55,555)	(10,103)

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

## **24.2. Risk management** (Continued)

	r		Indiv	idual
	{ Maturity	Reference value	09/30/2025	12/31/2024
Description	month/year	(notional amount)	Fair va	lue
Current asset position			86,073	174,331
Noncurrent asset position			395,999	380,946
Current liability position			(671,660)	(568,616)
Noncurrent liability position			(1,008,370)	(1,545,831)
Effect on P&L for the year (fair value of derivatives - swaps)  Effect on equity for the year (fair			94,944	(1,687,883)
value of derivative - swaps)			(105,469)	88,406

				Conso	olidated
	Maturity	Reference v	alue (notional	09/30/2025	12/31/2024
Description	month/year	am	ount)	Fair v	alue
Swan (aumanau)	06/30/2025				
Swap (currency) Long position	EUR/BRL + 1.0366%	EUR			
Short position	CDI+1.35%	R\$		_	55,609
Short position	ODI+1.55%	Ιζψ			33,003
Swap (currency)	02/03/2028				
Long position	USD/BRL + 5.80%	R\$	154,793		
Short position	BRL Fixed rate (14.86%)	R\$	823,282	(114,160)	-
Swap (index)	02/03/2028				
Long position	88.7% CDI	R\$	111,940		
Short position	BRL Fixed rate (14.82%)		111,940	(3,826)	_
			,	(-,/	
Swap (index)	09/05/2028				
Long position	104.52% CDI	R\$	-		
	BRL Fixed rate				
Short position	(13.305%)	R\$	913,581	(7,416)	-
Swap (index)	09/05/2028				
Long position	88.8% CDI	R\$	100,843		
Short position	BRL Fixed rate (12.83%)		100,843	92	_
Short position	DICE Fixed fate (12.03%)	Ιζψ	100,043	32	_
Swap (currency)	04/27/2027				
Long position	USD SOFR + 0.99%	US\$	61,385		
Short position	CDI + 1.63%	R\$	326,480	3,734	61,310
Swap (currency)	07/01/2025	1100	400 700		
Long position	USD/BRL + 1.8588%	US\$	100,786		04.407
Short position	CDI + 1.323%	R\$	549,997	-	24,497
Swap (currency)	01/18/2028				
Long position	USD Fixed rate (4.95%)	US\$	505,019		
Short position	BRL Fixed rate (11.82%)		2,685,993	1,075,824	1,464,880
,	11 111 ( 113=13)	*	,,	,,-	, - ,
Swap (index)	01/18/2028				
Long position	BRL Fixed rate (11.82%)		1,634,663		
Short position	CDI + 2.01%	R\$	1,634,663	(131,029)	(245,419)

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# 24. Financial instruments and financial risk management (Continued)

## 24.2. Risk management (Continued)

				Consolidated		
	Maturity	Referer	nce value	09/30/2025	12/31/2024	
Description	month/year	(notiona	ıl amount)	Fair va	alue	
Swap (index)	01/22/2030					
Long position	USD Fixed rate (4.525%)	US\$	504,250			
Short position	BRL Fixed rate (8.80%)	R\$	2,681,904	752,154	1,107,606	
Swap (index)	01/22/2030					
Long position	BRL Fixed rate (8.80%)	R\$	2,135,109			
Short position	CDI + 2.125%	R\$	2,135,109	(538,200)	(750,302)	
Swap (index)	01/22/2030					
ong position	USD Fixed rate (4.51%)	US\$	252.125			
Short position	BRL Fixed rate (8.65%)	R\$	1,340,952	334,377	505,150	
Swap (index)	01/22/2030					
Long position	BRL Fixed rate (8.65%)	R\$	1,116,094			
				(244.260)	(426 406)	
Short position	CDI + 2.40%	R\$	1,116,094	(311,268)	(426,196)	
Swap (index)	09/09/2035					
ong position	USD Fixed rate (6.45%)	US\$	501,881			
Short position	BRL Fixed rate (15.40%)	R\$	2,669,306	(116,593)	-	
Swap (index)	09/09/2035					
Long position	BRL Fixed rate (15.40%)	R\$	2,740,100			
Short position	CDI + 2.04%	R\$	2,740,100	45,836	-	
Swap (index)	06/20/2029					
ong position	CDI + 0.79%	R\$	1,042,823			
Short position	BRL Fixed rate (7.71%)	R\$	1,042,823	175,572	244,621	
Swap (index)	10/26/2026					
Long position	106.0% CDI	R\$	266,743			
	BRL Fixed rate (6.765%)	R\$	266,743	19,641	28,717	
Short position	DRL Fixed falle (0.700%)	KΦ	200,743	19,041	20,717	
Swap (index)	05/15/2036					
Long position	IPCA + 4.9347%	R\$	1,536,118			
Short position	CDI + 1.35%	R\$	1,536,118	(180,211)	(224,591)	
Swap (index)	12/15/2031					
ong position	IPCA + 5.5758%	R\$	407,874			
Short position	CDI + 0.56%	R\$	407,874	13,788	1,983	
Swap (index)	12/15/2036					
ong position	IPCA + 6.1017%	R\$	612,902			
Short position	CDI + 1.403%	R\$	612,902	(27,743)	(43,629)	
Swap (index)	06/15/2029					
ong position	IPCA + 5.83%	R\$	814,129			
Short position	102.7% CDI	R\$	814,129	19,996	(2,941)	
Short position	102.7 /0 001	IVΨ	014,129	13,330	(2,341)	
Swap (index)	06/15/2032	5.0	0.40.700			
ong position	IPCA + 6.01%	R\$	348,700	, <u>.</u>		
Short position	104.1% CDI	R\$	348,700	(2,633)	(10,272)	
Swap (index)	07/16/2029					
ong position	IPCA + 6.3828%	R\$	30,464			
Short position	103.65% CDI	R\$	30,464	1,436	(56)	

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

## 24.2. Risk management (Continued)

				Consoli	dated
	Maturity	Reference	ce value	09/30/2025	12/31/2024
Description	month/year	(notional	amount)	Fair va	alue
Swap (index)	07/15/2032				
Long position	IPCA + 6.5445%	R\$	71,110		(0.0=0)
Short position	104.8% CDI	R\$	71,110	913	(2,079)
Swap (index)	07/15/2037				
Long position	IPCA + 6.7692%	R\$	406,556		
Short position	107.9% CDI	R\$	406,556	(5,506)	(22,630)
Swap (index)	12/17/2029				
Long position	IPCA + 6.7947%	R\$	84,339		
Short position	108.1% CDI	R\$	84,339	2,244	(145)
Swap (index)	12/15/2032				
Long position	IPCA + 6.9354%	R\$	56,264		
Short position	110.1% CDI	R\$	56,264	(43)	(1,409)
Swap (index)	08/15/2030				
Long position	IPCA + 6.20%	R\$	562.147		
Short position	106.6% CDI	R\$	562,147	(80,871)	(68,791)
Swap (index)	08/15/2033				
Long position	IPCA + 6.55%	R\$	528,689		
Short position	109.3% CDI	R\$	528,689	(89,605)	(78,328)
Swap (index)	08/15/2033				
Long position	IPCA + 6.6941%	R\$	255,286		
Short position	CDI + 0.73%	R\$	255,286	(33,310)	(28,330)
Swap (index)	08/15/2038				
Long position	IPCA + 6.9527%	R\$	510,970		
Short position	CDI + 1.02%	R\$	510,970	(80,699)	(70,789)
Current asset position				114,012	174,331
Noncurrent asset position				2,784,704	3,550,934
Current liability position				(1,112,404)	(660,968)
Noncurrent liability position				(1,063,818)	(1,545,831)
Effect on P&L for the year (fair value of derivatives - swaps) Effect on equity for the year				(1,206,944)	51,587
(fair value of derivative - swaps)				(130,566)	26,950

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

### 24. Financial instruments and financial risk management (Continued)

### 24.2. Risk management (Continued)

#### f) <u>Derivatives</u> (Continued)

Given the changes in market rates, these amounts may suffer changes as well as early settlement or maturity of the transactions.

For derivative financial instruments, the Company considers as probable scenario (Scenario I) future exchange rates of the Brazilian real in relation to the US -Dollar, euro, IPCA inflation rates and future ID interest rate, obtained from BM&FBOVESPA at their maturities, calculated based on the nominal amount of the agreement.

The Company adopted the scenarios corresponding to -25% (Scenario II), -50% (Scenario III), +25% (Scenario IV) and +50% (Scenario V) in relation to the exchange rates and DI rates used to determine the probable scenario (Scenario I).

Debt - Citibank, JP Morgan, Bofa and Investment - ICO	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Exchange rate fluctuation Depreciation of US\$ (rate in R\$) Appreciation of US\$ (rate in R\$)	5% - 5.5845	(25%) 4.1884 -	(50%) 2.7923 -	25% - 6.9807	50% - 8.3768
Effect on liabilities Loan 4131 - Citibank, JP Morgan, Bofa and Swap ICO	(35,361)	176,804	353,608	(176,804)	(353,608)
Effect on derivatives Swap Net effect	35,361 -	(176,804) -	(353,608) -	176,804 -	353,608 -
Debt - Senior Notes I	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Exchange rate fluctuation Depreciation of US\$ (rate in R\$) Appreciation of US\$ (rate in R\$)	5% - 5.5845	(25%) 4.1884 -	(50%) 2.7923 -	25% - 6.9807	50% - 8.3768
Effect on liabilities Senior Notes	129,797	(648,986)	(1,297,973)	648,986	1,297,973
Effect on derivatives Swap Net effect	(129,797) -	648,986 -	1,297,973	(648,986) -	(1,297,973) -

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

## **24.2. Risk management** (Continued)

Debt – Senior Notes II	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Exchange rate fluctuation Depreciation of US\$ (rate in R\$)	5% -	(25%) 4.1884	(50%) 2.7923	25%	<b>50%</b> -
Appreciation of US\$ (rate in R\$)	5.5845	-	-	6.9807	8.3768
Effect on liabilities in US\$ Senior Notes II	174,635	(873,174)	(1,746,347)	873,174	1,746,347
Effect on derivatives					
Swap Net effect	(174,635) -	873,174 -	1,746,347 -	(873,174) -	(1,746,347) -
Debt - Senior Notes III	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Exchange rate fluctuation Depreciation of US\$ (rate in R\$)	5% -	(25%) 4.1884	(50%) 2.7923	25%	<b>50%</b>
Appreciation of US\$ (rate in R\$)	5.5845	-	-	6.9807	8.3768
Effect on liabilities in US\$ Senior Notes III	134,773	(673,866)	(1,347,732)	673,866	1,347,732
Effect on derivatives Swap	(134,773)	673,866	1,347,732	(673,866)	(1,347,732)
Net effect	-	-	-	-	-
Debt - Debentures	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Fluctuation of the DI rate	5%	(25%)	(50%)	25%	50%
Depreciation of the DI rate Appreciation of the DI rate	15.6450%	11.7338% -	7.8225% -	19.5563%	23.4675%
Effect on liabilities Debentures	9,756	(41,464)	(92,685)	60,977	112,197
Effect on derivatives Swap Net effect	(9,756) -	41,464 -	92,685 -	(60,977)	(112,197) -

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 24. Financial instruments and financial risk management (Continued)

#### 24.2. Risk management (Continued)

#### f) <u>Derivatives</u> (Continued)

Debt - Debentures (CRI)	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Fluctuation of the IPCA rate Depreciation of the IPCA rate Appreciation of the IPCA rate	5% - 5.4285%	(25%) 4.0714%	(50%) 2.7143%	25% - 6.7856%	50% - 8.1428%
Effect on liabilities Debentures	15,798	(67,141)	(150,081)	98,737	181,676
Effect on derivatives Swap Net effect	(15,798) -	67,141 -	150,081 -	(98,737) -	(181,676) -
Debt – Loan 4131	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Debt – Loan 4131  Fluctuation of the IPCA rate Depreciation of the IPCA rate Appreciation of the IPCA rate	5% - 6.5535	Scenario II (25%) 4.9151	(50%) 3.2767	25% - 8.1918	50% - 9.8302
Fluctuation of the IPCA rate Depreciation of the IPCA rate	5% -	(25%)	(50%)	<b>25%</b>	50%

#### g) Pricing risk

Currently, the Company has specific actuarial pricing models for each of its products, which ensure accuracy in determining the prices in view of the expected contractual commitments and expenses used to sell and manage contracts.

For insurance with higher individual risks and portfolios with less predictability or exposed to catastrophes, the Company uses reinsurance contracts, mitigating the risk of large and unexpected losses on contracts and transferring such risks to the reinsurers, assuming in return the credit risk of these partners. The purchase of reinsurance follows a specific policy established and described by the Company.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

### 24. Financial instruments and financial risk management (Continued)

#### 24.2. Risk management (Continued)

## g) Pricing risk (Continued)

One of the ways to measure possible impacts on profit or loss and equity, arising from underwriting risks, is the sensitivity analysis of the variables that may be affected by the product underwriting process, inadequacy of prices or even insufficiency of technical reserves.

The following sensitivity analyses simulate the possible impacts on profit or loss and equity of changes in operating parameters before and after the purchase of reinsurance.

Sensitivity analysis - Health

The sensitivity analysis considers a scenario where the stressed assumptions suffer a 5% impact (Increase and Decrease) and how this change would impact the Company's consolidated profit or loss and equity.

This type of analysis is based on the history of the Company's products and judges their results independently. Shocks of 5% mentioned in the table are determined by the total value of the amount calculated from the base for the reference period multiplied by the factor of 1.05 (in cases of increase) or 0.95 (in cases of decrease).

Impacts are evaluated in the amount of P&L realized, and the results as at September 30, 2025 and 2024 are as follows:

Con	solidated - 09/30/2025	
Assumptions	Income (loss) before taxes	Income (loss) after taxes
5% increase in claims	(917,320)	(550,392)
5% increase in cancelations	(1,104,995)	(662,997)
5% increase in interest rate	42,169	25,301
5% decrease in claims	917,320	550,392
5% decrease in cancelations	1,104,995	662,997
5% decrease in interest rate	(38,249)	(22,950)
Con	solidated - 09/30/2024	
Assumptions	Income (loss) before taxes	Income (loss) after taxes
5% increase in claims	(869,416)	(521,649)
5% increase in cancelations	(980,341)	(588,205)
5% increase in interest rate	289,916	173,950
5% decrease in claims	869,416	521,649
5% decrease in cancelations	980,341	588,205
5% decrease in interest rate	(309,347)	(185,608)

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# **24. Financial instruments and financial risk management** (Continued)

## 24.3. Changes in liabilities from financing activities

					Indiv	idual				
Individual	12/31/2024	Loans, financing and debentures raised	Interest, monetary and FX differences, net	Payment of acquisitions and principal	Payment of interest	Fair value of debt	Allocation of dividends and IOE	Payment of dividends and IOE	Other	09/30/2025
Loans, financing, debentures and leases Derivatives Dividends and IOE payable	36,955,928 2,114,447 56,938	5,985,539 - -	3,510,759 (62,682)	(3,504,901) (371,735)	(3,095,288)	603,463 - -	- - 1,350,000	- - (822,278)	211,455 (132,373)	40,666,955 1,680,030 452,287
	39,127,313	5,985,539	3,448,077	(3,876,636)	(3,095,288)	603,463	1,350,000	(822,278)	79,082	42,799,272
Current Noncurrent	5,173,194 33,954,119									3,566,525 39,232,747
					Indiv	idual				
Individual	12/31/2023	Loans, financing and debentures raised	Interest, monetary and FX differences, net	Payment of acquisitions and principal	Indiv	idual Fair value of debt	Allocation of dividends and IOE	Payment of dividends and IOE	Other	09/30/2024
Individual  Loans, financing, debentures and leases Derivatives Dividends and IOE payable	12/31/2023 34,222,672 1,037,392 88,499	financing and debentures	monetary and FX differences,	acquisitions	Payment of	Fair value of	dividends and	dividends and	Other  388,738 - (139,071)	09/30/2024 34,559,403 1,344,746 308,365
Loans, financing, debentures and leases Derivatives	34,222,672 1,037,392	financing and debentures raised	monetary and FX differences, net	acquisitions and principal (1,863,819)	Payment of interest	Fair value of debt	dividends and IOE -	dividends and IOE - -	388,738	34,559,403 1,344,746

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

# **24. Financial instruments and financial risk management** (Continued)

## 24.3. Changes in liabilities from financing activities (Continued)

					Conso	lidated				
Consolidated	12/31/2024	Loans, financing and debentures raised and leases	Interest, monetary and FX differences, net	Payment of acquisitions and principal	Payment of interest	Fair value of debt	Allocation of dividends and IOE	Payment of dividends and IOE	Other	09/30/2025
Loans, financing, debentures and leases Derivatives Dividends and IOE payable	42,473,072 2,206,799 69,192 44,749,063	8,115,539 - - - 8,115,539	2,462,009 512,141 - 2,974,150	(3,624,777) (542,718) - ((4,167,495)	(3,060,575) - - (3,060,575)	740,136 - - - 740,136	- - 1,553,032 1,553,032	- (1,025,557) (1,025,557)	(536,452) (132,373) (668,825)	46,568,952 2,176,222 464,294 49,209,468
Current Noncurrent	5,421,775 39,327,288	0,113,339	2,974,130	((4,107,493)	(3,000,373)	740,130	1,333,032	(1,023,337)	(000,023)	4,279,342 44,930,126
					Conso	lidated				
Consolidated	12/31/2023	Loans, financing and debentures raised and leases	Interest, monetary and FX differences, net	Payment of acquisitions and principal	Conso  Payment of interest	lidated Fair value of debt	Allocation of dividends and IOE	Payment of dividends and IOE	Other	09/30/2024
Consolidated  Loans, financing, debentures and leases Derivatives Dividends and IOE payable	37,758,574 1,210,922 99,769	financing and debentures raised and	monetary and FX differences,	acquisitions	Payment of	Fair value of	dividends and	dividends and	Other  482,851 - (121,467)	39,160,861 1,472,647 331,153

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

## 25. Assets, liabilities, revenues and expenses per segment

_				Consolidated			
	09/30/2025						
_	Hospital	Health	Life	Corporate	Total segments	Eliminations	Consolidated
Net revenues							
Foreign customers	23,301,308	23,336,677	733,880	109,395	47,481,260	(6,131,844)	41,349,416
Intersegment	-	497	29,753	-	30,250	(30,250)	-
Other revenues and expenses							
Operating expenses	(17,514,340)	(20,336,566)	(613,518)	(4,628)	(38,469,052)	6,113,924	(32,355,128)
Administrative expenses	(906,942)	(547,497)	(11,376)	(89,281)	(1,555,096)	(32,967)	(1,588,063)
Finance income (costs)	(3,407,592)	369,578	58,151	165,336	(2,814,527)	31,607	(2,782,920)
Other amounts that have an impact on income (a)	2,043,540	(769,988)	(66,246)	(33,564)	1,173,742	(2,281,073)	(1,107,331)
Net income	3,515,974	2,052,701	130,644	147,258	5,846,577	(2,330,603)	3,515,974
Assets	80,663,383	33,580,565	13,282,939	12,944,355	140,471,242	(31,804,313)	108,666,929
Assets classified as held for sale	1,366,328	-	•	-	1,366,328	•	1,366,328
Liabilities	52,102,359	19,928,926	11,308,451	685,905	84,025,641	(3,919,737)	80,105,904
Liabilities associated with assets held for sale	1,125,085	-	-	-	1,125,085	-	1,125,085

<sup>(</sup>a) Mainly composed of the intragroup equity pickup eliminated in the "Eliminations" column, totaling R\$2,300,363.

	Consolidated						
	09/30/2024						
	Hospital	Health	Life	Corporate	Total segments	Eliminations	Consolidated
Net revenues							
Foreign customers	20,760,178	20,942,292	623,909	85,743	42,412,122	(4,689,825)	37,722,297
Intersegment	-	167	12,396	-	12,563	(12,563)	-
Other revenues and expenses							
Operating expenses	(15,464,426)	(19,255,615)	(614,364)	(3,323)	(35,337,728)	4,679,674	(30,658,054)
Administrative expenses	(856,683)	(484,110)	(14,849)	(90,676)	(1,446,318)	(27,118)	(1,473,436)
Finance income (costs)	(2,279,109)	9	242,751	90,991	(1,945,358)	23,027	(1,922,331)
Other amounts that have an impact on	761,960	(416,624)	(69,623)	20,046	295,759	(1,042,315)	(746,556)
income (a)							
Net income	2,921,920	786,119	180,220	102,781	3,991,040	(1,069,120)	2,921,920
Assets	71,509,106	26,189,913	13,958,795	10,468,205	122,126,019	(24,265,203)	97,860,816
Liabilities	45,052,603	15,792,608	12,914,135	777,170	74,536,516	(3,132,203)	71,404,313

<sup>(</sup>a) Mainly composed of the intragroup equity pickup eliminated in the "Eliminations" column, totaling R\$1,077,948.

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

#### 26. Assets and liabilities available for sale

On April 16, 2025, the Company signed documents referring to the disposal of its entire equity interest in GSH Corp Participações S.A. ("GSH") to George Holding S.A. (the "Buyer"), a company owned by funds managed by CVC Capital Partners. As a result, the Buyer will acquire, on the closing date, 98.5% of GSH's capital, of which 41% is held by the Company. The price will be equivalent to the total enterprise value of R\$1,585,935, which will be deducted of net debt and subject to customary price adjustments for transactions of this nature. The Purchase Price will be paid as follows: (i) 70% on the closing date; (ii) 23.5% as a future portion payable on the second anniversary of the transaction closing date; and (iii) 6.5% as a future variable and contingent portion payable on the second anniversary of the transaction closing date, depending on the verification of metrics established in the agreement.

The transaction resulted in the classification of this asset as available for sale, primarily based on the following criteria: GSH is available for immediate sale and can be disposed of in its current state.

The transaction closed on October 31, 2025, subject to certain conditions precedent. For further details, see note 28.

In line with the definitions set forth in IFRS 5 (CPC 31) - Non-current assets held for sale and discontinued operations, management understands that the transaction does not involve the disposal of a major line of business; therefore, it is not a discontinued operation.

#### 27. Insurance

At September 30, 2025, the Company maintains insurance coverage at amounts deemed sufficient by management to cover risks, if any, on its assets and/or liabilities.

Type of coverage	Amount insured		
Property risk Civil liability (D&O) General civil liability	2,767,296 742,930 13,000		
Engineering risks	2,224,768		

Notes to interim financial information (Continued) September 30, 2025 (In thousands of reais, unless otherwise stated)

### 28. Event after the reporting period

On October 6, 2025, Rede D'Or completed the early settlement in full of its 31st issue of debentures, paying R\$ 500 million in principal and R\$ 40,868 million in interest.

On October 31, 2025, it completed the closing with George Holding S.A., a company owned by funds managed by CVC Capital Partners, of the sale of the entire equity interest held by the Company in the capital stock of GSH Corp Participações S.A.

On November 4, 2025, Rede D'Or announced the total optional early redemption of the second series of the 9th Debenture Issue of Sul América S.A., succeeded by Rede D'Or São Luiz S.A. due to merger, in the principal amount of R\$ 750 million, to be carried out on November 10, 2025.